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Chapter 1 
The work described in this thesis revolves around reprogramming cells into stem cells, to 
understand what happens during this transition and use this to further understand cell fate 
transformation and its pathological counterpart, cancer. In this introduction, we will discuss 
the background and impact of stem cells by highlighting the following topics:
- Definitions of stem cells
- Factors required to maintain embryonic stem cells
- History and recent discoveries of cellular reprogramming
- Impact of research into stem cells and reprogramming 
- Events during reprogramming of somatic cells to iPSCs
- A view of oncogenic transformation from a reprogramming perspective
Definitions of stem cells 
A stem cell can self-renew and give rise to one or multiple differentiated lineages. It can thus 
divide and give rise to a stem cell that is the same as its mother cell, but also give rise to a 
daughter cell that differentiates into one or more types of specialized cells1. A stem cell can 
be immortal; it normally retains its ability to proliferate. It has the privilege of expressing 
factors such as telomerase, which reduces loss of genetic integrity over time, increasing 
longevity2.
There is an important distinction between adult- and embryonic stem cells. Adult stem 
cells are probably best known; these are the stem cells that persist in the mature body, and 
continuously replenish the cells of the gut, the skin and blood. For example, hematopoietic 
stem cells reside in bone marrow throughout adult life to replenish all lineages of blood 
cells through increasingly more differentiated progenitor cells. Hematopoietic stem cells, 
however, will never give rise to skin or gut epithelium; they themselves are committed such 
that they are limited to producing blood. They are called multipotent; they can differentiate 
into ‘several’ but not many or all lineages. Pluripotent stem cells (PSCs) can differentiate 
into ‘many’ lineages. Pluripotency means that all cells of an embryo can be derived from 
this stem cell. Totipotency, or ‘can do all’ is a term reserved for a fertilized egg cell and 
its immediate progeny, which can form both embryonic and extra-embryonic cells such as 
placental cells (Figure 1). 
In this thesis, we are interested in PSCs. Examples of PSCs are Embryonic Stem Cells 
(ESCs), derived from a very early, blastocyst-stage embryo, or induced pluripotent stem 
cells (iPSCs), derived by ‘reprogramming’ a more differentiated somatic cell with defined 
transcription factors, in order to become pluripotent. The latter are indistinguishable from 
ESCs when compared under the right conditions3-6; we discuss the concept of reprogramming 
below.
11
Introduction
1
There has been enormous scientific progress in the pluripotent stem cell field in the 
past 20 years, such as the derivation of human embryonic stem cells7 and the discovery of 
four-factor reprogramming into induced pluripotent stem cells8. Also, there are new uses 
for stem cells in combination with new gene-editing methods and in vitro tissue generation 
techniques; these are applied to design cures for single-gene congenital diseases and 
degenerative disease. 
However, the word stem cell is nearly 150 years old9. The term was popularized by 
Edmund Wilson in 1896, but can be attributed to German biologist Ernst Haeckel, who in 
1868 referred to the fertilized egg as a “Stammzelle”. He later described a Stammzelle as the 
ancestor of all cells in multicellular organisms, the base of a tree of offspring like a common 
ancestor in a phylogenetic tree he called “Stammbäume”, hence the name. The first person 
who described ESCs and demonstrated their ability to form any embryonic tissue, was a 
Maine researcher called Leroy Stevensμ. He studied the teratomas that one of his strains 
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Figure 1. Different stages of differentiation and corresponding developmental potential.
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of mice kept suffering from. 
Teratomas are tumors that contain 
an unorganized mix of adult 
tissues, including bone, muscle 
and hair; tissues representative 
of all embryonic germ layers. We 
know now that teratomas can 
also be derived experimentally. 
(Figure 2). He found that certain 
undifferentiated cells in a 
teratoma were transplantable 
from mouse to mouse and 
produced new teratomas 
indefinitely. He also noted that 
early embryonic progenitors to 
germ cells, primordial germ cells, were responsible for the teratomas in his mouse strain.
Perhaps most importantly, he realized that primordial germ cells look like cells from the 
inner cell mass (ICM) of a few days-old embryo. In 1970 he showed that these cells were 
also capable of forming teratomas, calling them ‘pluripotent embryonic cells’ that ‘appear 
to give rise to both rapidly differentiating cells and others which like themselves remain 
undifferentiated’10. This is the definition of an embryonic stem cell. Due to their ability to 
also give rise to cancerous cells however, they became known as embryonic carcinoma 
cells (ECCs)10,11. Five years later, Mintz and Illmensee showed that these cells indeed were 
capable of giving rise to a whole new mouse12. In 1981 several groups managed to isolate 
similar cells from mouse blastocysts, which we now call embryonic stem cells (ESCs)13,14. 
Since then, a body of work has defined what genes are key to pluripotency, such as Oct4, 
Sox2 and Nanog15-18, how embryonic stem cells are best grown to maintain a pluripotent 
state19 or to differentiate into defined lineages20. 
Factors required to maintain embryonic stem cells
A combination of transcription factors, signaling factors and extracellular signals  can 
maintain PSCs in a pluripotent state. Three transcription factors have been found to form 
the core regulatory network of pluripotency. These transcription factors are influenced by 
three main signaling cascades.
PSCs
teratoma
Mesoderm
Endoderm
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Figure 2
Figure 2. Schematic presentation of a teratoma 
formation assay.
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Pluripotency gene regulatory network
Transcription factors OCT4, SOX2 and NANOG form what has been called the ‘pluripotency 
gene regulatory network (PGRN)’21. They are highly interconnected and maintain the 
pluripotent state through other transcription factors, in response to signaling cascades, 
epigenetic mechanisms and metabolic cues. 
OCT4 is essential to pluripotency both in vivo and in vitro. OCT4 prevents 
trophectoderm differentiation by interacting with CDX2. Cdx2 and Oct4 expression are 
mutually exclusive, directing cells either to trophectoderm or ICM formation17,22. SOX2 
is a key regulator of OCT4 and is, similar to OCT4, required to prevent trophectoderm 
differentiation18,22. SOX2 is also required for the formation of the epiblast, the structure 
within an implantation stage embryo which contains pluripotent cells23. Depending on the 
culture conditions, transcription factor NANOG can prevent differentiation into specific 
lineages.  Formation of primitive endoderm, which forms the extraembryonic membranes, 
can be induced by removing Leukemia Inhibitory Factor (LIF) or when embryoid bodies are 
formed (a differentiation test in culture, mimicking early embryogenesis). Artificial Nanog 
expression blocks primitive endoderm formation in these settings24,25. Also, neuronal 
differentiation, induced by removal of LIF or of bone morphogenetic protein (BMP) from the 
culture media, can be prevented by Nanog overexpression26. When mesoderm is formed, 
NANOG can reverse this specification by repressing Brachyury27.
According to Chromatin immunoprecipitation (ChIP) studies, these three factors 
co-occupy hundreds of regulatory elements including their own21. Thus, through positive 
feedback towards each other and downstream effectors, they stabilize the pluripotent state; 
however, disruption of the PGRN through (lack of) external signals quickly sends the cell to 
a path of differentiation. External signals are:
LIF
ESCs can differentiate into three cell types: primitive ecto- or endoderm, and under certain 
conditions, trophectoderm28. Extracellular signaling by LIF, a member of the interleukin-6 
cytokine family is a key factor in preventing differentiation. LIF binding to its receptor 
activates the JAK/STAT pathway. Activation of STAT3 upregulates targets including Klf4 
and Tfcp2l1 and represses non-neural differentiation. STAT3 expression is essential to 
maintenance of pluripotency29.
BMP
BMP exerts its signal through the SMAD transcription factors. SMAD transcription factors 
14
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suppress differentiation by upregulating inhibitor of differentiation (Id) genes. Together with 
LIF, BMP suffices to prevent differentiation mouse ESCs26.
WNT
In the absence of canonical WNT/β-catenin signaling, WNT effector and transcriptional 
repressor TCF3 co-localizes with OCT4 and SOX2 pluripotency-associated genes, 
antagonizing their function. GSK3-β marks β-catenin for degradation, and as a result GSK-β 
inhibition promotes pluripotency. However, GSK3-β inhibition is not sufficient to maintain a 
pluripotent state. 
Manipulation of these pathways is applied to maintain pluripotent stem cells in 
culture and promote reprogramming towards pluripotency. In this thesis, LIF is added to all 
reprogramming, iPSC or ESC cultures. Inhibition of GSK3β and the FGF4-ERK pathway is used 
to stimulate reprogramming efficiency. 
History and recent discoveries of cellular reprogramming
Eleven years ago, culturing ESCs and human ESCs had been well established. The discovery 
of four-factor reprogramming by the Yamanaka lab in 2006 allowed this knowledge to be 
applied to these new induced pluripotent stem cells. This boosted interest in the field 
because of the promise of biological insight into pluripotency through reprogramming. It 
also inspired clinical applications by means of disease modeling, and patient- (not embryo-) 
derived pluripotent stem cells for transplantable-tissue generation8.
The history of reprogramming starts with the realization that there is a program. 
The first step was demonstrating that all cells from an early embryo have the information 
to form a complete embryo. In 1902, Hans Spemann succeeded split the relatively large 
cells from salamander embryos in two with a baby hair, without killing the cells or their 
potential to form an enmbryo as long as the nucleus was preserved30. He went on to 
temporarily separate the cytoplasm from the nucleus to show that only the half of the cell 
with the nucleus would continue to divide and form an embryo, but that giving back the 
nucleus to the temporarily enucleated half of the cell would permit this cell to generate an 
embryo too31. Thus, the nucleus was shown to be programmed to- and essential to form an 
embryo. Based on this experiment, he suggested that a nucleus should be transplantable 
into an enucleated receiving cell and carry out its programmed destiny9. This prediction 
was confirmed by Briggs and King in 1952, when they performed the first ‘nuclear transfer’ 
experiment with tadpole embryos32. During their experiments, they made the interesting 
observation that such “cloning” attempts were more successful with cells from earlier 
embryos compared to later, more differentiated cells. However, future Nobel prize winner 
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John Gurdon made the important observation in 1958 that the nucleus from an adult cell 
can also form an embryo when transferred into an enucleated egg cell, that this capability 
is not lost upon cellular differentiation and adult cells thus retain all information required 
to make an embryo33. Somehow factors in the cytoplasm of the host egg cell can instruct a 
Figure 3. A historical overview of major events in stem cell- and reprogramming fields.
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differentiated cell to acquire an omnipotent state. 
During the 1970’s, 80’s and 90’s, several steps were made to expand nuclear transfer 
to mammalian animals, adult cell nuclei, and fully grown mammals including primates34-36. 
The first live mammal cloned from an uncultured adult breast cell, the sheep named ‘Dolly’, 
helped bring this technique under the attention of a wider public37. Definitive proof that 
a terminally differentiated cell could be reprogrammed to pluripotency, was supplied 
by performing nuclear transfer on T- and B-lymphocytes. As a mark of their terminal 
differentiation these cells had undergone DNA rearrangements of their antibody encoding 
sequences38 unlike their less differentiated precursors. The mice that were cloned from 
lymphocytes, contained the same DNA rearrangement in each of their cells.
The ability of cytoplasm factors to reprogram a nucleus of a differentiated cell was 
further demonstrated by alternative reprogramming methods. In 1976, Miller and Ruddle 
studied pluripotent embryonic carcinoma cells (ECCs), which, as discussed above, are derived 
from teratocarcinomas and can form tissues from all germ layers when injected in an early 
embryo39. They fused these ECCs with somatic cells and showed that the resulting cells were 
also pluripotent. Thus, the ECCs had reprogrammed the thymus cells. This experiment was 
also demonstrated with murine and human ESCs and another pluripotent cell line called 
embryonic germ cells (EGCs) which are derived from embryonic primordial germ cells40-42.
Next, the field looked to find which factors in the enucleated egg’s cytoplasm or 
pluripotent stem cell were responsible for the reprogramming of differentiated cells - factors 
dominant enough to overwrite the program of a differentiated nucleus. In Japan, Kazutoshi 
Takahashi and Shinya Yamanaka reasoned that factors in the cytoplasm of ESCs or egg cells 
should be capable of reprogramming a somatic cell’s nucleus as demonstrated by nuclear 
transfer and cell fusion reprogramming methods8. Therefore, they looked for factors that 
were known to be important for maintaining ESC fate, that were exclusively expressed in 
ESCs, and were known to contribute to ESC proliferation in culture. They found that a group 
of 24 candidates were capable of reprogramming somatic cells and systematically narrowed 
down the list to four transcription factors. The four ‘Yamanaka’ factors; OCT4, SOX2, KLF4 
and c-MYC, were capable of reprogramming adult murine cells. The resulting pluripotent 
cells were dubbed ‘induced Pluripotent Stem Cells’ (‘iPSCs’)8. His colleagues around the 
world, including our research group, quickly confirmed and expanded his results to different 
mammals including humans, and different cell types including terminally differentiated T- 
and B-lymphocytes43. Many candidates beyond the selected ‘reprogramming factors’ OCT4, 
SOX2, KLF4 and c-MYC, were later found to enhance reprogramming even though they are 
not essential. In this thesis, we describe the Yamanaka candidates in a screen for enhancers 
of reprogramming (chapter 3). It was found that the state of differentiation impacts the 
reprogramming efficiency; hematopoietic stem cells generated more iPSCs than blood 
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precursors who were in turn more easily reprogrammed than B-lymphocytes43.
To summarize, reprogramming towards a pluripotent stem cell is possible in sea 
urchins, but also in any mammal; from any kind of (un)differentiated somatic cell, and needs 
just overexpression of four transcription factors. Figure 3 gives an overview of the above 
historic events. However, an important question remains: why is it harder to reprogram 
adult cells? What are the molecular differences between differentiated somatic cells and 
pluripotent stem cells, and what factors control the pluripotent state? What roadblocks 
exist to prevent transformation to a pluripotent state? Further below we will discuss what 
changes take place inside a cell during reprogramming; changes that are generally more 
dramatic if the cell of origin has gone further down the path of differentiation. Understanding 
this would help us to understand why cells hold on to their cell fate normally, an important 
factor in optimizing iPSC generation and in our understanding of how they alter their fate in 
oncogenic transformation. 
Impact of research into stem cells and reprogramming 
Naturally, the fast developments involving direct reprogramming to pluripotency or to 
different somatic cells has fueled interest in stem cell-based therapies. On one hand, proof-
of-principle experiments, iPSC banks, drug testing experiments and even clinical trials 
have moved us closer to treating patients. On the other hand dubious clinics advertise 
stem cell treatments that are not supported by science and potentially dangerous; some 
serious concerns need to be overcome before pluripotent- or somatic stem cells can be 
applied that way44. In this thesis, we describe efforts to reproduce the promising and simply 
spectacular method of reprogramming by stressors to generate ‘STAP’ cells and -stem cells. 
Unfortunately, faults in the original data were discovered and independent laboratories 
were unable to reproduce the results. This thesis aims to better understand the mechanism 
of reprogramming, particularly the roadblocks to forming iPSCs, for several reasons:
To understand cell fate changes
The interest in cell fate changes occurring in vivo and that are induced in vitro seem to be 
stimulated by breakthroughs in reprogramming to pluripotent stem cells. Transdifferentiation 
entails an experimentally induced switch from one somatic cell type to another somatic cell 
type, without having to pass through a pluripotent state. Experiments of transdifferentiation 
were first described in 1987 when overexpression of the muscle transcription factor MyoD 
was found to turn fibroblasts directly into myoblasts45. Recently this line of research was 
revived, when the demonstrated plasticity induced by a handful of transcription factors 
used in iPSC derivation inspired transdifferentiation protocols using lineage specific factors. 
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Some of these protocols do require cells to go through a transient pluripotent state or 
can produce transiently pluripotent cells, possibly affecting safe application in the clinic46. 
There is also increased interest and understanding of plasticity in somatic tissues (in-vivo 
transdifferentiation), with labs showing remarkable ability of somatic cells to replace lost 
cells in their niche through transdifferentiation in liver, lung, intestine and even the inner ear. 
Mouse studies showed that inhibition of NOTCH signaling, an important factor in embryonic 
development, enables transdifferentiation of cochlear supporting cells to outer hair cells41. 
The latter are lost as a result from acoustic overexposure and age which causes irreversible 
hearing loss. In vivo transdifferentiation to replace lost hair cells could be the first curative 
approach to sensory hearing loss and is currently being tested in humans. Several molecules 
that were found to enhance reprogramming to iPSCs also enhance transdifferentiation, 
such as the four reprogramming factors47, inhibition of CAF-1, TGF-β signaling or GSK3b and 
supplementation of ascorbic acid48.
To understand a process that has many commonalities with oncogenesis
As detailed below, reprogramming to pluripotent stem cells shares molecular characteristics 
with oncogenic transformation, such as the switch in glucose metabolism, higher proliferation 
rate, reliance on oncogenes and a germline switch. However, resulting iPSCs do not share the 
same propensity to accumulate mutations and loss of the ability to differentiate; meaning 
that they could be seen as healthy counterparts to cancer cells. They thus serve as a useful 
model to study dramatic cell fate changes and as a reference for how non-cancerous cells 
conduct themselves when undergoing cellular transformation.
To improve speed and efficacy of patient-derived PSC generation 
Three clinic-oriented efforts can and to some degree have already benefitted from the iPSC 
technology: (i) regenerative medicine, aiming to replace damaged tissue in the patient with 
stem-cell derived transplants; (ii) disease modelling, using patient-derived cells to model 
and examine the development of diseases with poorly understood genetic predispositions; 
and (iii) drug testing, using these iPSC-derived disease models to predict drug response in a 
model close, or equal to the target patient.
An example is the idea of gene therapy; repairing genes that cause serious disease in 
a specific organ and giving the patient’s own, fixed cells back. A trial with HSC transplantation 
to cure the incurable severe combined immunodeficiency syndrome (SCID) showed its 
potential but also resulted in leukemia in some patients, frustrating further attempts at such 
therapy49. In recent years however, a series of increasingly powerful gene-editing techniques 
have been developed, as well as ever more affordable and thorough DNA sequencing 
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techniques and awareness of culture induced mutations. Together with better availability of 
patient tissues through reprogramming into iPSCs, very interesting efforts to cure diseased 
animals have been performed. This suggests that gene therapy for severe genetic disease is 
back on the table50. The next section discusses other applications for the clinic.
To facilitate therapeutic applications
Disease modeling: Using patient-derived iPSC lines, differentiated cells can be derived at 
a scale unimaginable with primary patient tissue. For example, neurons can be generated 
from expanded iPSCs from a patient. These secondary differentiated cells can be used for 
drug testing of thousands or even millions of compounds, to search for existing drugs that 
combat the patient’s disease51. iPSC banks hope to support research into patient-derived 
materials by deriving and maintaining up to 10,000 iPSC lines derived from patients for 
use on a not-for-profit basis52. Differentiation of iPSCs into neurons has been one of the 
most popular applications, giving access to a cell type that cannot normally be harvested 
through a biopsy. Another example is generation of organoids from iPSC to use for drug 
testing. A group treated organoids derived from iPSCs from cystic fibrosis (CF) patients with 
new CF drugs. Using the in vitro response of organoids on the drugs, they defined which 
subpopulation of patients would benefit most from which drug. They were able to link 
drug response to individual mutations of the CFTR gene53. The same group repaired the CF 
causing mutation with the CRISPR/CAS9 DNA editing tool to explore gene therapy for this 
single-mutation disease. Ideally, modern DNA editing techniques such as the CRISPR/CAS9 
system will proof reliable enough to generate healthy, repaired cells to give back to the 
patient they were derived from.  
Quality standards to be applied to research on induced pluripotent stem cells.
With the burst of publications on direct reprogramming following Yamanaka’s work, some 
concern exists about the quality of papers published under the pressure of the competition. 
One of the main concerns is to guarantee true pluripotency of PSCs that are derived 
experimentally. Unlike most medical and psychological fields, this field is depending on data 
quality more than measures of quantity and proper statistics. A guideline was published in 
2008 for the evaluation of pluripotent stem cells54. The guideline was widely supported by 
other stem cell groups55 and still is valuable to determine what scrutiny murine or human 
PSCs should be subjected to prior to paper submission. An important notion from this 
guideline is the hierarchy of pluripotency tests, from easy, scalable tests that are limited 
in specificity, to very time-consuming and expensive tests that represent the ultimate gold 
standard of pluripotency (Figure 4).
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For day-to-day monitoring, morphology is very helpful. Early changes in 
reprogramming mesenchymal cells such as fibroblasts, indicative of the mesenchymal-to-
epithelial transition (MET) taking place, can be seen by light microscopy as soon as 2 days 
after OKSM induction and reassure that the experiment is working56; cells reorganizing 
themselves into tightly packed colonies, and stably expanding in colonies even when OKSM 
expression is withdrawn are good visual indicators of pluripotent stem cells54.
The next step is a simple macroscopic stain for alkaline phosphatase, a stem cell 
marker that is not very specific for pluripotent stem cells but allows for macroscopic 
quantification of the iPSC clone yield. Strong staining of well-defined colonies after OKSM 
withdrawal correlates to endogenous pluripotency reporter expression, although this does 
not mean true pluripotency of each AP positive colony is guaranteed. A further step in 
demonstrating pluripotency is expression of an endogenous pluripotent stem cell specific 
transcription factor such as Oct4, Sox2 or Nanog, conveniently with a knocked-in fluorescent 
reporter such as GFP. Expression of these genes is very specific to PSCs.
Further proof of pluripotency requires transcriptional analysis by RNAseq or micro-
array, to establish a wider pluripotency-related transcription profile. Also, further functional 
testing such as in vitro directed differentiation54  can be tested along with the ability to maintain 
a PSC like growth pattern in appropriate PSC media, without exogenous factors. So-called 
‘partially reprogrammed’ iPSC can also be isolated after a reprogramming experiment and 
are dependent on residual expression of exogenous factors, either by continued expression 
of dox-inducible constructs, or 
upon incomplete silencing of 
constitutive vectors expressing 
OKSM. They can be converted 
to true iPSC by treatment 
with DNA demethylating small 
molecules57. Also, analysis of 
the transcriptional state of iPSC 
right after colony formation and 
withdrawal of exogenous factors 
suggests retention of some 
epigenetic memory of the cell-
of-origin. However, this memory 
is erased when passaging and 
culturing the iPSC longer in the 
absence of exogenous factors4.  
Formation of teratomas 
Morphology
AP-staining
Independence from exogenous factors
Expression of endogenous pluripotency genes
Transcriptional proling
In vitro functional testing; maintenance 
of PSCs and dierentiation potential
Teratoma formation with all germ layers
Chimera formation
All-donor cell derived embryo upon
tetraploid complementationM
or
e 
st
rin
ge
nt
M
ore convenient / scaleable
Figure 4Figure 4. Testing for pluripotency, a balance between 
stringency and convenience.
21
Introduction
1
upon subcutaneous injection can show differentiation into cell types from all germ layers58. 
More stringently, cells can be challenged to contribute to a chimeric mouse upon blastocyst 
injection, for which a contrasting coat color to the host embryo is most convenient to 
visualize chimerism. Chimera contribution is a very convincing test for pluripotency. One 
test is more stringent still, but technically even more challenging: tetraploid embryo 
complementation. This test uses tetraploid blastocysts generated by 2-cell fusion, which are 
incapable of forming other than extra-embryonic tissues. PSCs injected into such an embryo 
should give rise to the entire mouse59,60. iPSC clones that easily pass all other tests can still 
fail at tetraploid complementation. This deficiency has been linked to aberrant silencing of 
a single genetic locus, overcome by adding ascorbic acid to the reprogramming media61. 
Implications of failing this ultimate test are unclear as this test is usually not required for 
publication. 
In human cells, these high stringency tests are nearly impossible. Chimera-forming 
ability can be tested by generating interspecies chimeras, thus injecting human iPSC in mouse 
blastocysts, culturing the embryos shortly in vitro and assessing their contribution pattern 
and -efficiency in the very primitive embryo62. This procedure was found to be too inefficient 
for regular pluripotency testing and does not assess ability to form a viable neonate63,64.
Events during reprogramming of somatic cells to iPSCs
With the promise and pitfalls of research into reprogramming to pluripotent stem cells in 
mind, we will now discuss what is known about the molecular and cellular alterations during 
reprogramming. In this thesis, we mainly work with murine embryonic fibroblasts (MEFs); 
connective-tissue cells derived from the mesoderm lineage and harvested around day 14 
of embryonic development. Though embryonic, these cells are very far removed from 
the pluripotent state less than two weeks earlier. They differ at the levels of transcription, 
translation, and protein production, affecting their rate of cell growth and survival, their 
mode of metabolism, and their morphology (Figure 5). Here we zoom in on molecular and 
cellular changes that occur during OKSM induced reprogramming of MEFs to iPSCs.
Molecularly:
Transcription factors
Lineage-specific transcription factors are determinants of cell fate, depending on the context 
of a transcriptional network. Naturally, the transcriptional networks of MEFs and iPSCs differ 
strongly. Also, some transcription factors have no role in MEF or iPSC identity but affect the 
transition between the two cell types.  
22
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Several transcription factors were found to affect reprogramming based on 
their known function. When Takahashi et al realized that in the human system, early 
reprogramming cells at some point resemble cells from the primitive streak, they found 
that FOXH1, a transcription factor required for primitive streak specification, enhances 
reprogramming efficiency65. Many of the candidate reprogramming factors in their initial 
iPSC paper were transcription factors that, even though not essential, turned out to be 
upregulated during reprogramming and stimulated the induction of pluripotency. These 
include NANOG66 and UTF167. 
Reversily, the Tucker group reasoned that the transcription factor Bright/Arid3A 
might block reprogramming because its depletion led to increased developmental plasticity 
and pluripotency factor expression; indeed depletion in MEFs enhanced conventional 
reprogramming and even induced spontaneous reprogramming68. 
Another interesting group of transcription factors known to help induce 
reprogramming, and capable of replacing OCT4 or SOX2 from the 4 factor mix, consists of 
lineage specifiers such as GATA3, CEBPα and PAX169. Notably, these factors individually steer 
PSCs towards differentiation to a mesendodermal or ectodermal lineage. When combined 
they synergistically facilitate a pluripotent state and replace reprogramming factors OCT4 and 
SOX2. The authors suggest that the balance between the differentiation factors results in a 
neutral, pluripotency-prone state. Although these factors are not upregulated in pluripotent 
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stem cells, their temporary, combined overexpression steers cells towards pluripotency69.
Transcriptional regulation: DNA methylation and chromatin structure
The epigenetic program of MEFs changes during reprogramming, meaning that 
transcriptional regulation is altered in an inheritable manner without altering the DNA. This 
epigenetic program is enacted by DNA methylation, chemical modification and composition 
of the chromatin around the DNA, and binding of transcription factors and non-coding RNA 
strands to the DNA and chromatin. A particular gene may be regulated by all different modes, 
affecting transcription differently: DNA methylation is highly stable but slow to change while 
switching out of different histone subunits by histone chaperones is more dynamic70,71. As 
a result of epigenetic regulation, target genes may be up- or downregulated, or transiently 
altered during intermediate stages of reprogramming70,72,73.
In general, pluripotent cells maintain their genome in a more transcription factor 
accessible state, with ‘open chromatin’, to facilitate differentiation in many directions 
when prompted. On a molecular level, this is established by overall lower levels of DNA 
methylation at gene promotors of key developmental regulatory genes62. DNA methylation 
of gene promotors is a potent inhibitory mark to transcription of the target gene. It can 
be removed promptly during reprogramming via nuclear transfer, but during four-factor 
reprogramming is removed only partially. Marks reminiscent of the cell-of-origin can be 
detected in the iPSC, that only fade away after continued passaging of the iPSCs4,74. Remnant 
DNA methylation influences the differentiation potential of iPSC; there is a preference for 
forming tissues similar to the cell-of-origin and they contribute poorly to chimeras3,4. DNA 
methylation also influences the ability to be reprogrammed; higher overall levels of DNA 
methylation reduced nuclear transfer efficiency75. 
Induced pluripotent stem cells have been reported to aberrantly gain DNA methylation, 
for example hypermethylation of the Dlk1-Dio3 locus6. The resulting silencing of this locus 
prevents iPSCs from fulfilling the most stringent test of pluripotency: the formation of a 
complete mouse embryo upon injection in a tetraploid blastocyst (which itself can only form 
extraembryonic tissues). This aberrant silencing was overcome by culturing reprogramming 
cells with ascorbic acid, a cofactor to DNA and histone demethylases6,61. Ascorbic acid was 
already known to enhance reprogramming efficiency48. Moreover, passaged iPSC derived 
using ascorbic acid, a co-factor to various chromatin- and DNA methylation modifying 
enzymes, are indistinguishable from ESCs when compared within the same genetic 
background6,61.
On a gene-by-gene level, specific loci are activated or inactivated during 
reprogramming. Upon the start of reprogramming, so-called ‘euchromatic’ regions 
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with somatic genes contain chromatin that is accessible to transcription but need to be 
deactivated. This is achieved by factors such as the polycomb repressive complex (PRC2) that 
deposits repressive H3K27me3 (Histone 3 Lysine 27 trimethylation) marks on the chromatin. 
Also, inhibition of Dot1l- which keeps these loci active through deposition of H3K79me2- 
facilitates somatic gene repression76,77. In this thesis, inhibition of DOT1l amongst other 
factors is shown to dramatically reduce reprogramming time (chapter 4).  
Activation of heterochromatin-containing genes essential to pluripotency is 
facilitated by histone demethylases that remove repressive H3K9me3, or by inhibition of 
histone methyl transferases that deposit these repressive marks such as  G9a, Suv39h1 and 
Suv39h278-80.
Besides enzymes that deposit or remove these chemical modifications of histones, 
non-enzymatic DNA binding factors can also act as chromatin modulators by binding DNA 
and recruiting activating histone modifications. An example is Thrithorax complex member 
WDR5 which correlates with global levels of the activating H3K4me3 mark and is upregulated 
during reprogramming. Wdr5 knockdown-fibroblasts reprogram less efficiently81. In chapter 
5 we find that elevated WDR5 levels could explain more efficient reprogramming by 
knockdown of polyadenylation factor Nudt21.
In PSCs, one can identify three groups of loci depending on their DNA methylation- and 
chromatin state and corresponding accessibility for reprogramming factors82. For example, 
MEF specific and mesenchymal genes are immediately accessible by the transcription 
factors, and are inactivated first by chromatin modifications, their inactivation made more 
permanent later in the reprogramming process by DNA methylation70. Promotors and 
enhancers of early stem cell genes can be bound by some of the reprogramming factors 
that serve as pioneering factors to open up the chromatin. As a late step, heterochromatic 
regions with pluripotency-specific genes are demethylated to permit OKSM-binding and 
achieve stable expression of the pluripotency program. Some genes are not activated but 
brought into a rapid-inducible, ‘bivalent’ state; these are genes not expressed in pluripotent 
cells but can be rapidly activated as a first step in differentiation. They contain both active 
and repressive chromatin marks (H3K4me and H3K27me, respectively). 
RNA translation; alternative polyadenylation
There is an increasing understanding of the role of translational regulation of mRNAs, 
influenced by secondary structure of transcripts but also by binding of micro-RNAs (miRNAs) 
to untranslated regions beyond the stop codons (3’UTRs). MiRNAs have been found to have 
profound roles during development. When the miRNA biogenesis machinery is impaired, 
pluripotent stem cells have reduced differentiation potential and reprogramming to iPSCs 
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is impaired83,84. Specifically, the miR290/295 and miR302/367 clusters of miRNAs are highly 
expressed in pluripotent cells, important for human iPSC generation and ESC proliferation, 
and downregulated during early embryonic development72. MiRNAs affect their specific 
target mRNA by binding the 3’UTR, thereby preventing translation or marking the transcript 
for degradation. Binding sites for miRNAs and regulatory RNA binding proteins (RBPs) along 
the 3’UTR are essential for the mRNA to be regulated in this manner.  
Many 3’UTRs have multiple sites at which the UTR can be cleaved and polyadenylated 
by a process called alternative polyadenylation (APA)85 (Figure 6). Comparing differentiated 
cells with stem cells or iPSCs; or healthy cells with cancer cells, a general tendency for 
shorter 3’UTRs of transcripts has been described in less differentiated and more proliferative 
cells. This evidence suggests that the cleavage- and polyadenylation processes are altered 
during reprogramming and oncogenesis86-89. Transcripts that are polyadenylated harbor 
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Figure 6. Alternative polyadenylation of a single mRNA molecule and regulatory 
consequences.
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multiple polyadenylation sites (PAS), either within in the same or different exons. How the 
choice between multiple PAS is made is largely unknown; different models suggest a host 
of different influences, such as RNA binding regulatory proteins, the affinity of the APA 
machinery for the PAS, and transcription factors that recruit APA machinery components. 
Concentration of components of the cleavage- and polyadenylation complex 
can influence PAS choice: this has been shown previously for cleavage factor CFIm68135. 
Depletion of CFIm68 leads to a widespread shift to more proximal PAS. In this thesis, we 
find that downregulation of a component of the APA machinery, CPSF5/CFIm25, encoded by 
Nudt21, enhances reprogramming efficiency of MEFs into iPSCs (chapter 5). Transcriptome-
wide analysis of PAS site choice (PAS specific RNAsequencing; ‘PAS-Seq’) reveals APA occurs 
upon Nudt21 suppression. This occurs for many transcripts, including transcripts involved in 
reprogramming or pluripotency.
Proteome
The overall proteome of MEFs, reprogramming- and pluripotent cells is harder to study than 
the genome or transcriptome due to the limitations of proteomic analysis. Recent advances 
in multiplexing proteomics samples and improved data analysis for mass spectrometry 
promise to change this90. It is very important nonetheless as RNA levels may have no relation 
to resulting protein levels due to translational regulation, post-translational chemical 
modifications, protein tagging with ubiquitin or sumo peptides and protein degradation. 
A study directly comparing protein and RNA abundance found that protein abundance 
was primarily determined at the level of translation91. Moreover, organization of proteins 
in compartments of the cell may define the impact of a protein on the cell’s identity, as 
exemplified by B-catenin localization in gut stem cells92,93.
Proteomic analysis of reprogramming intermediates, similar to the molecular 
characterization of intermediates in chapter 3, has shown that pathways and associated 
proteins are regulated during different phases of reprogramming and that these proteins 
are important inhibitors or facilitators of reprogramming. An example is the nucleoporin 
NUP210 which is essential for reprogramming into iPSCs and was identified by proteomic 
analysis of reprogramming cells73.
Sumoylation
One particularly interesting protein modification is the tagging by the ubiquitin-like sumo 
peptide, a process called ‘sumoylation’. One or multiple SUMO peptides can be attached to 
a lysine, usually within a consensus sequence of the target protein. This posttranslational 
modification is referred to as ‘sumoylation’. This pathway is highly conserved; SUMO precursor 
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proteins are expressed in all eukaryotes that have been tested so far84. Sumoylation can 
affect target protein trafficking, stability, interaction with other proteins or DNA; depending 
on the multiplicity and paralog (SUMO1, SUMO2/3, SUMO4) of the SUMO tag85-87 (Figure 
7). The SENP group of enzymes can remove SUMO from its target. The SUMO paralogs are 
functionally redundant to some degree; however, in specific contexts, different peptides 
may have an opposite effect on the target protein; see examples below. 
In this thesis, we find that depletion of SUMO2 increases reprogramming efficiency 
and speed. However, the abundance of SUMO2 target proteins makes narrowing down 
the mechanism difficult. SUMO2 was previously described to be essential for embryonic 
development, unlike SUMO1 or SUMO3, suggesting a regulatory role for SUMO2 sumoylation 
in the early embryo88. Another study in HeLa cells found that active sumoylation inhibits 
expression of RNAs required for polymerases, histones, and protein biogenesis genes. Also, 
the SUMO machinery seemed to play a role in repressive chromatin found in senescent 
cells; suggesting that sumoylation of chromatin associated factors inhibits cell growth and 
proliferation89. However, no difference in cell proliferation was found upon downregulation 
of SUMO2 during reprogramming of embryonic fibroblasts (Chapter 4, this thesis). One 
report describes that preventing sumoylation by all SUMO variants through downregulation 
of the common sumoylation enzyme UBC9 inhibits reprogramming. However, different 
SUMO paralogs may have opposing effects, and loss of all sumoylation may be toxic90,91, 
explaining why the effect is opposite to specific SUMO2 downregulation. Also, the same study 
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Figure 7. Protein-level regulation by sumoylation.
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describes a loss of pluripotency in UBC9 depleted ESCs, which may reduce reprogramming 
yield upon reaching the iPSC stage. We found that iPSC derived upon SUMO2 depletion 
had no apparent problem in maintaining pluripotency or giving rise to healthy high grade 
chimeric mice. This points to the importance to regard sumoylation, not as a single mode of 
regulation. Instead one can specify the effects of the different Sumo paralogues, the site of 
sumoylation and the multitude of sumo peptides that are conjugated to the target protein. 
For example, many studies use antibodies or use genetic models that do not distinguish 
between SUMO paralogs SUMO1 and SUMO2. 
Notably, sumoylation has been implicated in different methods of repression of 
some genes and of activation of transcription of other genes through DNA methylation 
or chromatin modification92. Some observations that point to a possible mechanism in 
reprogramming are:
- Inhibition of transcriptional synergy of C/EBPα, a transcription factor previously 
implied in facilitating reprogramming of B-cells into iPSCs94;
- Increasing stability of GSK3b, a signaling molecule whose inhibition enhances 
reprogramming95,96; 
- Inhibition of c-MYB activity and downregulation of its targets such as reprogramming 
factor c-MYC upon stress; downregulation of SUMO-2 might enable higher expression 
of c-MYB targets97.
- Stimulation of SMAD4 transcriptional activity, therefor stimulating TGF-β signaling; 
inhibition of TGF-β is known to enhance reprogramming95; 
- Roles in both transcriptional activation and repression could favor a differentiated 
state, whereby inhibition of SUMO-2 could facilitate transcriptional repression and 
activation required for reprogramming to iPSCs100.
Cellular signaling
Cell fate determining transcription factors and chromatin modulators have been the focus 
of many studies looking into the mechanisms behind reprogramming. Regardless, signaling 
pathways responding to external signals play a major role in facilitating or inhibiting 
reprogramming of MEFs to iPSCs. One of the earliest examples is the TGF-β pathway, 
inhibition of which by a small molecule inhibitor or by the antagonistic factors BMP4 
or SMAD7, boosts reprogramming96,97. Of course, this fits with the necessity to undergo 
mesenchymal-to-epithelial transition, since TGF-β signaling is upregulated in mesenchymal 
cells.
Another important signaling pathway implied in reprogramming is the WNT pathway. 
WNT is an important factor both in stem cell self-renewal and somatic cell differentiation. 
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According to a study which dissected WNT’s role during early and late phases of 
reprogramming, WNT  inhibits early reprogramming steps but enhances the later steps98. 
In this thesis (addendum to chapter 3) we describe a role for embryonic stem cell- 
specific Ras (ERas), a constitutively active RAS family member expressed in pluripotent stem 
cells and upregulated during reprogramming. Overexpression of ERas boosts reprogramming 
efficiency, independent of the growth factor presence needed by somatic RAS members 
KRas and NRas.    
Metabolism
As mentioned above, altering the mode of metabolism is essential to facilitate the rate 
of cell proliferation. An important metabolic switch that occurs during reprogramming of 
MEF, is from predominant oxidative phosphorylation of glucose, which yields more cellular 
energy and just CO2 and water as end products, to predominantly aerobic glycolysis, 
which yields less energy but produces building blocks for fatty acids, amino acids and 
nucleotides99. Important glycolysis regulating factors such as hexokinase are upregulated 
during reprogramming; and inhibition of glycolysis inhibits reprogramming99. Importantly 
the pentose phosphate pathway (PPP), which leads to the production of nucleotides, 
is activated during reprogramming; the PPP is fueled by aerobic glycolysis. Threonine-
glycine metabolism is also activated to fuel the 1-carbon pathway to give rise to S-Adenyl-
methionine, a universal methyl donor necessary for chromatin- and DNA methylation. This 
in turn is implicated in facilitating activating chromatin modifications (H3K4 trimethylation) 
for a pluripotent state100.
In this thesis, we study the oncogenic mutations in the important metabolic enzymes 
Isocitrate Dehydrogenase 1 and -2 (IDH1 and IDH2). These mutations alter the product of the 
enzyme and as a consequence the ‘oncometabolite’ 2-HG is produced at high levels. Mutant 
IDH (mIDH) has been implied in impaired differentiation in leukemic cells, possibly through 
interfering with establishment of a differentiated chromatin state by epigenetic regulators 
that are inhibited by 2-HG. Other effects of mutant IDH, such as disturbance of metabolic 
pathways, cannot be ruled out. Our analyses suggest that early steps of reprogramming 
are facilitated by mIDH expression; later steps of establishing pluripotency appear mostly 
unaffected. Loss of MEF identity as monitored by Thy1 expression is enhanced in mIDH 
expressing reprogramming cells. This could be due to aberration of metabolic pathways as 
well as interference with 2-HG sensitive epigenetic regulators (chapter 6).
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Genomic alterations during reprogramming
There have been various concerns regarding the genomic alterations brought on by 
reprogramming somatic cells into iPSCs. The original reprogramming protocols required 
infection of MEFs with viral vectors carrying the four reprogramming factors8. This results 
in random viral insertions in the genome, potentially disturbing endogenous genes or 
regulatory sequences. This raised the suspicion that specific insertions were required 
to form iPSC. Our lab did find that some insertion sites were common amongst multiple 
independent iPSC lines, such as one that perturbs TGF-β signaling, leading to the discovery 
of its negative role in reprogramming95. However, no insertion sites were common to all iPSC 
lines excluding the requirement for particular DNA mutations during iPSCs derivation101. 
Later, successful iPSC derivation without viral vectors, using mRNA, protein, or episomal 
vectors to deliver the four factors, further strengthened this point102-105. 
To study general genomic damage in iPSC and iPSC-derived transplantable tissues, 
reprogramming cells and resulting iPSC have been examined for genomic stability and 
random mutations during the prolonged time in culture required for deriving and expanding 
iPSCs. Of a considerable amount of mutations, in iPSC lines, a large proportion can be traced 
back to the parent cell line106,107. The remaining mutations however seem to be caused 
specifically by the reprogramming process108. Thus, careful analysis of iPSC clones seems 
to be required to ensure safety of iPSC-derived transplants for patients and to avoid bias in 
experiments with iPSC-derived cells.
On the cellular level:
Morphology
By far the most obvious change during reprogramming is the transition from large, spread-
out, highly structured fibroblasts to small, round, dense colony-forming pluripotent 
cells. Under the light microscope, unstained iPSC can no longer be observed individually; 
the clonally expanding cells form three-dimensional clumps, densely packed together. 
Macroscopic morphology is not a specific identifier of their pluripotent state, but facilitates 
monitoring and picking iPSC colonies for expansion. However, one can study morphology 
at the nanoscale using electron microscopy (EM); this has been done for murine109 and 
human110 pluripotent stem cells. These groups found iPSCs to be indistinguishable from 
ESCs. When slicing through an iPSC colony with EM, they describe a more regular, smaller 
and round cell compared to the fibroblast of origin. Also they note that like ESCs, iPSCs form 
stronger adhesions to each other, and less to their surrounding fibroblasts or cell culture 
surface. MEFs on the other hand primarily attach to the culture surface, not each other. 
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They also noted that mitochondria in ESCs and iPSCs are more rounded in shape with less 
internal membranes compared to MEF, possibly linked to their altered metabolic state and 
overall reduced mitochondrial activity. To illustrate the distinct mitochondrial function in 
stem cells: mitochondrial staining can be used to distinguish hematopoietic stem cells from 
their progeny in cord blood111. However, this has not been shown to help characterizing 
pluripotent stem cells. 
Cell growth and survival
Although embryonic fibroblasts still readily divide; they gradually slow down their rate 
of proliferation, to retreat to a senescent state eventually (depending on derivation and 
culture conditions, after 8 passages or later). Senescence is an irreversible quiescent state 
possibly followed by apoptosis and is an important mechanism for somatic cells to prevent 
malignant transformation upon cellular aging112. Immortalization by downregulation of the 
apoptosis machinery through knockdown of Trp53 is a major roadblock of reprogramming113. 
Moreover, it has been suggested that any cell will reprogram eventually if it goes through 
enough cell divisions, when using cells that will not senesce114.
Pluripotent cells continue to proliferate when cultured in conditions inhibitory to 
their differentiation. During reprogramming, induced pluripotent cells reactivate their 
telomerase to maintain telomere length115, downregulate pro-apoptotic factors113,  and 
adjust their mode of metabolism to facilitate cell growth116. Their rate of proliferation is 
increased so much, that by the time the reprogramming process is completed, the resulting 
iPSCs have started to outnumber the reprogramming-resistant fibroblasts by far, despite low 
reprogramming efficiencies. 
Germline switch; mesenchymal-to-epithelial transition (MET)
At several stages during development, starting with gastrulation, embryonic cells go 
through an epithelial-to-mesenchymal transition (EMT) or mesenchymal-to-epithelial 
transition (MET). A mesenchymal-to-epithelial transition is required for reprogramming of 
mesenchymal fibroblasts to the epithelial-like pluripotent stem cells56,117,118. Cdh1, which 
encodes E-cadherin, is a major regulator of the epithelial state. Cdh1 is downregulated during 
EMT and involved in regulation of pluripotency119. Mesenchymal transcription factors such 
as SNAIL, TWIST and ZEB as well as mesenchymal specific surface markers THY1 and CD44 
are downregulated during reprogramming118,120. EMT inducer TGF-β blocks reprogramming 
and inhibition of its receptor enhances reprogramming95. Moreover, EMT-related miRNAs 
are downregulated and MET-related miRNAs upregulated56. In conclusion, early essential 
steps of reprogramming fibroblasts to pluripotent stem cells closely resemble the MET 
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required for normal development. 
Epithelial cells do not require MET to form iPSCs. Indeed, several studies comparing 
reprogramming efficiency of cells of epithelial origin (e.g., keratinocytes) to cells of 
mesenchymal origin (e.g., fibroblasts) found that epithelial cells reprogram with a much 
greater efficiency121,122. However, others found no difference54. Also, a direct epithelial to 
mesenchymal cell comparison is difficult since these cell types differ in more aspects than 
just their origin. Also, reprogramming 
factor Klf4 is highly expressed in 
epithelial cells, explaining why 
epithelial cell reprogramming does not 
require exogenous KLF4 expression56 
and hypothetically contributing to 
a higher reprogramming efficiency 
of epithelial cells in general. To our 
knowledge, no study was performed 
comparing epithelial and mesenchymal 
cell types on a molecular level during 
reprogramming towards iPSC. 
Experimental parameters of 
reprogramming: Markers to 
follow reprogramming of MEFs 
into iPSCs
Certain proteins are of importance 
not just to understand the biology 
of reprogramming, but as reference 
points for studying it. We use several 
proteins as markers for different stages of reprogramming or as pluripotency markers. Cell 
surface markers are useful in combination with live cell staining and flow cytometry. Defined 
reprogramming intermediates have been isolated based on a combination of cell-surface 
markers70,123. The first intermediates lose expression of MEF-marker THY1, then they start 
expressing stem cell markers Alkaline Phosphatase (AP), SSEA1 and later EPCAM and PECAM. 
Finally, we use a pluripotency-specific transcription factor such as Oct4 through a knock-in 
of a GFP reporter at the Oct4 locus, as a sign of reaching pluripotency. Other pluripotency 
reporter systems use Nanog or Sox2124. For macroscopic quantification of reprogramming 
efficiency, the stem cell specific expression of Alkaline Phosphatase (AP) can be used in a 
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Fluorescence microscopy:
Oct4-GFP reporter
Figure 8
Figure 8. Characterisation methods of pluripotent 
stem cell colonies in culture.
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substrate-based assay, giving strong red staining to iPSCs colonies so they can be counted 
without a microscope (Figure 8; see section on quality standards above). This assay is not as 
stringent as pluripotency- transcription factor-reporters as it is expressed very early during 
reprogramming, well before establishment of a pluripotent state. However, in combination 
with the macroscopic colony morphology and persistence beyond withdrawal of ectopic 
reprogramming factors, it correlates well with expression of pluripotency reporters such as 
Oct4-GFP.
Experimental parameters of reprogramming: Independence from exogenous 
factors
When doxycycline is withdrawn from the culture, only bona fide iPSCs that have fully activated 
their endogenous pluripotency network, can maintain stem cell phenotype, whereas any 
partially reprogrammed cells or reprogramming intermediates regress back to a MEF-like 
state within 48 hours (Mikkelsen et al57 and own observations). Thus, it is important to note 
that the transition is stable and independent from expression of the exogenous factors 
used to induce reprogramming. For example, exogenous Oct4 expression could activate the 
endogenous locus by itself through a positive feedback loop64, but cells are not considered 
fully reprogrammed iPSC until they keep expressing endogenous Oct4 after withdrawal of 
exogenous Oct4. The molecular and cellular characteristics of iPSC described above, are not 
dependent on exogenous signals other than those present in ESC growth conditions, once 
they are established during reprogramming.
A view of oncogenic transformation from a reprogramming 
perspective 
Similarities between somatic cell reprogramming and oncogenic 
transformation: germline switches
Cancer cells use mechanisms of transformation normally only seen during development- or 
during somatic cell reprogramming. Somatic cell reprogramming to pluripotency results in 
embryonic stem cells capable of forming healthy adult animals; oncogenic transformation 
results in cancer cells that form unorganized tumors and acquire many cellular aberrations 
in the process. We study stem cells to generate healthy new tissues from them and cancer 
cells to learn how to kill them. Nevertheless, these cells and the processes that form them 
share important molecular characteristics.
Here we will shortly discuss similarities with oncogenic transformation. A well-known 
similarity is the acquisition immortality; the ability to divide without senescing; along with 
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a heightened proliferation rate. This leads to expansion of the cell population, regardless of 
growth signals from the environment or endogenous signals of DNA instability in the case of 
cancer. Molecularly there are many parallels as well: 
DNA methylation and modulation of chromatin structure 
Although cancer is still considered a disease of the DNA, caused by DNA mutations and 
progressive genomic instability, the role of epigenetic reprogramming during transformation 
has been recognized as well. In a proof-of-principle experiment, a Japanese group 
reprogrammed cells in vivo using the Yamanaka factors in an inducible reprogrammable 
mouse model similar to our model. They found that by withdrawing the reprogramming 
factors before iPSC had formed in the mice, they instead got tumors in various tissues with 
widespread DNA methylation changes; however cells from the same experiment could still 
be reprogrammed into iPSC and generate normal mouse tissue suggesting no oncogenic 
DNA mutations had occurred125. These results made the point that epigenetic aberrations 
alone may suffice to turn somatic cells into cancer cells. Widespread epigenetic alterations 
found in cancer cells as well as mutations in epigenetic regulators support this point126. 
For example, cancer-associated hypermethylation was found  to occur very frequently at 
target sites of the repressive polycomb complex 2 (PC2), which is an essential repressor of 
differentiation associated genes in pluripotent stem cells127. 
At the same time, global hypomethylation, is a hallmark of cancer as well as pluripotent 
stem cells. DNA methyltransferases (DNMT1, DNMT3A) which maintain or establish DNA 
methylation are lost in some cancers or experimentally found to support malignancy when 
inhibited128-130.Inhibition of DNMT1 enhances reprogramming to iPSCs131. Finally, cancer cells, 
in this case melanoma, have been found to use epigenetic reprogramming to temporarily 
gain independence from pathways inhibited by cancer drugs; this therapy resistance is lost 
when treatment is paused due to the growth advantage inferred by the target pathways. 
This way, cancer cells use epigenetic programming to adapt to the environment132.
Translational regulation
Regulation of protein production at the RNA level is also similar between stem cells and 
cancer cells in some cases. For example, alternative polyadenylation which determines 
protein production by manipulating miRNA binding sites or truncating proteins, occurs also 
in cancer cells, upregulating oncogenes by shortening their 3’UTR86.
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Metabolic switches
Transforming and reprogramming cells share an important switch of glucose metabolism: 
from oxidative phosphorylation to aerobic glycolysis. Cancer cells make this switch to 
facilitate cell division, called the ‘Warburg effect’ after its discoverer Otto Warburg133. 
Glycolysis increases glucose uptake in tumors to such an extent that can be used for 
diagnostics. To monitor cancer metastasis, imaging where radioactive labeled glucose is 
highly used provides a clear image (PET scan).
Scope of this thesis
The introduction discusses progress in the field of induced pluripotency in the 10 years 
since the discovery of iPSCs, about general stem cell and reprogramming fields 100 years 
prior, and what we have learned about the biology of pluripotent stem cells and possible 
applications. This thesis aims to expand our understanding of reprogramming towards a 
stem cell state and use this as a model for oncogenesis.
A model for reprogramming murine somatic cells into pluripotent stem cells
In chapter 2 we describe a model system that enabled studying reprogramming to 
pluripotency in a more reproducible and standardized way than was possible before. This 
model system, named the ‘reprogrammable mouse’ was used in all following projects to 
generate murine iPSCs. During the development of this model system I supported the first 
author with verification experiments and cell culture. 
Defining transitions during reprogramming; Screening for enhancers of 
reprogramming
Chapter 3 describes efforts from our lab to characterize intermediate stages of reprogramming 
into iPSCs on an RNA and chromatin level. The addendum describes a more in-depth, 
systematic candidate-based screen for enhancers of reprogramming. This screen identified 
the embryonic specific signaling protein ERas as a potent enhancer of reprogramming, 
validating the finding that this factor is upregulated in reprogramming intermediates in 
chapter 3.
Screening for inhibitors of reprogramming
In chapter 4 and 5 we sought to perform an unbiased screen for protein-coding genes 
involved in reprogramming. We applied a genome-wide, RNA interference screens, and 
36
Chapter 1 
design a screening method to be able to apply this during reprogramming into iPSCs. 
The addendum specifies the dilemmas and considerations required to perform a large 
scale screen. The screen identified the sumoylation peptide SUMO2 and the alternative 
polyadenylation factor CPSF5 (Nudt21) as important inhibitors of reprogramming. Reduction 
of SUMO2 levels allowed for more efficient and faster reprogramming in mouse and human 
model systems, independent of known reprogramming-enhancing pathways, suggesting 
an important role for SUMO2-sumoylation in maintaining cell fate. CPSF5 is a regulator of 
3’UTR length by determining the site of cleavage and polyadenylation of 3’ UTRs of many 
messenger RNAs, thereby modulating sensitivity to microRNAs and protein length in the 
case of intronic polyadenylation sites.  
Modeling cancer during reprogramming
In chapter 6 we apply the ‘reprogrammable mouse’ model system to study an oncogenic 
mutation in a metabolic enzyme. Mutations in isocitrate dehydrogenases (IDH) 1 and 2 
occur frequently in glioblastomas, leukemias and cholangiocarcinomas. Mutations in IDH1 
or IDH2 are dominant and neomorphic; wildtype IDH generates the metabolite α-KG, but 
mutant IDH generates the highly similar oncometabolite 2-HG. Here we characterize early 
reprogramming cells as a model for oncogenic transformation, when they express mutant 
IDH1 and IDH2. We look both at transcriptional and metabolic perturbations as well as 
functional outcome. The results suggest that mutant IDH derails reprogramming, facilitating 
loss of cell identity but not promoting gain of pluripotency. Ascorbic acid is a co-factor to 
α-KG dependent enzymes including DNA demethylating TET enzymes and Jumanji domain-
containing histone demethylases134, Partial reversal of the phenotype by ascorbic acid 
strengthens the hypothesis that specific epigenetic regulators are affected by mutant IDH. 
Finally, we specify which metabolic pathways are affected transcriptionally and metabolically 
by the mutant enzymes.
Assessing a role for cellular stress during reprogramming
In chapter 7 we revisit a new approach to establishing pluripotency, as was described to occur 
by applying mechanical or chemical stress to somatic cells. Unfortunately, several stem cell 
laboratories including our own showed that this method was irreproducible and the original 
data a result of artifact or sample mix-ups. This chapter highlights a vulnerability in the way 
researchers and journals assess new discoveries, which is a consequence of the high interest 
in the stem cell field combined with pressure to publish high impact manuscripts. Moreover, 
it documents a large and swift collaboration between normally competing researchers to set 
the record straight. 
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Abstract
The derivation of induced pluripotent stem cells (iPSCs) usually involves the viral 
introduction of reprogramming factors into somatic cells. here we used gene targeting to 
generate a mouse strain with a single copy of an inducible, polycistronic reprogramming 
cassette, allowing for the induction of pluripotency in various somatic cell types. as these 
‘reprogrammable mice’ can be easily bred, they are a useful tool to study the mechanisms 
underlying cellular reprogramming. 
Introduction
Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by 
transcription factors c-MYC, KLF4, OCT4 and SOX21. The study of the molecular mechanisms 
underlying this conversion is hampered by the low efficiency of reprogramming and by the 
requirement to introduce the reprogramming factors into target cells. To circumvent these 
constraints, ‘secondary systems’ have been developed, which are based on iPSCs made with 
doxycycline-inducible lentiviruses2–6. 
Secondary systems based on viral vectors have several limitations. First, many iPSC 
lines show viral transgene silencing, leading to heterogeneous expression and thus variable 
results. Second, viral integrations at random genomic locations can alter endogenous gene 
expression. Third, the breeding of mice derived from such iPSCs is complicated by the need 
to screen their offspring for multiple viral transgenes. 
Results
To develop an improved reprogramming system, we placed a doxycycline-inducible 
polycistronic cassette encoding the four reprogramming factors OCT4, KLF4, SOX2 and 
c-MYC (OKSM)7 in the 3′ untranslated region of the Collagen type I, alpha 1 gene (Col1a1, 
herein referred to as Collagen)8 (Figure 1a). This gene targeting was mediated by Flp 
recombinase and was performed in embryonic stem cells (ESCs) that express an optimized 
reverse tetracycline-dependent trans-activator (M2-rtTA) from the ubiquitously expressed 
Gt(ROSA)26Sor (Rosa26) locus8. We refer to this allele as Rosa26-rtTA. 
The OKSM cassette integrated into the Collagen locus in 12 of 12 picked ESC clones 
named Collagen-OKSM ESCs (Supplementary Figure 1). To test the function of this transgenic 
system in comparison to a viral secondary system, we isolated mouse embryonic fibroblasts 
(MEFs) derived from either Collagen-OKSM ESCs (called Collagen-OKSM MEFs) or from iPSCs 
originating from Rosa26-rtTA MEFs carrying two copies of a doxycycline-inducible lentiviral 
vector expressing the same polycistronic OKSM (Figure 1b). Upon culture in the presence 
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Figure 1. An ESC-based reprogramming system. (A) In Collagen-OKSM MEFs, cDNA 
encoding the optimized reverse tetracycline-dependent transactivator (M2-rtTA; triangles) 
was targeted to the Rosa26 locus and a polycistronic cassette encoding OCT4 (O), KLF4 
(K), SOX2 (S) and c-MYC (M) (OKSM) was targeted to the Col1a1 locus under control of a 
tetracycline-dependent promoter (tetOP). In the presence of doxycycline (dox.), M2-rtTA 
binds to tetOP, inducing expression of the four reprogramming factors. (B) Outline for a 
secondary reprogramming system based on Collagen-OKSM ESCs or Lenti-OKSM iPSCs. (C) 
Brightfield images of a chimera-derived MEF iPSC clone at passage 0 (top, dark appearance 
due to dying or differentiating cells at the centre of the colony) and after three passages 
(bottom). (D) Alkaline phosphatase staining of colonies derived from Collagen-OKSM MEFs 
or MEFs carrying two copies of a doxycycline-inducible lentiviral vector encoding the same 
polycistronic cassette (Lenti-OKSM). (E) Efficiency of iPSC formation as a percentage of 
input cells (n = 3). (F) Fluorescence images of Collagen-OKSM MEFs and Lenti-OKSM MEFs 
cultured for 2 days in the presence of doxycycline and stained with an antibody to Oct4 
(anti-Oct4). Percentages of Oct4+ cells are indicated. (G) Histological section through a 
teratoma derived from a Collagen-OKSM iPSC clone showing differentiation into ectodermal 
(EC; keratinized epithelium), endodermal (EN; glandular structures) and mesodermal (MS; 
muscle) derivatives. (H) Image of an adult coat color chimera (arrow) from MEF-derived 
iPSCs. Also shown is a nonchimeric BDF1 mouse. (I) Image of an embryonic day (E)13.5 
embryo derived after injection of MEF iPSCs into tetraploid blastocysts (‘all iPSC’ fetus). 
Scale bars, 500 µm (C), 10 mm (D), 100 µm (F), 50 µm (G) and 2 mm (I). 
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of doxycycline, both Collagen-OKSM MEFs and Lenti-OKSM MEFs formed colonies with ESC-
like morphology that stained positive for pluripotency-associated markers such as alkaline 
phosphatase, NANOG and endogenous OCT4 (Figure 1c and Supplementary Figure 2). Such 
colonies could be expanded apparently indefinitely (>25 passages when submitting this 
manuscript) in the absence of exogenous factor expression, and we will refer to them as 
iPSCs. Collagen-OKSM MEFs produced iPSC colonies approximately tenfold more efficiently 
than Lenti-OKSM MEFs (Figure 1d,e), consistent with the observation that Collagen-OKSM 
MEFs homogenously expressed exogenous Oct4 after addition of doxycycline to the cultures, 
whereas we observed only patchy reactivation in Lenti-OKSM MEFs (Figure 1f). Collagen-
MEF iPSCs formed highly differentiated teratomas in severe combined immunodeficient 
(SCID) mice (Figure 1g) and contributed to adult coat color chimeras (Figure 1h). These cells 
supported the development of ‘all-iPSC’ midgestation fetuses after injection into tetraploid 
blastocysts (Figure 1i), further demonstrating pluripotency. 
To track cells undergoing reprogramming, we labeled Collagen-OKSM MEFs with a 
constitutively active lentiviral vector expressing the reportergene tdTomato. We established 
MEF cultures from chimeric embryos and plated brightly red-fluorescent cells at single-cell 
density onto irradiated feeder cells. MEFs expressing the four reprogramming factors were 
smaller and proliferated faster within the first 48 h of doxycycline administration compared 
to uninduced cells. This resulted in clusters of coalescent cells between days 4 and 6, from 
which iPSC colonies emerged between days 8 and 14 of culture (Supplementary Figure 3). 
Withdrawal of doxycycline at different time points showed that the first stably 
reprogrammed cells appeared by day 7, consistent with previous reports using lentiviral 
vectors2,3 (Supplementary Figure 4a). When we withdrew doxycycline before day 7, MEFs 
that had undergone morphological changes reverted back to a fibroblast-like shape and 
ceased proliferation (Supplementary Figure 4a). Re-exposure of these cells to doxycycline 
after 1 week of withdrawal did not yield stable iPSC colonies from more than 100 regressed 
colonies assayed, suggesting that these cells had become refractory to reprogramming, 
possibly owing to the exhaustion of their proliferative capacity9. 
The observation that cells undergoing reprogramming revert to a fibroblast-
like state upon premature withdrawal of doxycycline suggests that previously reported 
‘partially reprogrammed cells’10,11 are not a common phenotype during factor-mediated 
reprogramming but rather may be the consequence of incomplete retroviral transgene 
silencing, which drives continuous cell proliferation without acquisition of pluripotency. 
We next established a mouse strain carrying the inducible reprogramming cassette 
in all tissues. We bred Collagen-OKSM chimeras (Figure 2a) with mice that carried the 
EGFP gene in the Pou5f1 (also known as Oct4) locus, which serves as a faithful indicator for 
the acquisition of pluripotency12. We will refer to the resulting mice as ‘reprogrammable 
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2mice’ (Figure 2b). Notably, some reprogrammable mice developed a single aggressively growing tumor that histologically presented as a largely undifferentiated teratoma 
(Supplementary Figure 5a,b). This phenotype is likely due to leaky transgene expression in 
an undefined cell type and raises the possibility that somatic cells can be reprogrammed 
into pluripotent cells not only in vitro but also in vivo. To validate the Collagen-OKSM–Oct4-
EGFP reprogramming system, we grew postnatal tail-tip fibroblasts (TTFs) in the presence 
of doxycycline, which resulted in the formation of green fluorescent ESC-like colonies at 
a frequency of approximately 0.1% (Figure 2c,d). The lower reprogramming efficiency 
of TTFs compared to that of MEFs (Figure 1e) was not due to incomplete reactivation of 
the reprogramming cassette (data not shown), indicating that fetal fibroblasts are more 
amenable to reprogramming than postnatal cells, as recently reported13. The efficiency of 
TTF reprogramming increased approximately twofold when we grew the cells in medium 
containing serum replacement (Figure 2d). These iPSCs adopted an ESC-like morphology 
faster than cells in serum-containing medium, consistent with previous observations14. In 
the absence of feeder layers, TTFs grown in serum-replacement medium had to be seeded 
at a high density (~10,000 cells cm−2) to reach optimal reprogramming efficiencies compared 
to cells grown in serum-containing medium, which required a sparse starting culture 
(~1,000 cells cm−2) (Figure 2e). Together, these results suggest that reprogramming is not 
entirely cell-autonomous but is influenced by both inhibitory and supportive signals from 
the culture environment. 
Collagen-OKSM TTFs homozygous for the Rosa26-rtTA allele reached reprogramming 
efficiencies of 0.5–1% (Figure 2d) and reprogrammed faster than heterozygous cells, as 
demonstrated by the earlier appearance of doxycycline-independent green fluorescent 
colonies (Figure 2f). This shows that higher levels of transgene expression are favorable for 
both reprogramming kinetics and efficiency. 
To reprogram a defined somatic cell lineage, we isolated different hematopoietic 
cell types from adult reprogrammable mice (Supplementary Figure 6). We consistently did 
not obtain iPSC colonies from mature T cells, B cells and granulocytes heterozygous for 
both Rosa26-rtTA and Collagen-OKSM, although we occasionally observed colonies from 
monocytes with this genotype (Figure 2g). In contrast, Collagen-OKSM heterozygous cells that 
were homozygous for Rosa26-rtTA reproducibly gave rise to green fluorescent iPSCs from all 
tested cell types at frequencies ranging from 0.01% (B cells) to 0.3% (monocytes) (Figure 2g 
and Supplementary Figure 7). This suggests that a critical level of factor expression is required 
for reprogramming of terminally differentiated blood cells. In contrast, hematopoietic 
stem cells and granulocyte-macrophage progenitors from Rosa26-rtTA heterozygous mice 
generated iPSCs at high (5–10%) efficiencies (Figure 2h), consistent with our previous finding 
that reprogramming potential inversely correlates with differentiation stage15. Notably, we 
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derived iPSCs from hematopoietic stem cells homozygous for Rosa26-rtTA at frequencies of 
up to 40% (Figure 2h), which is to our knowledge the highest reprogramming efficiency for 
an adult somatic cell type. 
Reprogramming of blood cells was equally successful in the presence or absence of 
cell type–specific cytokines supporting hematopoietic cell survival and proliferation, with 
two exceptions. First, granulocytes did not form iPSCs in the presence of the growth factor 
granulocyte-macrophage colony stimulating factor, and second, Rosa26-rtTA heterozygous 
hematopoietic stem cells and granulocyte-macrophage progenitors reprogrammed 3–4 
times less efficiently without cytokines (Figs. 2g,h). Rosa26 homozygous hematopoietic 
stem cells and granulocyte-macrophage progenitors did not show this effect (Figure 2h), 
suggesting that higher expression levels of reprogramming factors can substitute for the 
signals provided by cytokines. 
The mouse strain described here overcomes several of the limitations of viral 
secondary reprogramming systems and should be a useful tool to study the mechanisms 
underlying the conversion of somatic cell types into iPSCs. It may be especially attractive 
for dissecting the biochemistry of induced pluripotency in the context of adult stem and 
progenitor cells that reprogram at high efficiency. Another crucial question that can be 
addressed with this system is whether ESCs and iPSCs are molecularly and functionally 
equivalent. Specifically, the possibility to compare ESCs to genetically matched iPSCs from 
different tissues will allow this question to be resolved. 
Methods 
Mice 
Derivation, handling and genotyping of Oct4-EGFP12 and Rosa26-rtTA8 mice were described 
previously. Collagen-OKSM reprogrammable mice will be deposited with The Jackson 
Laboratories once the colony has been expanded. All animal studies were carried following 
approved guidelines of the animal protocol of the Massachusetts General Hospital Cancer 
Center. 
Cell culture 
ESCs and iPSCs were cultured in ESC medium (DMEM with 15% FBS, L-glutamine, penicillin-
streptomycin, nonessential amino acids, β-mercaptoethanol and 1,000 U ml−1 LIF) on 
irradiated feeder cells. ESC-derived MEFs were isolated by trypsin digestion of midgestation 
(E14.5) chimeric embryos followed by culture in fibroblast medium (DMEM with 10% FBS, 
l-glutamine, penicillin, streptomycin, nonessential amino acids and β-mercaptoethanol) 
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Figure 2. Derivation and characterization of reprogrammable mice. (A) Representative 
chimeras derived from Collagen-OKSM MEFs. (B) Outline for the establishment of 
reprogrammable mice. (C) Brightfield (top) and green fluorescence (bottom) images of an 
iPSC colony derived from postnatal tail-tip fibroblasts (TTFs) from a reprogrammable mouse. 
Scale bar, 500 µm. (D) Effect of serum (FBS) and serum replacement (SR) on reprogramming 
efficiency from Rosa26-rtTA heterozygous or homozygous TTFs. Reprogramming efficiencies 
were determined by counting green-fluorescent transgene-independent colonies with 
ESC- like morphology per number of input cells. Error bars, s.d. (n = 3). (E) Effect of cell density 
on the reprogramming efficiency of Rosa26-rtTA homozygous TTFs grown in FBS or SR. (F) 
Reprogramming efficiencies after culture of TTFs heterozygous or homozygous for Rosa26-
rtTA in doxycycline-containing medium. Doxycycline was withdrawn on the indicated days and 
colonies were scored on day 20. (G) Reprogramming efficiencies of mature hematopoietic 
cell types from the reprogrammable mice heterozygous or homozygous for Rosa26-rtTA. 
Cells were cultured either in the presence (+) or absence (−) of cytokines. (H) Reprogramming 
efficiencies of hematopoietic stem cells (HSCs) and granulocyte-macrophage progenitor cells 
(GMPs) from reprogrammable mice.      
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containing puromycin. TTF cultures were established from tail-tip biopsies of newborn 
(3–8 d) mice and maintained in fibroblast medium. Hematopoietic cells were isolated from 
peripheral blood and bone marrow as previously described15. 
Gene targeting of ESCs 
A polycistronic cassette encoding OCT4, KLF4, SOX2 and c-MYC was cloned into the shuttle 
plasmid pBS31 using NotI and ClaI digestion. The resulting plasmid was electroporated into 
KH2 ESCs together with a plasmid driving expression of Flp recombinase8. Correct targeted 
clones were screened for by hygromycin selection and confirmed by Southern blotting as 
previously described8.
Lentiviral vectors 
To produce infectious viral particles, 293T cells cultured on T75 flasks were transfected 
with a lentiviral vector expressing tdTomato from the ubiquitin promoter (11 µg) together 
with the packaging plasmids VSV-G (5.5 µg) and Δ8.9 (8.25 µg) using Fugene (Roche) 
transfection reagent. Viral supernatants were collected on 3 consecutive days starting 24 h 
after transfection, yielding a total of ~50 ml of supernatant per virus. Viral supernatant was 
concentrated ~200-fold by ultracentrifugation at 60,000g for 1.5 hour at 4 °C and resuspension 
in 250 µl of PBS. Viral concentrates were stored at −80 °C. iPSCs were transduced in 0.2 ml 
ES medium containing 5 µg ml−1 polybrene using 20–40 µl of viral concentrate on a 48-well 
plate. Regular ESC medium was added 24 h after infection and red-fluorescent iPSCs isolated 
by flow cytometry. 
Immunofluorescence 
iPSCs were cultured on pretreated cover slips, fixed with 4% PFA and permeabilized with 0.5% 
Triton X-100. The cells were then stained with primary antibodies to murine OCT4 (Santa 
Cruz, sc-8628) and to mNANOG (Abcam, ab21603), followed by staining with the respective 
secondary antibodies conjugated to either Alexa Fluor 488 or 546 (Invitrogen). Nuclei were 
counterstained with DAPI (Invitrogen). Cells were imaged using a Leica DMI4000B inverted 
fluorescence microscope equipped with a Leica DFC350FX camera. Images were processed 
and analyzed using Adobe Photoshop software. 
Teratoma formation
iPSCs were collected by trypsinization and injected into the flanks of nonobese diabetic 
(NOD)-SCID mice, using ~5 million cells per injection. Mice were killed 3 weeks later, and 
teratomas were isolated and processed for histological analysis. 
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Female BDF1 mice were superovulated by intraperitoneal injection of pregnant mare serum 
(PMS) and human chorionic gonadotropin (hCG) and mated to BDF1 stud males. Zygotes 
were isolated from females with a vaginal plug 24 h after hCG injection. Zygotes for diploid 
(2n) blastocyst injections were cultured for 3 days in EmbryoMax KSOM medium (Millipore); 
blastocysts were identified, injected with ESCs or iPSCs and transferred into pseudopregnant 
recipient females. For tetraploid (4n) blastocyst injections, zygotes were cultured overnight 
until they reached the 2-cell stage, at which point they were electrofused. One hour later, 
1-cell embryos were carefully identified and separated from embryos that did not fuse, 
cultured in KSOM for another 2 days and then injected. 
Reprogramming 
MEFs and TTFs were counted and seeded in fibroblast medium at the desired density on 
either gelatin-coated plates or plates that also contained a layer of irradiated feeder cells. 
The next day, ESC medium containing 2 µg ml−1 doxycycline was added and replenished 
every 3 days. Upon doxycycline withdrawal, cultures were washed twice with PBS and then 
continued in standard ESC medium until colonies were either picked, scored by fluorescence 
microscopy or stained for alkaline phosphatase activity (Vector Red substrate kit; Vector 
Labs). Freshly isolated hematopoietic cells were isolated by flow cytometry and immediately 
plated on top of irradiated feeder layers in ESC medium containing doxycycline on either 
35-mm or 100-mm plates. Cell densities were 200 cells per well for hematopoietic stem 
cells (HSCs) and granulocyte-macrophage progenitors (GMPs), and 5,000–100,000 cells 
per well for all other cell types. The following cytokines were used: IL-15 (2 ng µl−1) and 
IL-7 (10 ng µl−1) for B cells, ConA (2.5 µg ml−1) and IL-2 (10 ng µl−1) for T cells, M-CSF (5 
ng µl−1) for monocytes, G-CSF (10 ng µl−1) for granulocytes and Flt3-ligand (10 ng µl−1), SCF 
(10 ng µl−1) and TPO (10 ng µl−1) for HSCs and GMPs. All cytokines were purchased from 
Peprotech. Doxycycline was withdrawn from HSCs and GMPs after 2 weeks and from the 
slower reprogramming peripheral blood cells after 4–6 weeks. 
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Supplementary Figure 2. Expression of pluripotency markers in Collagen-OKSM iPSCs.
Immunofluorescence images after staining iPSCs cultured for several weeks in the absence 
of doxycycline (upper panel), ESCs (middle panel) and Collagen-OKSM fibroblasts cultured in 
the absence of doxycycline (lower panel) with antibodies against OCT4 and NANOG. Nuclei 
were counterstained with DAPI.
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Supplementary Figure 3. Morphological changes of reprogramming fibroblasts. RFP+ MEFs 
isolated from midgestation chimeras derived after blastocyst injections with Collagen-OKSM 
ESCs transduced with a lentivirus expressing tdTomato were cultured either in the presence 
(+ dox, left panel) or absence (no dox, right panel) of doxycycline. Images were taken after 
the indicated days of culture.
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Supplementary Figure 4. Effect of premature dox withdrawal. (A) Reprogramming
efficiencies of Collagen-OKSM MEFs after culture for 5, 7 and 9 days in the presence of
doxycycline. (B) RFP fluorescence images of two representative intermediate colonies 
formed after culturing MEFs for 6 days in the presence of doxycycline (upper panel). After 
withdrawal of doxycycline cells (Day 6 + 6, middle panel) cells stopped reprogramming, 
reverted to an elongated fibroblast-like morphology (compare to Supplementary Figure 3) 
and upon passaging stopped dividing (Day 6 + 20, bottom panel).
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Supplementary Figure 5. Tumor formation in Collagen-OKSM mice. (A) Histological
sections through two tumors found in adult chimeras derived after blastocyst injection of
Collagen-OKSM ESCs. (B) Curve showing percentage of tumor-free mice at the indicated
timepoints.
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Supplementary Figure 6. Isolation of hematopoietic cells. Gating logic for the isolation of 
four different mature hematopoietic cell types from blood (upper panel) as well as two 
immature cell types from bone marrow (lower panel). Cells were defined by the following 
criteria: Monocytes (MAC1+ SSClow), Granulocytes (MAC1+ SSChigh), B cells (CD19+ CD3- 
MAC1-), T cells (CD3+ CD19- MAC1- ), GMPs (LinKit+ SCA1- CD34+ FcγR+ ) and HSCs (LinKit+
SCA1+ CD150+ CD48-).
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Supplementary Figure 7. Hematopoietic iPSC colonies. (A) Brightfield and GFP fluorescence
images of nascent iPSC colonies forming from granulocytes and HSCs cultured in the 
presence of doxycycline for 10 days. Note that Oct4-GFP fluorescence is patchy and that GFP- 
cells with ES morphology can be identified (highlighted by arrows), indicated incomplete 
reprogramming at this timepoint. (B) Images of the same colonies after 6 additional days of 
culture in the absence of doxycycline. GFPcells are absent and GFP fluorescence has become 
homogenous.

67
A roadmap of reprogramming to induced pluripotent stem cells
3

69
Chapter 3
A Molecular Roadmap of Reprogramming 
Somatic Cells into iPS Cells 
Jose M. Polo*, Endre Anderssen*, Ryan M. Walsh, Benjamin A. Schwarz, 
Christian M. Nefzger, Sue Mei Lim, Marti Borkent, Effie Apostolou, Sara Alaei, 
Jennifer Cloutier, Ori Bar-Nur, Sihem Cheloufi, Matthias Stadtfeld, Maria 
Eugenia Figueroa, Daisy Robinton, Sridaran Natesan, Ari Melnick, Jinfang 
Zhu, Sridhar Ramaswamy#, and Konrad Hochedlinger# 
*equally contributing authors
# corresponding authors
Cell December 2012
70
Chapter 3 
Abstract 
Factor-induced reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) 
is inefficient, complicating mechanistic studies. Here, we examined defined intermediate 
cell populations poised to becoming iPSCs by genome-wide analyses. We show that induced 
pluripotency elicits two transcriptional waves, which are driven by c-MYC/KLF4 (first wave) 
and OCT4/SOX2/KLF4 (second wave). Cells that become refractory to reprogramming activate 
the first but fail to initiate the second transcriptional wave and can be rescued by elevated 
expression of all four factors. The establishment of bivalent domains occurs gradually after 
the first wave, whereas changes in DNA methylation take place after the second wave when 
cells acquire stable pluripotency. This integrative analysis allowed us to identify genes that 
act as roadblocks during reprogramming and surface markers that further enrich for cells 
prone to forming iPSCs. Collectively, our data offer new mechanistic insights into the nature 
and sequence of molecular events inherent to cellular reprogramming. 
Introduction
Induced pluripotent stem cells (iPSCs) have been generated from a number of mouse and 
human cell types upon enforced expression of transcription factors such as OCT4, KLF4, 
SOX2, and c-MYC (OKSM)1,2. iPSCs provide a valuable source of patient-specific cells for the 
study and potential treatment of human diseases3. In addition, iPSC technology offers a 
unique tool to dissect the principles of cell fate determination during normal development 
and its dysregulation in disease4. 
In general, less than 3% of somatic cells expressing OKSM give rise to iPSC colonies, 
complicating efforts to dissect the mechanisms of reprogramming. Owing to this limitation, 
most previous studies focused on the immediate response of somatic cells to factor 
expression. For example, fibroblasts were shown to go through a process that was reminiscent 
of a mesenchymalto-epithelial transition (MET) within a few days of OKSM expression5,6. At 
the epigenetic level, widespread remodeling of certain histone modifications, but not of 
DNA methylation patterns, was seen within the first few cell divisions of iPSC induction7. 
However, intermediate and late stages of reprogramming have remained inaccessible for 
more detailed molecular analyses. 
We and others have documented that fibroblasts undergoing reprogramming 
pass through a number of defined intermediates8,9. Briefly, cells expressing OKSM from 
doxycycline (dox)-inducible lentiviral vectors initially downregulate the fibroblast-associated 
marker THY1 (day 1–2), then activate the SSEA1 antigen (day 3–5) and eventually upregulate 
an Oct4-GFP reporter (day 8–10) before forming stable iPSC colonies at approximately 1.5 
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weeks.  
Importantly, isolation of these rare cell populations with the aforementioned markers 
allowed us to significantly enrich for cells that are poised to becoming iPSCs. Here, we have 
utilized this approach, in combination with a transgenic system that enables homogeneous 
dox-inducible OKSM expression in somatic cells (chapter 2, 10), to purify intermediate stages 
of iPSC formation with the goal to elucidate the nature and sequence of molecular changes 
specific to cellular reprogramming. 
Results
Experimental Approach to Studying Rare Reprogramming Intermediates 
We first determined whether the reprogramming of fibroblasts with a recently reported 
dox-inducible transgenic system (‘‘reprogrammable system’’, chapter 2)10 generates the 
same subpopulations of cells that we have previously described by using direct lentiviral 
infection. As shown in Figure 1A, murine embryonic fibroblasts (MEFs) carrying the Col1a1-
tetO-OKSM transgene, the ROSA26-M2-rtTA allele, and an Oct4-GFP knockin reporter gave 
rise to THY1 cells, SSEA1+ cells, and Oct4-GFP+ cells with the expected kinetics. To verify that 
these intermediate populations were indeed enriched for cells that would form iPSCs, we 
sorted cells on feeders based on THY1, SSEA1, and GFP expression and treated them with 
dox for an equal number of days (see Extended Experimental Procedures). Consistent with 
our previous report, intermediate cells with the potential to give rise to iPSCs were initially 
present within both the THY1 and SSEA1+ populations, then progressed to SSEA1+ cells, and 
ultimately transited to the SSEA1+, Oct4-GFP+ population (Figures 1B and 1C). Importantly, 
sorting of THY1+ cells after day 3 and of THY1 cells after day 6 consistently failed to yield iPSC 
colonies, indicating that these cell populations had become refractory to reprogramming. 
To examine the phenotypic progression of reprogramming intermediates, we sorted 
THY1+, SSEA1+, and Oct4-GFP+ cells after 3, 6, 9, and 12 days of dox induction, followed 
by culture in dox for another 3 days before reassessing their surface phenotype (Figure 
1C). This analysis, combined with the abovementioned reprogramming results (Figure 1B), 
documents that (1) cells undergoing successful reprogramming with the Col1a1tetO-OKSM 
transgenic system transit in a linear fashion from a THY1+ to a THY1 to a SSEA1+ state in 
the first 6 days and eventually to a SSEA1+, Oct4-GFP+ state by days 9–12 (see Figure 1D for 
graphic summary; red arrows connect intermediates progressing toward iPSCs); (2) SSEA1+ 
cells are phenotypically still plastic until days 9–12 when they undergo commitment to a 
stable pluripotent cell fate; and (3) THY1+ cells lose their ability to progress toward a THY1 
and SSEA1+ state as early as day 3. Note that progressing intermediates account for only 
5%–10% of cells in regular reprogramming cultures compared with 90%–95% of THY1+ cells. 
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We generated gene expression profiles for these intermediate cell populations as well 
as for noninduced THY1+ MEFs (day 0) and dox-independent iPSCs (see Table S1, available 
online, for searchable database). Examination of candidate genes confirmed that THY1 was 
downregulated and SSEA1 (synthesized by the gene product of Fut911) was upregulated in the 
THY1 and SSEA1+ populations, respectively (Figure 1E; note that red line depicts progressive 
intermediates as defined in Figure 1D by red solid arrows, whereas black line shows 
refractory THY1+ cells). In addition, we noticed that Snai1 became downregulated, whereas 
E-Cadherin was upregulated at day 3, consistent with the occurrence of a MET. Alkaline 
phosphatase (Alpl) and Fbxo15, early markers of pluripotent cells, gradually increased their 
expression, whereas endogenous OCT4 and SOX2 transcripts were detectable only late 
during iPSC generation. Lastly, Cyclin B1 became upregulated and the CDK inhibitor Cdkn2b 
(encoding for p15) was downregulated early in reprogramming. It is worth mentioning 
that THY1+ cells mirrored the gene expression changes of progressing cells until day 3 but 
then failed to sustain this trend at later time points, which correlated with their inability to 
produce iPSCs after day 3 (Figure 1B). We conclude that our sorting strategy allows us to 
analyze gene expression patterns of progressive intermediate cell populations transitioning 
toward iPSCs (Figure 1C) and to distinguish these from patterns in the bulk population of 
cells that are refractory to reprogramming. 
Major Gene Expression Changes Occur in Two Discernible Phases during iPSC 
Formation 
Principle component analysis (PCA) of the cell populations revealed a molecular connectivity 
reflecting their progression from the initial THY1+ cells toward THY1 cells and ultimately 
SSEA1+ cells, Oct4-GFP+ cells and iPSCs as depicted by the dashed red line (Figure 2A). PCA 
analysis further showed that all intermediates at day 3 clustered together, indicating that 
cells responded homogeneously to OKSM activation within the first few days. After day 3, 
however, SSEA1+ cells progressed toward Oct4-GFP cells, which were most closely related 
to established iPSCs, demonstrating that the SSEA1+ population gradually evolved toward 
a bona fide pluripotent state with time. Unsupervised clustering confirmed the similarities 
of SSEA1+ cells at days 3–9 and of Oct4-GFP+ cells at day 12 and iPSCs (Figure 2B). An 
examination of the number of differentially expressed genes between progressing (SSEA1+) 
(continued from right) (D) Scheme illustrating the different subpopulations throughout 
reprogramming. Solid red arrows connect cell populations progressing toward iPSCs as 
inferred from data in (B). (E) Expression analyses of indicated genes at day 0, 3, 6, 9, and 12 
of reprogramming and in established iPSCs (black lines depict THY1+ populations; red lines 
depict cells undergoing successful reprogramming as defined by red arrows in Figure 1D). 
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Figure 1. Strategy for Isolating Reprogramming Intermediates. (A) FACS analysis of 
reprogrammable MEFs at indicated time points. 12+4 denotes transgene-independent 
growth for 4 days. (B) Comparison of reprogramming efficiencies of intermediates purified 
at indicated time points. Note that established iPSCs have a colony formation efficiency 
of ~30%9. Data are represented as mean ± SEM (n = 3). (C) Pie charts summarizing FACS 
analysis of reprogrammable cells at indicated time points (top row). Bottom row shows FACS 
analysis for THY1, SSEA1 and Oct4-GFP 3 days after sorting and plating of the above cell 
populations in the presence of doxycycline.  (continued on left)
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and refractory (THY1+) cell populations at each time point showed a gradual increase, which 
culminated at ~1,500 genes by day 12 (Figure 2C). These observations document that the 
isolation of subpopulations with experimentally proven distinct reprogramming potentials 
are distinguishable by global gene expression patterns. 
Remarkably, a comparison of relative gene expression changes among pairs of 
progressing cell populations at successive time points revealed two distinct waves of major 
gene activity (Figure 2D, left). The first wave occurred between days 0 and 3, whereas a 
second wave was detectable toward the end of reprogramming, after day 9. Refractory 
THY1+ cells initiated the first wave but failed to undergo the second wave (Figure 2D, right). 
Gene ontology (GO) analysis showed that expression changes within the first phase involved 
activation of processes related to cell proliferation, metabolism, cytoskeleton organization, 
and downregulation of genes associated with development. Genes upregulated during the 
second phase were associated with embryonic development and stem cell maintenance. A 
parallel study, which applied proteomics to study the same intermediates of reprogramming, 
concurs with our findings and further shows that molecular changes are highly coordinated 
during both phases12. Together, these data demonstrate that cells undergoing reprogramming 
into iPSCs, as defined by populations upregulating SSEA1+ at early time points and SSEA1+/
Oct4-GFP at late time points, undergo a biphasic process at the transcriptional level that is 
separated by a period of less pronounced transcriptional change. 
Defining Reprogramming-Specific Gene Expression Patterns 
To gain further insights into the mechanisms of iPSC induction, we next determined 
categories of genes that changed their expression in characteristic patterns (Figure 2E and 
Table S1). A large number of genes became abruptly upregulated (cluster I; ~750 genes) 
or downregulated (cluster VI; ~1,200 genes) early in reprogramming and then remained 
largely unchanged until the iPSC state. Genes in these two categories were mainly involved 
in controlling DNA replication and cell division processes (upregulated genes) as well as 
cell adhesion and cell-cell contacts (downregulated genes) and account for the first 
transcriptional wave during reprogramming. Another category was comprised of ~400 genes 
that were gradually upregulated, such as the pluripotency-associated genes Alpl, Fbx15, 
(continued from right) red trendlines depict gene expression patterns in cells undergoing 
successful reprogramming as defined in Figure 1D). Each gene is only represented once per 
category. (F) Expression analysis of candidate genes selected from (E) for overexpression or 
knockdown experiments shown in (G). Gene expression categories are shown in brackets. 
(G) Reprogramming potential of OKSM transgenic MEFs infected with lentiviral vectors 
expressing the indicated candidate genes or hairpins. Data are represented as mean ± SEM 
(n = 3). See also Figure S1. 
75
A roadmap of reprogramming to induced pluripotent stem cells
3
Figure 2. Gene Expression Dynamics during iPSC Formation. (A) Principal component 
analyses of global gene expression data of FACS-sorted subpopulations at indicated time 
points. (B) Unsupervised hierarchical clustering of gene expression profiles of indicated cell 
populations. (C) Number of differentially expressed genes between THY1+ and SSEA1+ cells 
at indicated time points. (D) Number of differentially expressed (DE) genes in progressing 
SSEA1+ cells at successive time points. Right panel shows gene expression changes in 
refractory THY1+ cells. (E) Gene expression categories (I to IX) clustered by common 
expression changes during reprogramming (black trendlines depict gene expression patterns 
in THY1+ population; (continued on left)
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Nr0b1, Tcfcp2l1, and Sall1 (cluster II), whereas roughly 350 genes were induced late during 
reprogramming and contained genes enriched for the categories stem cells and DNA binding 
(cluster III). The latter group, which contained well-known core pluripotency factors such as 
Nanog, Oct4, and Sox2 as well as Esrrb, Dnmt3L, Tcl1, and Nr5a2, is in part responsible for 
the second transcriptional wave and marks the acquisition of a stable pluripotent state. 
Intriguingly, we also identified categories of genes that were either transiently upor 
downregulated during iPSC formation (cluster IV and VIII, respectively) or upregulated early 
and downregulated late (cluster V). Genes within those categories included a number of 
developmental and cell-type-specific regulators such as Bcl11a, Prx, and Tbx21 among the 
transiently upregulated genes and Spp1, Pitx2, and Six4 among the transiently downregulated 
genes (Figure 2E). 
Lastly, we hypothesized that the manipulation of dynamically regulated genes 
from these categories might enhance reprogramming. We selected the Akt coactivator 
Tcl1, the transcription factors Tcfap2c and Hesx1 and the ESC-specific Ras isoform ERas 
for overexpression experiments and the fibroblast-enriched genes Meox1 and Meox2 
for knockdown experiments (Figure 2F). Accordingly, upregulation or downregulation 
of theses genes gave rise to up to seven times more Oct4-GFP+ colonies compared with 
control cells (Figure 2G). Collectively, these experiments prove that our gene expression 
categories facilitate the identification of molecules that positively or negatively influence 
the reprogramming process. 
Gene Expression Patterns of Refractory Cells 
Another category of genes (cluster IX) contained about 200 genes that were aberrantly 
activated in refractory THY1+ cells (Figure 2E and Table S1). Genes within this class were 
related to extracellular space/matrix, plasma membrane, retinoic acid binding, and immune 
response processes (e.g., Mmp13, Rarres2, Fgf18, Fndc1, Aqp1 and -4, Il1f10, Hsd11b1, and 
Figure S1A) and likely contributed to the failure of THY1+ cells to reprogram. 
To further understand the molecular reasons for the inability of THY1+ intermediates 
to reprogram, we analyzed other genes that were differentially expressed between 
SSEA1+ and THY1+ cells. This analysis revealed that mesenchymal genes were not properly 
downregulated, whereas epithelial genes failed to be upregulated in THY1+ cells compared 
to SSEA1+ cells after day 3 (Figure S1B). We also searched for differentially expressed genes 
between THY1+ and SSEA1+ cells at day 3, when overall gene expression patterns were 
still highly similar among all populations (Figure 2A). This analysis yielded a small number 
of significantly up and downregulated genes (e.g., Il6, Nup210, and Bex1) that might serve 
as valuable early discriminators between cells that succeed or fail in reprogramming 
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(Figure S1C). We conclude that THY1+ cells become refractory to reprogramming for a 
variety of reasons that include (1) an inability to undergo a MET, (2) aberrant activation of 
differentiation and immune-response-associated genes, and (3) a failure to maintain global 
gene expression trends beyond day 3. 
Impact of Cellular Heterogeneity on Molecular Dissection of Reprogramming
We employed different strategies to determine the degree of heterogeneity among SSEA1+ 
cells. First, we used Fluidigm technology to perform single-cell expression analysis for 26 
genes (see Figure S2A) in FACS-purified SSEA1+ intermediates at days 3, 6, and 9 as well 
as in day 0 THY1+ MEFs and established iPSCs. Correspondence analysis (COA) of all 26 
genes across the different cellular groups showed that the three intermediate populations 
formed separate clusters that partially overlapped and gradually progressed from MEFs to 
iPSCs (Figure 3A). COA confirmed the early and late transcriptional waves and illustrated an 
increased degree of variation within SSEA1+ intermediates compared with MEFs and iPSCs 
(Figure 3B). Biplot analysis suggested that activation of Nr5a2, ERas, Zfp42, Esrrb, Dnmt3l, 
and PECAM was most informative for predicting the iPSC state, followed by activation of 
Nanog, Lin28, and EpCAM (Figure 3C). A comparison of the expression dynamics of individual 
genes between SSEA1+ bulk populations and single SSEA1+ cells revealed a similar overall 
kinetics and allowed us to differentiate between MEF- and ESC-associated genes that were 
either downregulated or upregulated immediately, gradually or late upon reprogramming 
factor expression (Figure 3D). 
We next examined the shape of the violin plots (Figure 3D) in order to deduce whether 
gene expression changes took place in a minority or majority of SSEA1+ intermediates; 
whereas unimodal plots are consistent with uniform gene expression in a majority of cells, 
bimodal plots are indicative of distinct expression patterns and thus heterogeneous cell 
populations. We could distinguish between three characteristic patterns of gene expression 
change (Figure 3D and Figure S2B): (1) exclusively unimodal expression patterns, which were 
mostly characterized by genes that changed in one of the two transcriptional waves and 
included MEF genes that were silenced early (Fibin, Snai1) or gradually (Fbn1) as well as 
all examined pluripotency genes that were activated late (Zfp42, Esrrb, Nr5a2, ERas, Lin28, 
PECAM, Tcl1, Dnmt3l); (2) unimodal expression early and late with bimodal expression 
at intermediate stages of reprogramming, which contained the MEF gene Zfpm and the 
early iPSC marker EpCAM, Nanog and Tcfap2c; and (3) bimodal expression patterns at all 
time points. Examples included the MEF gene Hoxa10 and the intermediate-specific genes 
Cldn11, Tbx21, and Six4. Coexpression analysis of representative genes from each category 
showed that they were indeed activated within the same cells (Figure S2C). 
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To determine whether intermediate-specific genes were always expressed 
heterogeneously within SSEA1+ cells (Figure 3D), we performed immunohistochemistry 
(IHC) for PRX (Figure 3E) in reprogrammable MEFs induced with dox for 9 days. Costaining 
with antibodies recognizing SSEA1 and PRX revealed that all SSEA1+ cells also expressed 
PRX (28/28 examined cells) (Figure 3F). This result suggested that Prx and probably other 
intermediate-specific genes are expressed homogeneously among SSEA1+ cells and thus 
mark cells poised to becoming iPSCs. In contrast, other intermediate-specific genes such as 
Tbx21 are expressed in more rare subsets of SSEA1+ cells (Figure 3D) whose fate remains 
unclear. To test whether activation of the latter group of genes correlated with their ability to 
form iPSCs, we infected tail fibroblasts isolated from Tbx21-ZsGreen mice with a polycistronic 
viral vector expressing OKSM. Flow cytometric analysis of SSEA1+ intermediates at days 6 
and 9 confirmed the heterogeneous expression pattern (Figure 3G). Plating of equal numbers 
of SSEA1+ Tbx21-ZsGreen+ and of SSEA1+ Tbx21-ZsGreencells from day 6 on feeders gave 
rise to roughly equal numbers of iPSC colonies, indicating that Tbx21 upregulation at this 
time point was neither necessary nor inhibitory for reprogramming (Figure 3H). However, 
SSEA1+ Tbx21-ZsGreen+ cells isolated at day 9 of reprogramming almost entirely lost their 
ability to form iPSC colonies, suggesting that a failure to downregulate this marker at later 
stages of reprogramming prohibited iPSC formation (Figures 3G and 3H). We conclude 
that our analysis of SSEA1+ bulk populations correlates well with expression patterns in 
individual SSEA1+ cells, thus validating our approach to study FACS-enriched intermediates 
of reprogramming. However, our observation that SSEA1+ cells exhibited some degree 
of heterogeneity warrants a search for markers that allow for further purification of 
reprogramming intermediates destined to form iPSCs (see Identification of Molecules to 
Enrich for Cells Poised to Becoming iPSCs). 
Comparison with piPSCs and Bulk Populations Expressing OKSM 
Partially reprogrammed iPSCs (piPSCs) are assumed to represent intermediate stages of 
reprogramming13,14. piPSC lines are stable cell lines that have silenced the somatic program 
(Continued from right) Size of ovals indicates degree of variation. (C) Biplot displaying 
overlay of COA with genes associated with individual groups. (D) Comparison of Affymetrix 
(left) and single-cell (right) expression data for nine selected genes. Gene expression 
categories, as defined in Figure 2E, of selected candidates are shown in brackets. (E) 
Immunofluorescence for OCT4, SSEA1, and PRX on reprogrammable MEFs treated with 
dox for 9 days. (F) Quantification of data shown in (E). (G) FACS analysis of Tbx21-ZsGreen 
tail fibroblasts infected with dox-inducible lentivirus expressing OKSM at indicated time 
points. (H) Reprogramming potentials of indicated cell populations at days 6 and 9. Data are 
represented as mean ± SEM (n = 3). See also Figure S2.
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Figure 3. Characterization of Cellular Heterogeneity within SSEA1+ Cells. (A) 
Correspondence analysis (COA) of single-cell expression data obtained with Fluidigm 
technology for 26 genes in indicated cell populations. (B) COA of same groups as shown in 
(A) illustrates variation in gene expression. (Continued on left)
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but failed to activate the pluripotency program and depend on continuous expression of viral 
transgenes. To assess whether their overall gene expression signature closely resembled 
any of our profiled cell populations, we performed PCA analysis between our data sets 
and published results from six different piPSC lines. Consistent with previous observations, 
piPSC lines derived from distinct cell types and produced in different laboratories clustered 
together, suggesting a similar molecular makeup (Figure S1D, gray symbols). Unexpectedly, 
these cell lines were quite distinct from any of our profiled intermediate populations along 
the depicted PC axes, showing essentially no overlap with one notable exception; piPSC 
line BIV113 that was generated with dox-inducible lentiviruses clustered together with 
retrovirally induced piPSCs in the presence of dox (‘‘dox+’’ marked triangle) but grouped 
with our late SSEA1+ intermediates after ~10 days of dox withdrawal (‘‘dox-’’ triangle). 
We conclude that piPSCs originate from cells that have exited the normal reprogramming 
route at an early time point and became immortalized, hence showing little overlap with 
progressing intermediates. 
A comparison of gene expression profiles from SSEA1+ intermediates with those 
obtained from reprogrammable ‘‘secondary’’ cells exposed as bulk populations to dox 
for 0, 4, 8, 12, or 16 days13 further showed that the latter samples clustered most closely 
with THY1+ and THY1 cells around day 3 but not with SSEA1+ intermediates at comparable 
later time points (Figure S1D, turquois triangles). This finding indicated that this previous 
study of bulk populations predominantly captured expression changes of cells that failed to 
reprogram after day 3 and underscores the importance of enriching for the rare subsets of 
cells that are prone to generating iPSCs, particularly at later stages of reprogramming. 
Transcription Dynamics Predicts Distinct Reprogramming Factor Activities 
We next wondered whether the biphasic transcriptional pattern could be explained by the 
activity of any individual or combinations of transcription factors. To this end, we compared 
our gene expression data with published genome-wide occupancy studies for OCT4, SOX2, 
KLF4, c-MYC, and NANOG in pluripotent stem cells (see Table S1 and Methods). Whereas a 
similar number of targets of OCT4, SOX2, and KLF4 were upand downregulated during both 
transcriptional waves, targets of c-MYC were mostly upregulated (~80%) with a bias for the 
first wave (Figure S3A). 
Given that many pluripotency-associated genes are targets of OCT4, SOX2, KLF4, and 
c-MYC in ESCs/iPSCs, we next distinguished between expression changes of individual and 
combinatorial OKSM targets during both waves. This analysis confirmed that c-MYC alone or 
in combination with other factors is a dominant force behind early gene induction (shown 
for c-MYC and KLF4 targets in Figure S3B). To assess the contributions from individual 
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factors to reprogramming, we applied a mathematical approach that models and predicts 
transcription factor activities by using network component analysis15. As expected, c-MYC 
targets showed a striking upregulation during the first few days of OKSM expression, with no 
major changes detectable until the end of reprogramming (Figure 4A, left). 
Notably, an analysis of transcriptional activity for genes that are bound by pairs 
of factors in ESCs showed a gradual change, as exemplified for OCT4/SOX2(OS) targets, 
suggesting that the combined activity of certain pluripotency factors is more likely to 
modulate targets than individual factors (Figure 4A, middle). To experimentally verify this 
mathematical prediction, we picked 3 OS targets that became upregulated early (Fut9, day 
3) or late (Nanog and Lefty1, days 9–12) during reprogramming and performed chromatin 
immunoprecipitation (ChIP) on SSEA1+ intermediates with OCT4 and SOX2-specific 
antibodies, combined with real time PCR. Indeed, we found that Fut9 was occupied by both 
OCT4 and SOX2 as early as day 3, whereas Nanog and Lefty1 were occupied by OCT4 alone 
at early time points and by both OCT4 and SOX2 by day 12, consistent with their robust 
transcriptional activation (Figure 4B and Figure S3C). The different susceptibilities of OS 
targets to be transcriptionally activated correlated well with an underlying permissive or 
repressive chromatin structure (Figure S3D). 
KLF4 was exceptional in that its targets changed their expression early and late in 
reprogramming with a phase of less activity change during intermediate stages (days 3 to 
9), supporting a possible dual role of KLF4 in early somatic gene repression and subsequent 
pluripotency gene activation (Figure 4A, right). Accordingly, regulated KLF4 targets were 
comprised of factors associated with differentiation, such as Tgfb1, Pdgfra, and Col6a1, 
at early time points and of pluripotency-associated genes including Pou5f1 (Oct4), Tdgf1, 
and Klf5 at late time points of reprogramming. Altogether, these results suggest that the 
first transcriptional wave is mostly mediated by c-MYC and occurs in both progressing and 
nonprogressing cells, whereas the second wave is the consequence of a gradual upregulation 
of OS targets, ultimately leading to the activation of other pluripotency genes, including 
Nanog, to consolidate the pluripotent transcription factor network. KLF4 seems to support 
both phases by suppressing genes during the first phase and enhancing pluripotency gene 
expression during the second phase. 
MicroRNA Expression Follows Biphasic Pattern and Inversely Correlates with 
Known and Predicted Target mRNAs 
Similar to the expression analysis for coding genes, miRNA expression analysis allowed us 
to cluster cell populations into different groups based on their phenotype by using PCA and 
unsupervised clustering (Figures 4C–4E and Table S2). Pairwise comparisons of progressing 
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SSEA1+ populations at successive time points again revealed two transcriptional waves, 
which both showed an over representation of downregulated versus upregulated miRNAs 
(Figure 4F). miRNAs changed their expression in similar patterns to mRNAs over the course 
of reprogramming (see Figure 4G for representative examples). Moreover, miRNAs that 
have previously been documented to inhibit (e.g., let-7, miR34c) or promote (e.g., miR-
294, miR-106a)16 iPSC formation, showed the expected downregulation and upregulation, 
respectively, in progressing intermediates (Figure 4G and Figure S3E). We conclude that 
forced expression of OKSM controls the expression of both coding and noncoding loci in a 
similar fashion. 
A comparison of many miRNAs and their known targets indicated an inverse 
correlation (Figure S3E). This is exemplified for miR-294, which targets TgfbR2, and for let-7, 
which targets Lin2817. To extend this analysis beyond well-established miRNA-mRNA pairs, 
we built a table that links the expression changes during reprogramming of all differentially 
expressed miRNAs to their putative mRNA targets (Figure 4H, Figure S3F and Extended 
Experimental Procedures). Indeed, the previously validated let-7c targets Lin28, N-Myc, and 
Sall4 and the miR-294 targets Lats2, TgfbR2, and Akt1 exhibited high negative correlation 
scores (Figure S3F). This analysis further suggested that the pluripotency factor Esrrb, 
the histone methyltransferases Suv39h1/2, and the coactivator Ncoa3, all of which are 
implicated in cellular reprogramming, are likely targets of let-7c, whereas the documented 
iPSC-inhibitory factor Prrx118 is predicted to be targeted by miR-294. 
Unexpectedly, Mir-302a, whose forced expression was also shown to enhance iPSC 
generation in the context of the Yamanaka factors17, exhibited transient activation specifically 
in Oct4-GFP+ cells at day 12 but remained otherwise unchanged (Figures S3G and S3H). Mir-
302a is normally expressed in mouse epiblast stem cells16 but barely detectable in mouse 
ESCs, suggesting that iPSC induction might entail a transient passage through an epiblast-
like state before reaching naive pluripotency. In agreement with this idea, we detected 
(Continued from right) (C) Principle component analysis of microRNA expression data of 
FACS-sorted subpopulations at the indicated time points. (D) Unsupervised hierarchical 
clustering of indicated microRNA expression profiles. (E) Number of differentially expressed 
(DE) microRNAs between THY1+ and SSEA1+ cells at indicated time points. (F) Number 
of differentially expressed microRNAs between progressing SSEA1+ cell populations 
at successive time points. (G) Examples of microRNA profiles that change in dynamic 
patterns. (H) Predicted target genes of let-7c (Targetscan database) are shown based on 
inverse expression patterns with let-7c. Examples of putative targets with an inverse 
expression score of 0.8 or lower are shown. Targets marked by red asterisks have previously 
been validated. (I and J) iPSC formation efficiencies (I) and Oct4-GFP FACS quantification of 
reprogrammable MEFs treated with mimics for miR-182 or miR-214 (J). Data are represented 
as mean ± SEM (n = 3). See also Figure S3. 
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Figure 4. Predicted Reprogramming Factor Activities and MicroRNA Expression Dynamics 
(A) Transcription factor (TF) activities for c-MYC, KLF4 and the SOX2-OCT4 dimer based on 
network component analysis. Shown below are examples of activated (red) or repressed 
(green) targets. (B) Expression dynamics of an early (Fut9; left) and late (Lefty1; right) OCT4/
SOX2 target during reprogramming. Shown below is promoter ChIP analysis for OCT4 and 
SOX2. (Continued on left) 
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transient downregulation of a number of putative Mir-302a targets in Oct4-GFP+ cells such 
as Rbl2, Rab11fip5, Rbbp6, and transient, albeit modest, upregulation of epiblast stem cell-
associated markers including Brachyury (T), Cer1, Foxa2, Eomes, and Fgf5 (Figures S3G and 
S3I). It remains to be tested whether activation of Mir-302a and associated transcripts takes 
place in all or only a subset of Oct4-expressing intermediate cells. Also, we cannot rule out 
the possibility that these transient expression changes are the result of aberrant targeting of 
exogenous OKSM to the respective genes, resulting in their activation or repression. 
We finally wondered whether our miRNA expression data would allow us to identify 
novel modulators of reprogramming. Indeed, gain-of-function of miR-182 by mimics 
increased, whereas that of miR-214 decreased iPSC formation, consistent with their 
transcriptional changes during reprogramming (Figures 4G, 4I, and 4J). 
Differential Chromatin States Provide an Epigenetic Logic for Early, Gradual, 
and Late Gene Regulation 
We and others have previously shown that both transcriptional and DNA/histone 
methylation patterns are reset from a somatic state to a pluripotent state upon 
reprogramming into iPSCs13,19. However, it is unknown when these epigenetic changes 
occur during reprogramming and whether there is a hierarchy in their establishment and 
erasure, respectively. In an attempt to resolve these questions, we analyzed active and 
repressive histone methylation marks (histone H3 lysine 4 and lysine 27 trimethylation 
H3K4me3/H3K27me3) and DNA methylation patterns at a genome-wide scale in SSEA1+ 
cells throughout reprogramming. Analysis of H3K4me3 and H3K27me3 ChIP-seq patterns 
in progressing intermediates showed two waves (Figures 5A and 5B), which coincided with 
the observed mRNA and miRNA phases (Figures 5C and 5D). Kinetic analysis of bivalency 
formation (H3K4me3/H3K27me3 enriched promoters)20 at genes that changed expression 
during reprogramming showed an initial burst of ~110 targets by day 3, which gradually 
increased to ~130 at day 9, ~160 by day 12, and ~180 in established iPSCs (Figure 5F, Figure 
S4A). Thus, activating and repressive histone marks individually exhibit a biphasic pattern 
akin to coding and noncoding genes, whereas the establishment of differentially expressed 
bivalent promoters is a more gradual process. 
An examination of histone marks at genes that changed their transcription in 
characteristic patterns allowed us to study their underlying chromatin dynamics (Figure 
5G and Table S1). Consistent with the different gene expression categories (Figure 2E), we 
were able to distinguish between genes that changed their H3K4me3 and H3K27me3 status 
early (day 3), at intermediate stages (day 6–9), or late (day 12). For example, the fibroblast-
associated gene Pdgfrb was downregulated by day 3, which coincided with the early loss 
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of H3K4me3 and subsequent acquisition of H3K27me3 marks, suggesting efficient access 
of this locus by chromatin silencers. In contrast, the MEF expressed gene Zfpm2 showed 
a gradual decrease in H3K4me3 marks and a concomitant increase in H3K27me3 marks, 
resulting in a bivalent state and transcriptional silencing around day 9, whereas the Lats2 
gene became decorated by H3K27me3 and was transcriptionally silenced only by day 12. 
Similar to the deposition of H3K27me3 marks and the concomitant silencing of MEF-
specific genes, we observed distinct classes of pluripotency genes that gained H3K4me3 and 
lost H3K27me3 at different time points (e.g., Fgf4, Sall4, and Lin28) (Figure 5G). Lastly, genes 
that changed their expression transiently acquired H3K4me3 or H3K27me3 in a temporally 
restricted manner (e.g., Prx, Klf2) (Figure 5G). We deduce from these results that the kinetics 
of silencing of MEF genes and activation of ESC genes is determined by a combination of 
parameters, including the type and complexity of underlying histone modifications as well 
as the availability and accessibility of transcription factors to regulate a given target (see 
Figure 4B). Indeed, the vast majority of genes (~90%) that were activated early or gradually 
(categories I and II; see Figure 2E) already carried activating H3K4me3 marks in MEFs (Figure 
5E and Figure S4B), thus complementing observations made in a previous study (Koche et 
al., 2011). In contrast, genes that were activated late (category III, e.g., Oct4, Nanog) are 
often unmarked (~15% of genes) or bivalent (~15%) in MEFs, suggesting that loci associated 
with these chromatin patterns are more resistant to transcriptional activation. 
DNA Methylation Patterns Are Reset Late in Reprogramming 
In contrast to gene expression and histone modification patterns, genome-wide promoter 
DNA methylation changes occurred predominantly late in reprogramming as determined 
by HELP analysis (Figure 5H). Equal numbers of methylated restriction sites were gained 
and lost after day 9, indicating that a comparable number of loci became methylated 
and demethylated, respectively. In agreement, we found that enzymes implicated in 
DNA methylation and demethylation, such as Dnmt3a, Dnmt3L, Apobec2, and Tet1 were 
transcriptionally upregulated late and specifically in SSEA1+ cells (Figure 5I). To confirm these 
global changes of DNA methylation at single base-resolution, we investigated promoter 
methylation levels at a number of candidate loci by mass array EpiTYPEr on genomic DNA 
isolated from SSEA1+ intermediates. We found that pluripotency-associated genes, such 
as Nanog, OCT4, and Zfp42 (Rex1) became demethylated very late during reprogramming 
(~days 9–12) (Figure 5J and Table S3). Similarly, genes that are normally methylated in 
pluripotent cells but demethylated in fibroblasts, including HoxA10 and Gja8, became de 
novo methylated late. 
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Rescue of Refractory Cells by Increased OKSM Expression 
A comparison of gene expression intensities among the different subpopulations showed 
that THY1 and THY1+ cells generally failed to regulate ESC-enriched and MEF-enriched 
mRNAs and miRNAs to the same extent as SSEA1+ cells (Figures 6A and 6B). Although this 
observation cannot be explained by differential transcription of the OKSM transgene in these 
subpopulations (Figure 6C), we were surprised to detect substantially increased protein levels 
for OCT4 in SSEA1+ cells compared with THY1+ cells (Figures 6D and 6E). Consistently, we 
observed a 20%– 25% reduction in the number of THY1+ and THY1 cells and a concomitant 
400% increase in the number of SSEA1+ cells when inducing reprogrammable MEFs carrying 
two copies of the OKSM cassette and Rosa26-M2rtTA allele (Ho/Ho), respectively, with dox 
compared with MEFs that only contained one copy of each transgene (Het/Het) (Figure 6F). 
To test whether elevated OKSM protein levels could rescue refractory THY1+ cells at 
different stages of reprogramming, we infected THY1+ cells isolated at days 3, 6, 9, and 12 of 
dox induction from Het/Het reprogrammable MEFs with viral vectors expressing additional 
copies of OKSM (Figure 6G). Remarkably, THY1+ cells receiving extra copies of OKSM, but not 
untreated control cells or cells infected with c-MYC vector alone, gave rise to a substantial 
number of Oct4-GFP+ iPSC colonies (Figures 6H and 6I). This result thus documents that the 
inability to sustain OKSM protein expression in THY1+ cells on or after day 3 contributes to 
their failure to form iPSCs. 
Identification of Molecules to Enrich for Cells Poised to Becoming iPSCs 
In a last set of experiments, we aimed to identify new surface markers that would allow 
further enrichment for subpopulations of cells undergoing reprogramming in comparison 
with THY1, SSEA1, and Oct4-GFP expression. We focused on the molecules c-KIT, EpCAM, 
and PECAM1 because of their expression patterns specifically in SSEA1+ intermediates 
(EpCAM, early gene; c-Kit, intermediate gene; PECAM1, late gene) (Figure 7A and Figure 
(continued from right) in relation to their chromatin status in MEFs. (F) Number of 
differentially expressed genes that become bivalent (H3K27me3 and H3K4me3 enriched) 
during reprogramming (red dots = bivalent promoters) and quantification. 
(G) Integration of gene expression and histone modification data define subsets of genes 
with characteristic expression changes. Shown are examples of fibroblast-associated (top), 
pluripotency-associated (center), and transiently changing genes (bottom). (H) Number 
of genes, which change DNA methylation status in progressing cell populations during 
reprogramming as determined by genome-wide methylation analysis (HELP). (I) Expression 
dynamics of candidate genes associated with DNA methylation and demethylation. (J) 
Heatmap of DNA methylation patterns of specific CpGs (boxes) in the promoter regions of 
indicated genes during reprogramming with EpiTYPER DNA methylation analyses. Yellow 
indicates 0% methylation, and blue represents 100% methylation. See also Figure S4.
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Figure 5. Histone and DNA Methylation Dynamics during Cellular Reprogramming (A and 
B) Enrichment for H3K4me3 or H3K27me3 at promoters of differentially expressed genes 
in progressing intermediates. (C and D) Superimposition of principal component analyses 
for genes enriched in H3K4me3 (C) or H3K27me3 (D) (triangles) with gene expression data 
(circles) of the same cell populations (see Figure 2A for color coding). (E) Display of activated 
genes from gene expression categories I, II, and III (see Figure 2E) (Continued on left)
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S5A). Notably, EpCAM+ cells were first detectable at day 6 in a fraction (~25%) of SSEA1+ 
cells. In contrast, c-Kit became upregulated only by day 9 in ~25% of SSEA1+ cells, whereas 
PECAM1 was detectable exclusively in SSEA1+, Oct4-GFP+ cells at day 9. Altogether, these 
results show that EpCAM, c-Kit, and PECAM1 become activated at successive time points 
in subsets of SSEA1+ cells. This experiment further documents that SSEA1+ intermediates 
that activated the endogenous Oct4(-GFP) locus are generally more homogeneous for these 
three markers than are SSEA1+ Oct4-GFP+ cells at day 6 and day 9. 
To assess the functional value of these markers, we sorted SSEA1+ EpCAM and SSEA1+ 
EpCAM+ cells 6 days after dox induction and plated equal numbers on feeders for another 
8 days in the presence of dox. Counting of dox-independent alkaline phosphatase-positive 
colonies 5 days later showed a modest but significant increase in reprogramming efficiency 
among SSEA1+ EpCAM+ intermediates (Figure 7B). In agreement, expression analysis of 
both subpopulations revealed subtle differences with 68 genes being upregulated and 
48 genes being downregulated more than 2-fold (Figure 7C). Upregulated genes included 
Nanog (11-fold), ERas (7-fold), Sox2, Nr0b1, Sall4, Nr5a2, and Tdgf1 (3to 5-fold). Surprisingly, 
the core transcription factor Oct4 was not differentially expressed, which is consistent with 
the absence of Oct4-GFP signal at this time point. At the epigenetic level, Nanog promoter 
methylation levels were reduced by 50%, whereas OCT4 promoter methylation levels 
decreased only mildly (Figure 7D and Figure S5B). These findings thus suggest that there is a 
hierarchy in the activation of core pluripotency factors within SSEA1+ cells with Nanog and 
associated transcripts being activated before. 
Discussion
Our results constitute a comprehensive analysis of transcriptional and epigenetic changes 
in phenotypically defined intermediates of iPSC induction. These data have elucidated 
the identity and order of molecular changes inherent to transcription factor-induced 
reprogramming (see Figure 7 for summary of observations) and provide a rich resource of 
data to further dissect the mechanisms of induced cell fate transitions. Our findings suggest 
that the reprogramming of somatic cells follows a similar sequence of epigenetic changes 
as is seen during normal somatic cell differentiation; differentiating cells are thought 
to undergo transcriptional and histone modification changes before DNA methylation 
changes21. It will be interesting to assess whether the rather abrupt loss of methylation after 
day 9 is solely the consequence of a replication-dependent passive process or also involves 
active demethylation. Notably, methylation changes coincided with the acquisition of a 
stably reprogrammed state and are in line with the interpretation that methylation patterns 
stably lock in the reprogrammed state. 
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Our molecular analysis allowed us to define nine categories of dynamically expressed 
genes, which characterize distinct stages of reprogramming and whose overexpression or 
knockdown enhanced iPSC formation. We surmise that a failure to activate these (Figure 
2F) and related genes constitute roadblocks of reprogramming and is part of the reason 
why iPSC formation is inefficient and takes relatively long. Our observation of two major 
transcriptional waves and an intermediate period of less transcriptional change is reminiscent 
of a previous study that has identified an ‘‘initiation,’’ ‘‘maturation,’’ and ‘‘stabilization’’ 
phase when examining bulk populations of cells expressing OKSM6. The observed transient 
activation/repression of developmental regulators may indicate that the OKSM proteins 
aberrantly activate/repress these targets or, alternatively, that (some) reprogramming 
intermediates undergo a transient phase of transdifferentiation or dedifferentiation as 
part of the reprogramming process. Our results might thus explain recent successes in 
deriving epiblast stem cells, neural progenitors, or cardiomyocytes directly from fibroblasts 
upon brief expression of OKSM and exposure to culture conditions conducive of the 
respective cell type22. This finding could be potentially exploited to generate other desired 
cell fates directly from fibroblasts. We have applied a mathematical model that faithfully 
predicts activation of OKSM targets in the course of reprogramming. Our results provide 
a transcriptional logic for the previously seen early requirement for c-MYC14 and the late 
requirement for SOX223 during reprogramming and suggest an unanticipated dual function 
for KLF4 by predominantly repressing somatic targets early and activating pluripotency 
targets late in iPSC formation. Our finding that THY1+ refractory cells produce less OKSM 
protein and thus fail to properly regulate target gene expression compared with SSEA1+ 
cells warrants further examination. One plausible molecular explanation is that the OKSM 
factors are prone to more ubiquitination-mediated degradation in THY1+ cells24. 
We recognize the fact that SSEA1+ cells, although enriched for cells poised to forming 
iPSCs, still exhibit some degree of heterogeneity. Single-cell analysis of 26 genes as well as 
FACS analysis of three additional genes (EpCAM, c-Kit, and PECAM) documented that gene 
expression changes occur more homogeneously at early (0–3 days) and late time points 
(day 9 onward), whereas they are more heterogeneous at intermediate stages (days 6–9). 
There is some debate as to whether reprogramming entails a hierarchic/deterministic or 
probabilistic/stochastic process25. A previous study identified an early deterministic phase of 
reprogramming26, whereas another recent report concluded that reprogramming involves 
an early stochastic and a late deterministic phase27. Our data may explain both observations, 
and we therefore suggest that iPSC formation follows an early and late deterministic phase, 
which is separated by a more probabilistic phase. With the aid of new surface marker, such 
as EpCAM, PECAM, and c-KIT, or novel reporter alleles, it may be possible to identify rare 
intermediates that progress toward iPSCs in a purely deterministic manner. 
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Methods
Reprogramming Experiments
Murine Embryonic fibroblast (MEF) cultures were established from E13.5 embryos from 
reprogrammable mice carrying one (het/het) or two (ho/ho) copies of the OKSM cassette 
and ROSA26-M2rtTA allele10. Reprogramming was performed in ESC medium (KODMEM with 
15% FBS, L-Glutamin, penicillin-streptomycin, nonessential amino acids, b-mercaptoethanol 
and 1000 U/ml LIF) in the presence of doxycycline. Tail fibroblasts were established from 
3cm tail snips after removing skin and hair and chopping up the tail with scalpels in trypsin. 
Reprogramming was initiated by direct infection of cells with two separate lentiviral vectors 
delivering tetOP-OKSM and M2rtTA, respectively as described previously9,28. All procedures, 
including maintenance of animals, were performed according to a mouse protocol approved 
by the MGH Subcommittee on Research Animal Care. Tbx21-ZsGreen mice were generated 
as previously described29; these mice were bred and maintained in the NIAID-specific 
pathogen free animal facility and the experiments were done under a protocol approved by 
the NIAID Animal Care and Use Committee.
Viral Vectors and Production
293T cells were transfected with lentiviral vectors, VSV-G and Δ8.9 plasmids and Fugene. 
Viral supernatant was collected after 36, 48 and 60 hr. postinfection and filtered through a 
40um filter. Supernatant was concentrated approximately 100-fold by ultracentrifugation at 
20,000rpm for 1.5 hr. at 4C, resuspended in 300 μl 1× PBS, and stored at −80°C. Infections 
were carried out in 1 ml medium with polybrene diluted 1:2,000 and 20 μl of each viral 
concentrate were used per well of a 6-well plate for 12 hr. Infected cells were trypsinized 
and replated in triplicate at densities of 3,000-5,000 cells per well of a 6-well on irradiated 
feeder cells for reprogramming experiments.
Calculation of Reprogramming Efficiencies
Equal numbers of cells were plated in the absence or presence of doxycycline on 100 mm 
dishes coated with gelatin and containing a layer of irradiated MEF feeders. Efficiencies 
(Continued from right) (G) Experimental outline to rescue refractory THY1+ cells by supplying 
viral copies of OKSM. (H) Alkaline phosphatase stained colonies obtained after infecting 
THY1+ reprogrammable cells at indicated days with a dox-inducible vector expressing 
OKSM. Controls were uninfected, dox-treated THY1+ cells (‘‘Dox’’) and THY1+ cells infected 
with c-MYC virus alone. Representative Oct4-GFP+ colonies are shown at the bottom. (I) 
Quantification of results in (G). Data are represented as mean ± S.E.M. (n = 3)
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Figure 6. Rescue of Refractory THY1+ Cells by Increased OKSM Expression. (A) Box plot 
depicting average expression levels in THY1+ cells, THY1 cells and SSEA1+ cells of genes that 
are significantly upregulated between MEFs and iPSCs. (B) Expression dynamics of indicated 
MEF-associated and ESC-associated transcripts in THY1+, THY1 and SSEA1+ cells (see Figure 
2A for color coding). (C) Exogenous OCT4 expression levels, normalized to GAPDH for the 
indicated cell populations and time points. 
(D) Western blot analysis for OCT4 and gamma-tubulin (g-tub) for the indicated cell 
populations and time points. Higher molecular weight band for exogenous OCT4 compared 
with endogenous OCT4 (iPSC) reflects unprocessed protein originating from the polycistronic 
construct as described previously by Carey et al. (2011)35. (E) Densitometric quantification of 
western blot analysis shown in (D). AU is an abbreviation for arbitrary units. 
(F) FACS analysis of reprogrammable fibroblasts carrying one (Het/Het) or two (Ho/Ho) 
copies each of the OKSM cassette and Rosa26-M2rtTA allele (top row). Bottom row shows 
FACS analysis for SSEA1 and Oct4-GFP of the same samples. (Continued on left)  
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were determined ~20 days later by dividing the number of Alkaline Phosphatase positive or 
Oct-4-GFP positive iPSC colonies that grew after withdrawal of doxycycline by the number 
of seeded cells. For determining reprogramming efficiencies of FACS-sorted intermediates 
at different time points (Figure 1), isolated cells were plated on feeders and grown in the 
presence of dox for an additional number of days, so that every cell population was exposed 
to dox for a total of 12 days, followed by withdrawal of dox for 5 days before colonies were 
scored.
Alkaline Phosphatase Staining
Alkaline phosphatase (AP) staining was performed with an Alkaline Phosphatase substate kit 
(Vector laboratories) according to manufacturer’s recommendations.
RNA Analysis, mRNA profiling and microRNA profiling
iPSCs were harvested when they reached about 50% confluency and preplated on 
nongelatinized T25 flasks for 45 min to remove feeder cells. Intermediate cell types were 
harvested after FACS sorting. Cells were spun down and the pellet used for isolation of total 
RNA with the miRNeasy Mini Kit (QIAGEN) without DNase digestion. RNA was eluted from 
the columns with 50 ml RNase-free water or TE buffer, pH 7.5 (10 mM Tris-HCl and 0.1 mM 
EDTA) and quantified with a Nanodrop machine (Nanodrop Technologies).
Total RNA samples (RIN > 8) were subjected to transcriptomal analyses with Affymetrix 
HTMG- 430A mRNA expression microarrays as previously described. All microarray data will 
be available from the GEO repository.
For miRNA, RNA was isolated with the miRNeasy Mini Kit (QIAGEN) and submitted to Exiqon 
for micro-RNA profiling with the miRNAmiCURY LNA microRNA Profiling platform. Each 
sample was labeled with the miRCURY Hy3/Hy5 power labeling kit and hybridized on Exiqon 
BWA 0.5.9 arrays against a pool of all samples. All microarray data will be available from the 
GEO repository.
Quantitative PCR Detection of mRNA and miRNA
cDNA was produced with the first Strand cDNA Synthesis Kit (Roche) with 1 mg of total 
RNA input. Real-time quantitative PCR reactions were set up in triplicate with 5 ml of cDNA 
(1:100 dilution) with the Brilliant II SYBR Green QPCR Master Mix (Stratagene) and run on a 
Mx3000P QPCR System (Stratagene). Primer sequences are listed in Table S1.
miRNAs were extracted from MEFs, iPSCs and reprogramming intermediates (SSEA1+ cells 
at day 3, SSEA1+ cells at day 6, SSEA1+ cells at day 9, SSEA1+/Oct4-GFP+ cells at day 12) 
with the mirVana miRNA isolation kit (Life Technologies). Using the first Strand III kit (Life 
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Technologies), we reverse transcribed 10 ng of RNA into cDNA by using specific primers 
for miRNA-302a or housekeeper snoRNA-135 (Life Technologies). Subsequently Taqman 
assays (LifeTechnologies) against miRNA-302a or snoRNA-135 were used for quantification 
on a LightCycler 480 instrument (Roche). The housekeeping snoRNA-135 was used for 
standardization.
HELP DNA Methylation Analysis
High-molecular-weight DNA was isolated from iPSCs with the PureGene kit from QIAGEN 
(Valencia, CA) and the HELP (HpaII tiny fragment enrichment by ligation mediated PCR) 
assay was carried out as previously described30. Briefly, One microgram of genomic DNA 
was digested overnight with either HpaII or MspI (NEB, Ipswich, MA). On the following day 
the reactions were extracted once with phenol-chloroform and resuspended in 11 μl of 10 
mM Tris-HCl pH 8.0 and the digested DNA was used to set up an overnight ligation of the 
JHpaII adaptor with T4 DNA ligase. The adaptor-ligated DNA was used to carry out the PCR 
amplification of the HpaII and MspI-digested DNA as previously described30. All samples 
for microarray hybridization were processed at the Roche-NimbleGen Service Laboratory. 
Samples were labeled with Cy-labeled random primers (9mers) and then hybridized onto a 
mouse custom-designed oligonucleotide array (50-mers) covering 25,720 HpaII amplifiable 
fragments (HAF) (>50,000 CpGs), annotated to 15,465 unique gene symbols (Roche 
NimbleGen, Design name: 2006-10-26_MM5_HELP_Promoter Design ID = 4803). HpaII 
amplifiable fragments are defined as genomic sequences contained between two flanking 
HpaII sites found within 200-2,000 bp from each other and is represented on the array 
by 15 individual probes, randomly distributed across the microarray slide. HAF were first 
realigned to the MM9 July 2007 build of the mouse genome and then annotated to the 
nearest transcription start site (TSS), allowing for a maximum distance of 5 kb from the TSS. 
Scanning was performed with a GenePix 4000B scanner (Axon Instruments) as previously 
described (Figueroa et al., 2009). Quality control and data analysis of HELP microarrays were 
performed as described30.
Signal intensities at each HpaII amplifiable fragment were calculated as a robust 
(25% trimmed) mean of their component probe-level signal intensities. Any fragments 
found within the level of background MspI signal intensity, measured as 2.5 mean-absolute-
differences (MAD) above the median of random probe signals, were categorized as “failed.” 
These “failed” loci therefore represent the population of fragments that did not amplify 
by PCR, whatever the biological (e.g., genomic deletions and other sequence errors) or 
experimental cause. On the other hand, “Methylated” loci were so designated when 
the level of HpaII signal intensity was similarly indistinguishable from background. PCR-
amplifying fragments (those not flagged as either “methylated” or “failed”) were normalized 
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with an intra-array quantile approach wherein HpaII/MspI ratios are aligned across density-
dependent sliding windows of fragment size-sorted data. DNA methylation was therefore 
measured as the log2(HpaII/MspI) ratio, where HpaII reflects the hypomethylated fraction 
of the genome and MspI represents the whole-genome reference. Analysis of normalized 
data revealed the presence of a bimodal distribution. For each sample a cutoff was selected 
at the point that more clearly separated these two populations and the data were centered 
around this point. Each fragment was then categorized as either methylated, if the centered 
log HpaII/MspI ratio was less than zero, or hypomethylated if on the other hand the log ratio 
was greater than zero. All microarray data will be available from the GEO repository.
Quantitative DNA Methylation Analysis by MassARRAY EpiTyping
Single locus methylation analysis was performed by MALDI-TOF mass spectrometry 
with EpiTyper by MassARRAY (Sequenom, CA) on bisulfite-converted DNA following 
manufacturer’s instructions46 but with the Fast Start High Fidelity Taq polymerase from 
Roche for the PCR amplification of the bisulfite converted DNA. MassArray primers were 
designed to cover the promoter regions of the indicated genes and sequences are given in 
Table S1.
DNA Methylation Analysis by Pyrosequencing
Frozen cell pellets were sent to EpigenDx (Hopkinton, MA) for DNA isolation, bisulfite 
treatment, and pyrosequencing. For Nanog, CpGs 1-7 correspond to positions −541, 
−502, −491, −434, −412, −302, and −280 from the transcription start site, respectively. For 
OCT4, CpGs 1-6 correspond to positions −165, −140, −127, −103, −99, and −47 from the 
transcription start site, respectively.
Flow Cytometry and Immunofluorescence
For flow cytometry, harvested cells were incubated with antibodies against THY1.2 (PE or 
eFluor450, 53-2.1, eBioscience) and SSEA-1 (purified, MC-480, Developmental Hybridoma 
Bank; biotin, MC-480, eBioscience; or AlexaFluor647, MC-480, BioLegend) for 20 min. Cells 
were washed in PBS and then incubated for 20 min with APC conjugated anti mouse IgM 
(eBioscience), streptavidin PerCP (BD PharMingen), or streptavidin Pacific Blue (Invitrogen). 
The cells were washed in PBS, resuspended in propidium iodide or 4’,6-diamidino-2-
(continued from right) (B) Potential of EpCAM subpopulations at day 6 to form iPSC 
colonies. (C) Affymetrix expression analysis of EpCAM subpopulations. 
(D) Methylation analysis of Nanog promoter by bisulfite sequencing of ESCs, MEFs and 
intermediates shown in (B). The following abbreviations are used: S, SSEA1; Ep, EpCAM. 
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Figure 7. Identification of Surface Markers to Enrich for Reprogramming Intermediates, 
and Model. (A) Expression data and histogram plots of FACS analysis for c-Kit, EpCAM, and 
PECAM1 in SSEA1+ and Oct4-GFP+ populations at the indicated days of reprogramming. Red 
lines depict antibody-specific signal, blue lines show signal obtained with isotype control. 
No expression was seen before day 6. (continued on left)
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phenylindole 5% FBS/PBS solution and passed through a 40mm cell strainer to achieve 
single-cell suspension. Cells were sorted on a FACSAria (BD Biosciences), Influx cell sorter 
instrument (BD Biosciences) and/or analyzed in a LSRII (BD Bioscience). For analysis and/or 
sorting of intermediates, cells were stained with THY1.2 and SSEA1 antibodies and sorted 
or analyzed as indicated. Additional antibodies include anti-EpCAM (PE, G8.8, eBioscience), 
anti-PECAM-1 (PE, 390, eBioscience), Rat IgG2a κ Isotype Control (PE, eBR2a, eBioscience), 
and anti-c-Kit (APC, 2B8, eBioscience). For the c-Kit stain, an APC unstained control was used 
as the negative staining control.
MicroRNA Mimics Experiments
Reprogrammable MEFs were counted and seeded in fibroblast medium at a density of 
20,000 cells/well on 12-well gelatin-coated plates. The following day, MEFs were transfected 
in 12-well plates, with Lipofectamine RNAiMAX Reagent (Life Technologies) according to 
the manufacturer’s instructions. MiR-182 and hsa-miR-214 overexpression and inhibition 
were obtained from mirVana miRNA Mimics and Inhibitors (Life Technologies). Briefly, 
miRNA mimics and inhibitors (30 pmol) in 100 μl of serum and antibiotic-free medium Opti-
MEM (Life Technologies), were mixed with 2 μl of Lipofectamine RNAiMAX Reagent (Life 
Technologies), dissolved in 100 μl of Opti-MEM (Life Technologies), and left to incubate 
at room temperature for 20 min. Both transfection solutions (200 μl volume) were added 
to each well containing 1 ml of ES cell medium containing LIF and doxycycline (minus 
antibiotic). Four hours later, the cultures were replaced with 1 ml of fresh ES cell medium 
supplemented with antibiotics. All test and control experiments were performed in triplicate 
wells. After 15 days of culture in the presence of doxycycline, followed by an additional 5 
days in the absence of doxycycline, the presence of iPS cell colonies was scored according 
to morphology and GFP fluorescence (indicative of Oct-4 expression) on an Olympus 1x71 
inverted fluorescence microscope and processed with the analySIS image capture software.
For flow cytometry analysis, day 20 transfected cultures were dissociated into 
single cells with 0.25% Trypsin-EDTA (Life Technologies) and filtered through a 40-μm 
cell strainer (Falcon). Live cells were gated according to side-scatter, forward-scatter and 
propidium iodide exclusion. Flow cytometric gates were designed with control ES cells with 
the inclusion of propidium iodide. Flow cytometric analysis of GFP was used as a reporter 
for monitoring endogenous Oct-4 expression. Analysis was performed with the BD LSR II 
flow cytometer (BD Biosciences). Flow cytometric analysis was processed with Flowlogic 
software (Flowlogic).
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Immunofluorescence
For immunofluorescence, cells were washed twice with PBS, fixed with 10% formalin 
solution (Sigma-Aldrich) for 15 min, washed twice with PBS and blocked for 1 hr. at room 
temperature (RT) with PBS containing 2% BSA (Fisher Scientific) and 0.1% Triton X-100 
(Fisher Scientific). The cells were then stained with primary antibodies diluted in blocking 
solution against mouse OCT4 (IgG, 1:200, Santa Cruz sc-8628), mouse SSEA1 (IGM, 1:200, 
eBioscience MC-480) and mouse PRX (IgG, 1:100, Santa Cruz sc-240773). The cells were 
washed twice with PBS and incubated with the appropriate secondary antibodies for 1 hr. 
in RT. The secondary antibodies used were Alexa Fluor 546 donkey anti goat IgG, Alexa Fluor 
488 goat anti mouse IgG and Alexa Fluor 488 goat anti mouse IgM. DNA was counterstained 
with DAPI (Invitrogen). Images were taken with Leica DMI4000B inverted fluorescence 
microscope equipped with a Leica DFC350FX camera.
Chromatin Immunoprecipitation and ChIP-Seq analysis
Cells were fixed in 1% formaldehyde for 10 min, quenched with glycine and washed 3 times 
with PBS. Cells were then resuspended in lysis buffer and sonicated 10 × 30 s in a Bioruptor 
(Diagenode, Philadelphia, PA) to shear the chromatin to an average length of 600 bp. 
Supernatants were precleared with Protein-A/G Dynabeads (Invitrogen) and 10% input was 
collected. Immunoprecipitations were performed with antibodies to H3K4trimethylated, 
H3K27trimethylated (Millipore) and OCT4 and SOX2(Santa Cruz). DNA-protein complexes 
were pulled down using Protein-A/G Dynabeads (Invitrogen) washed. DNA was recovered 
by overnight incubation at 65°C to reverse crosslinks and purified using QIAquick PCR 
purification columns (QIAGEN, Maryland). Enrichment of the modified histones at different 
genes was validated by quantitative real time PCR.
For ChIP-Seq, Libraries were prepared from ChIP DNA experiments with the ChIP-seq 
Sample Prep Kit (Illumina) following manufacturer’s instructions46. The libraries were then 
sequenced with single end for 50 bp in GAII Illumina sequencer at the MGH next-Generation 
Sequencing Core. Raw reads were filtered with standard quality control measures and reads 
that passed this prefiltering step were aligned with the BWA algorithm (version 0.5.9) to the 
mouse genome (Mm9 build).
Single-Cell Expression Analysis
Template for single-cell PCR was produced with Life Technologies’ Single cell to Ct kit 
according to manufacturer’s instructions. Briefly, single cells for each time point (MEFs; 
SSEA1+ cells at day 3, day 6, day 9; and iPSCs) were directly sorted (Influx cell sorter 
instrument, BD-Biosciences) into separate wells of qPCR 96-well plates containing cell 
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lysis solution. Following a cDNA synthesis step, target sequences were preamplified for 18 
cycles according to instructions. Single-cell PCR and data collection were performed with 
a Biomark instrument (Fluidgm). For both preamplification and single-cell PCR, Taqman 
probes (Life Technologies) were used (see Table S1). Results are expressed as Log2Ex = LOD 
(Limit of Detection) Cq – Cq [Gene]. The limit of detection was set to 30. If Log2Ex value is 
negative, Log2Ex = 0.
Statistical and Bioinformatic Analyses
All statistical and bioinformatics analysis was performed with the R / Bioconductor software 
suite. mRNA and miRNA data were preprocessed and quantile normalized with the RMA 
method 31. HELP DNA methylation data were normalized with an intra-array quantile 
approach. Differentially expressed or methylated genes were identified for different 
comparisons with a t test with Benjamini and Hochberg correction (p ≤ 0.05)32. Hierarchical 
clustering was performed with correlation distances and the Ward method. For transcription 
factor meta-analysis, we identified three ChIP-Chip data sets from the published literature 
for Oct4, Sox2, Klf4, Myc, and Nanog14,33,34. Of our differentially expressed mRNA targets, 
we identified those that were bound by each of these factors in at least two published 
experiments. We then used this information and our differentially expressed mRNA profiles 
to calculate transcription factor activity profiles with network component analysis15. ChIP-
seq coverage was plotted by centering a −10Kb and +5Kb window on the transcriptional start 
site for each gene. Differential histone methylation changes were determined with a 2-fold 
cutoff. Gene ontology analysis was performed with the GOstats package. To integrate mRNA 
and miRNA expression data, we listed potential mRNA targets based on a scoring algorithm 
that combined the presence of seed sequences (with “targetscan” and “mirSVR” databases) 
and inverse mRNA-miRNA expression patterns. Genes whose expression inversely correlated 
with that of their predicted microRNA (high negative correlation value) are expected to be 
high confidence targets.
Supplemental Information includes three tables and can be found with this article online at 
http://dx.doi.org/10.1016/j.cell.2012.11.039.
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Figure S1. Comparison of Gene Expression Data from Progressing Intermediates with Those 
of Refractory Cells, Partially Reprogrammed iPSCs and Bulk Populations Expressing OKSM, 
Related to Figure 2 (A) Ten of the <?>200 genes that are aberrantly activated in refractory 
THY1+ cells (see Figure 2E). (B) Failure to regulate mesenchymal-to-epithelial (MET)-
associated genes in refractory cells. (C) Potential biomarker that might distinguish refractory 
(THY1+) cells from progressing (SSEA1+) cells at day 3 when overall gene expression is very 
similar. Shown are all genes that are differentially expressed (DE) more than two-fold. (D) 
Principal component analysis of gene expression profiles of FACS-sorted populations (circles) 
in comparison with published data sets for partially reprogrammed iPSCs (piPSCs) (gray 
symbols) and bulk populations expressing Oct4, Sox2, Klf4 and c-Myc (turquois triangles). 
Dashed red line depicts reprogramming path. ‘‘dox+,’’ dox-dependent piPSC line on dox; 
‘‘dox-,’’ same cell line <?>10 days after dox withdrawal. (E) iPSC formation frequencies upon 
overexpression of individual or combination of genes shown in Figure 2G.
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Figure S2. Fluidigm Single-Cell Gene Expression Analysis of Reprogramming Intermediates, 
Related to Figure 3 (A) Heatmap of Fluidigm single-cell expression data and hierarchical 
clustering. Note that related genes cluster together within MEFs (black bar), intermediates 
at day 3 (green bar), day 6 (blue bar), day 9 (purple bar) and iPSCs (red bar). (B) Violin plots 
of gene expression data that are not shown in Figure 3. (C) Three examples of genes that 
show coexpression in single cells, either transiently (example #1), gradually (example #2) or 
late (example #3).
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Figure S3. OKSM Target Gene Analysis, Predicted miRNA/mRNA Pairs, and Transient 
Upregulation of Epiblast Stem Cell-Related Genes in Reprogramming Intermediates, Related 
to Figure 4 (A) Number of differentially expressed (DE) genes that are targets of OCT4, SOX2, 
c-MYC or KLF4 when comparing progressive SSEA1+ cell population at successive time points 
(d3 and d0, d6 and d3, d9 and d6, d12 Oct4-GFP and d9, and iPSCs and d12 Oct4-GFP). 
DE target genes of OCT4, SOX2and KLF4 represent both single targets and multi-targets. 
Only single targets are shown for c-MYC. Note dominant effect of c-MYC on gene activation 
specifically in the first wave. (B) Number of single and shared KLF4 and c-MYC target genes 
that are either upregulated or downregulated during the two gene expression waves. Note
overrepresentation of c-MYC targets among upregulated genes and of KLF4 targets 
among downregulated genes during first wave. Similar observations were made for other 
combinations of reprogramming factors and motivated us to generate a mathematical 
model of ‘‘transcription factor activities’’ that predicts the contribution of individual factors 
to gene expression by controlling for the respective other factors. (Continued on next page)
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(Continued from previous page) (C) Chromatin immunoprecipitation for OCT4 and SOX2at 
the Nanog promoter in SSEA1+ intermediates at indicated time points of reprogramming. 
(D) H3K4me3 and H3K27me3 maps of Nanog, Lefty1 and Fut9 promoter regions in SSEA1+ 
intermediates during reprogramming. (E) Expression dynamics of proven miRNA-mRNA 
pairs let-7i/Lin28 and miR-294/Tgfbr2. (F) Expression dynamics of miR-294 and miR-106a 
(left panels) and their predicted mRNA targets ranked by targetscan or mirSVR score and 
inverse expression score (r). Shown are examples of top anticorrelated putative targets 
with r = 0.8 or higher. (G) Transient upregulation of epiblast stem cell-associated mir-302 
and concomitant downregulation of two known targets (Rab11fip5 and Rbl2) at day 12. 
Epiblast marker Foxa2, Cer1 and T (brachyury) show similar transient activation at day 
12. (H) Verification of transient Mir-302a upregulation by quantitative PCR in indicated 
reprogramming intermediates. (I) Quantitative PCR for additional epiblast stem cell-
associated marker Fgf5 and Eomes at indicated time points of reprogramming.
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Figure S4. Bivalency Formation during iPSC Induction, and Correlation of Gene Expression 
Categories, I-IX, with Chromatin Marks in ESCs and MEFs, Related to Figure 5 (A) Number of 
bivalent domains (H3K27me3 and H3K4me3) at promoters depending on expression changes 
of associated genes (red dots = bivalent domains). Quantification is shown on the right. (B) 
Correlation of gene expression categories (I-IX) presented in Figure 2E with chromatin status 
in MEFs and ESCs/iPSCs (ESC/iPSC chromatin status is shown along the x axis, MEF status is 
shown by color coding). Note that genes that are induced early or gradually (categories I and 
II) show the most striking correlation with H3K4me3 enrichment status in MEFs.
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Figure S5. Flow Cytometry Analysis of EpCAM, PECAM1 and c-KIT in MEFs and ESCs, and 
Oct4 Promoter Methylation Analysis in EpCAM Subpopulations, Related to Figure 7 (A) 
Differential expression of EpCAM, c-Kit and PECAM on MEFs and ESCs, as determined by 
flow cytometry. Red lines depict antibody-specific signal, blue lines show signal obtained 
with isotype control. (B) Oct4 promoter methylation in day 6 SSEA1+ EpCAM+ and SSEA1+ 
EpCAM- intermediates.

109
Gain-of-function screen for enhancers of reprogramming identifies ERas
a3

111
Addendum 
chapter 3
A candidate screen for facilitators of 
reprogramming to pluripotency
identifies ERas and Tcl1
Marti Borkent, Matthias Stadtfeld, Jose Polo and Konrad Hochedlinger
112
Addendum to chapter 3 
Abstract 
Somatic cell reprogramming holds great promise to study cell plasticity and epigenetic 
regulation, to model diseases and to potentially regenerate tissues and organs. To further 
our understanding and usability of the technique, we sought to define factors that facilitate 
reprogramming to pluripotency. To this end, we selected candidates from the literature 
related to pluripotency, epigenetics, cell proliferation and apoptosis in order to overexpress 
during Oct4, Sox2, Klf4 and c-Myc (OKSM)-mediated reprogramming of mouse embryonic 
fibroblasts (MEF). Notably, out of the 24 candidates that were screened, Embryonic Ras 
(ERas) increases reprogramming efficiency up to 9-fold by colony count and reduces OKSM 
expression requirement by two days, while ERas knockdown reduces reprogramming 
efficiency by 60%. T Cell Leukemia 1 (Tcl1) overexpression boosts reprogramming up to 4 
fold and like ERas, is known to activate the PI3K/AKT signaling pathway. Accordingly, we 
find that PI3K inhibition, but not MAPK inhibition, rescues the effect of ERas overexpression 
on reprogramming. In conclusion, our data suggest that ERas and Tcl1 are involved in 
reprogramming, most likely through activation of the PI3K-AKT signaling pathway. Results 
from our group and other groups validate our approach of a candidate screen to study 
the poorly understood process of reprogramming cells to pluripotency based on educated 
guesses. 
Introduction
Pluripotency is the ability of a cell to form any tissue in the body. One kind of pluripotent 
cell is the embryonic stem cell (ESC), derived from the inner cell mass of a blastocyst stage 
embryo. Because ESCs can self-renew and be maintained in culture, they are of great 
promise to generate new tissue to treat degenerative disease by transplantation. Ethical and 
practical constraints limit the supply of human ESCs however, and ESC derived transplants 
are at risk of being rejected by the patient’s immune system. Induced pluripotent stem cells 
(iPSCs) derived from somatic cells can be used as a patient-specific alternative to embryonic 
stem cells (ESCs) for generating transplantable cells and tissues1. Moreover, the patient 
specific iPSCs can be used for modeling genetic diseases in vitro2. Hence, a better knowledge 
of the factors that are involved in the reprogramming process is key to predicting cellular 
behavior and the quality of the iPSCs if they are to be used for cell replacement therapy or 
for modeling diseases3,4 5. In addition, reprogramming into iPSC provides a platform to study 
cell fate changes, cellular plasticity and establishment of pluripotency on a molecular level6,7. 
Therefore, molecular and genetic approaches to determine key players in the reprogramming 
process are important for the understanding and usability of this technology8.
113
Gain-of-function screen for enhancers of reprogramming identifies ERas
a3
Facilitating factors in iPSC generation
Before the discovery of iPSCs, somatic cell reprogramming could be achieved by alternative 
methods such as somatic cell nuclear transfer (SCNT, or ‘cloning’) or fusion between a 
somatic cell and ESC. Transcription factor-mediated reprogramming into iPSCs does not 
require existing oocytes or ESCs, making it much more practical and applicable, but it is also 
much slower. SCNT or fusion-induced pluripotency is established within 24-48 hours, and 
is thought to be ‘deterministic’ because cells reprogram with a short latency. In contrast, 
iPSC derivation takes about two weeks at a minimum, because expression of the four 
reprogramming factors alone is not enough for the somatic cell to become pluripotent. Thus, 
these factors need to induce expression of other factors. Work in a defined homogenous 
cell population has shown that every somatic cell has the potential to form an iPSC, 
after a sufficient number of cell divisions, suggesting that transcription factor-mediated 
reprogramming is a stochastic process9.
To understand which factors are essential to reprogramming, we reasoned that 
overexpression of such ‘facilitators’, along with OKSM would increase the speed and 
efficiency of iPSC formation and eventually make it a more deterministic process. Facilitators 
could be known pluripotency regulators present in ESCs or oocytes, but absent from the 
transcription factor cocktail. They could also help cells upregulate the necessary regulators 
by modifying epigenetic marks or preventing senescence and apoptosis. We used this 
rationale to select candidate facilitators from the existing literature and test the effect of 
overexpression on iPSC formation from mouse embryonic fibroblasts.
Results
Selecting candidate factors to enhance direct reprogramming
We hypothesized that genes involved in pluripotency, ESC biology, epigenetic regulation, 
growth and survival regulation, could facilitate reprogramming. In 2007 Surani et al 
reviewed known regulators of pluripotency, that were shown to help the establishment of 
pluripotent cell lines10. Also, in his 2006 landmark  paper, Yamanaka selected 24 factors 
to screen for reprogramming induction resulting in the discovery of Oct4, Klf4, Sox2 and 
c-Myc as reprogramming factors to generate iPSCs11. Most of these 24 factors had not 
yet been described for their role in reprogramming and were added to our screening list. 
Furthermore, individual candidates were selected from different publications linking them 
to cellular reprogramming into pluripotent cells. For example, we selected the putative DNA 
demethylation factor AID, as it is required for reprogramming by cell fusion between mouse 
ESCs and human fibroblasts12. ERas and HRas were selected because somatic Ras family 
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members are well known oncogenes in a range of cancer types, and ERas was described 
to stimulate tumor-like growth properties of ESCs. Aiding growth and preventing OKSM-
triggered senescent or cell death could be essential for MEFs to transform into iPSCs. 
Moreover, publications about the role of the p53 apoptosis pathway and the role of 
cell division rate during reprogramming suggested that cellular survival and cell cycling should 
be promoted, possibly to prevent apoptosis or senescence induced by transgene expression 
and in vitro cell culture9,13,14. Finally, we screened molecules that could potentially establish 
and maintain the new expression patterns obtained by iPSCs. These molecules comprised 
epigenetic regulators form the third group of candidates, such as chromatin modifiers and 
DNA-methylation related factors. Chemical inhibitors blocking methylation have already 
been shown to increase the efficiency of reprogramming. The DNA-demethylating drug 
5-aza-deoxycytidine enhances reprogramming by the four factors15. It was also shown that 
reprogramming without c-MYC or KLF4 occurs efficiently when the histone deacetylase 
(HDAC) inhibitor valproic acid is administered16. Lastly, reprogramming without c-Myc, 
Oct4 or Sox2 can be facilitated by the histone methyltransferase inhibitor G9a17. In total, 75 
candidate genes were selected for screening, as shown in Figure 1. 
Figure 1. Selection of candidate facilitators of reprogramming based on literature.
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ERas and Tcl1, but not HRas overexpression increases reprogramming 
efficiency
Of all candidates, 24 were tested so far after being cloned into a doxycycline-inducible 
overexpression vector and validated by sequencing and quantitative PCR (qPCR) for total 
cDNA levels upon infection and doxycycline induction. Next, we tested each individual 
candidate by overexpression in mouse embryonic fibroblasts (MEF) derived from a 
‘reprogrammable mouse’, containing a doxycycline-inducible polycistronic cassette with 
the four Yamanaka reprogramming factors (Oct4, Sox2, Klf4 and c-Myc)(Col1A-OKSM), a 
Tet-on advanced transactivator (Rosa26-M2rtTA) and a fluorescent pluripotency reporter 
(Oct4-GFP). Oct4 is expressed in ESCs and EpiSCs, but not in somatic tissues or somatic stem 
cells18. These cells were then tested for their ability to form iPSC colonies upon 12 days of 
doxycycline induction, allowing the reprogramming factors and the candidate cDNA to be 
expressed (Figure 2). After 12 days, doxycycline was removed to select for true iPSC colonies 
that could maintain pluripotency without exogenous OKSM expression. The resulting iPSC 
colonies were counted by Alkaline Phosphatase (AP) staining, which is a surrogate assay 
to detect pluripotent stem cell colonies (Figure 2a-b). Repeated experiments showed that 
overexpression of Embryonic stem cell specific Ras (ERas) and T-cell Leukemia 1 (Tcl1) 
increased reprogramming efficiency by up to 9 and 4 fold by colony count, respectively. 
ERas is specifically expressed in ESCs and is 43 to 47% identical to the family members KRas, 
NRas and HRas19. ERAS is a small GTPase that stimulates growth of teratomas derived from 
ESCs, suggesting it helps ESCs expand through maintenance of pluripotency, proliferation 
or prevention of cell death. In contrast to other family members like HRas and KRas, ERas 
is not expressed in MEFs and is constitutively active in ESCs19. Conversely, although HRas 
belongs to the same family and is known to drive tumor growth, HRas overexpression nearly 
abolishes iPSC formation. To validate the overexpression on a protein level, we confirmed 
the presence of ERAS protein in ERas overexpressing MEFs by Western Blot (Figure 2c). Tcl1 
is an oncogene activated by regulatory elements of T cell receptors after translocations and 
inversions in T cell leukemia’s20 and stimulates cell growth and survival in mature T cells and 
cancer cells21,22. 
ERas overexpressing MEFs reprogram faster
To assess if ERas could also accelerate reprogramming when overexpressed alongside OKSM, 
doxycycline was removed prematurely (after 6 days) to select for iPSCs, which had lost their 
dependency on exogenous OKSM expression. Both control cells and ERas overexpressing 
cells formed iPSCs when treated with doxycycline for 12 days (Figure 3). However, upon 
6 days of doxycycline administration, only ERas overexpressing cells could form iPSCs. 
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Thus ERas overexpression reduces the time necessary for reprogramming cells to become 
independent of exogenous reprogramming factors.
MEFs that reprogram upregulate ERas and Tcl1, but not HRas
Earlier work in our lab showed that the MEF marker THY1 and the early stem cell marker 
SSEA1 predict which populations will progress towards fully reprogrammed, Oct4 expressing 
iPSCs. Cells that silence Thy1 and turn on Fut9 (encoding SSEA1) at sequential time points, 
are intermediates of reprogramming; a transient population of cells that are increasingly 
likely to form iPSCs after 13 days and following dox withdrawal23. Our lab performed 
genome-wide microarray expression analysis, identifying genes that are upregulated in 
intermediate cell populations (chapter 3)24. Both ERas and Tcl1 were upregulated during 
reprogramming (Figure 4a). So is Nanog, a core pluripotency transcription factor that is 
required for reprogramming25. ERas closely follows the pattern of upregulation of Nanog, 
Figure 2. Overexpression of ERas and Tcl1 enhances reprogramming efficiency. (A) Compiled 
data of independent experiments testing overexpression of individual candidates. Y axis 
represents fold increase of efficiency compared to GFP control. Error bars show the standard 
deviation. (B) Example of Alkaline Phosphatase (AP) staining to quantify iPSC colonies derived 
from control- (GFP) and candidate- (ERas) expressing MEFs. Each bright, well-defined red 
dot is one iPSC colony. (C) Validation of ERas overexpression by Western Blot.
GFP ERas
B C
A
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starting in SSEA1+ populations at day 6 of OKSM expression. In contrast, Tcl1 is upregulated 
late, when the Oct4-GFP reporter is activated and iPSC have become independent from 
exogenous factor expression. Cells that do not reprogram and maintain expression of the 
MEF marker THY1, maintain low or absent transcription of all three genes (Figure 4b). HRas 
expression stays constant in all cell populations. Thus, cells that are prone to form iPSCs 
upregulate ERas and Tcl1, supporting the notion that ERas and Tcl1 may be important or 
even required for iPSC formation.
Requirement for ERas expression in iPSC formation
To test whether ERas upregulation is essential for somatic cell reprogramming, we depleted 
ERas transcript from reprogrammable MEFs by RNA Interference. To this end, we screened 
6 short hairpin RNAs (shRNAs), delivered by a constitutive lentiviral vector, for their ability 
to knock down transcript levels of ERas individually or as a pool (Figure 5a). The ‘shERas#1’ 
exhibited an 85% reduction of ERas transcripts by quantitative PCR and was therefore used 
in the following experiments. The average loss of reprogramming efficiency after knock-
down of ERas was 60% compared to a shRNA targeting Firefly luciferase (shFF) (Figure 
5b-c). Thus, reductions in ERas transcript are correlated with impaired iPSC formation. 
Knockout experiments should be performed to determine whether ERas is required for 
reprogramming.
Mechanism by which ERas and Tcl1 facilitate reprogramming
To define the mechanism underlying the ERas and Tcl1 phenotype, we sought to manipulate 
downstream signaling pathways and determine their effects on reprogramming. Based 
on published data, we hypothesized that ERas and Tcl1 would enhance reprogramming 
through activation of the PI3K/Akt signaling cascade. To test this possibility, we treated 
reprogrammable MEFs with PI3K inhibitor LY294002 (PI3Ki). Furthermore, we sought to 
Figure 3 When ERas is 
overexpressed, MEFs need 
reprogramming factor expression 
for just 6 days. Y axis: Total iPSC 
colonies observed after two 
weeks, upon 6 or 12 days of 
doxycycline induction. Induction 
corresponds to expression of 
OKSM alone, or in combination 
with GFP or ERas.
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exclude the possibility that during reprogramming ERAS does signal through the MAPK/ERK 
pathway, contrary to what is the case in ESCs,  by treating with MAPK inhibitor PD98059 
(MAPKi)19. We treated both GFP- and ERas- overexpressing MEFs during reprogramming 
to test the synergy with ERas overexpression (Figure 6). Both PI3Ki and MAPKi treatment 
sharply reduced iPSCs formation in control MEFs, compared to a treatment with solvent 
alone. Co-treatment with the two compounds abrogated reprogramming completely. 
However, MAPKi failed to affect iPSC formation in ERas overexpressing cells, suggesting that 
indeed, ERas overexpression does not enhance reprogramming through the MAPK pathway. 
Conversely, PI3K inhibition almost completely returned reprogramming efficiency to that of 
control cells, suggesting that the PI3K/AKT pathway is key to ERAS action. Co-treatment also 
inhibits reprogramming in ERas overexpressing cells, suggesting that MEFs need activity of 
at least one of the pathways to reprogram, regardless of ERas expression. Reproduction 
of this experiment and inclusion of Tcl1 overexpressing cells can lead to a more conclusive 
result on the role of AKT and MAPK pathways during reprogramming. 
A
B
Figure 4. 
ERas and Tcl1 are 
upregulated during 
reprogramming 
in cells that are 
progressing towards 
pluripotency, based 
on global gene 
expression analysis. 
Relative transcript 
levels of Nanog, 
ERas, HRas and Tcl1 
in populations of 
(A) reprogramming 
intermediates, 
MEFs and iPSCs; 
(B) refractory 
populations at 
corresponding time 
points. Error bar: 
standard deviation.
119
Gain-of-function screen for enhancers of reprogramming identifies ERas
a3
Discussion
We selected candidates based on the literature in order to identify facilitators of transcription 
factor mediated reprogramming into iPSCs. After screening 24 candidates of our library, we 
found two interesting genes. The first, ESC-specific Ras or ERas, enhanced reprogramming 
efficiency up to 9-fold and gave rise to doxycycline-independent iPSC colonies after only 
6 days of exogenous factor expression, compared to 8 days in control infected cells. The 
second gene, T Cell Leukemia 1 or Tcl1, enhanced reprogramming up to 4-fold. ERas 
A
B
Figure 5. Downregulation of ERas reduces reprogramming efficiency. (A) qPCR analysis of 
ERas mRNA levels, normalised by GAPDH mRNA levels. Empty vector control =1.  shRNA 
pool: combination of shERas 1-5. (B) reprogramming efficiency of shERas#1 infected MEFs 
compared to empty vector control, per experiment and on average.
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expression is absent in MEFs but upregulated during reprogramming in a pattern similar to 
Nanog, suggesting it could be required for reprogramming. Tcl1 also is upregulated late in 
reprogramming nascent-formed iPSCs become transgene-independent. Next, we examined 
the importance of ERas for iPSC formation by shRNA-mediated knockdown, demonstrating a 
more than 2-fold reduction in reprogramming efficiency when 85% of transcript is depleted. 
Further studies should examine reprogramming ability of ERas-null cells. Also, ERas-
overexpression-derived iPSC should be subjected to an analysis of differentiation potential 
and genomic integrity to confirm that true iPSC formation is facilitated by ERas.
To determine the mode of action of ERas and Tcl1, we noted that both factors are 
known to activate the PI3K/Akt1 signaling pathway. Notably, other forms of Ras also activate 
MAPK/ERK signaling. Preliminary data on the effect of a PI3K inhibitor or MAPK inhibitor 
in combination with ERas overexpression suggest that PI3K activity is indeed required for 
the ERas phenotype, whereas MAPK activity is dispensable. A recent publication supports 
our preliminary conclusions by showing that the ERAS-AKT-FOXO1 signaling axis stimulates 
reprogramming, and that AKT inhibition or knockdown suppresses reprogramming26. FOXO1 
is degraded by active AKT and is found to inhibit reprogramming, which could be due to 
induction of a G0/1 arrest, apoptosis or unfavorable glucose metabolism regulation27-29. 
Chemical inhibition of FOXO1 may be an interesting approach to enhance reprogramming 
efficiency and study the role of AKT targets in iPSC formation. 
Another explanation for the observed ERas overexpression phenotype is that 
ERas simple stimulates higher cell proliferation or prevents cell death, without changing 
the inherent reprogramming potential of cells. AKT is known to inhibit apoptosis through 
inhibition of MAD and CASP9, as well as increase proliferation by inhibiting cell cycle regulators 
and activation of MTORC signaling30. However, HRAS is also a potent activator of AKT but 
seems to diminish iPSC formation. This could mean that simultaneous MAPK activation by 
HRAS prevents reprogramming, or that ERAS promotes pluripotency independently from 
increasing proliferation and survival through AKT activation. 
Figure 6. Effect of PI3K 
and MAPK inhibition on 
reprogramming of ERas 
or GFP overexpressing 
MEFs. Y axis: Total 
number of iPSC 
colonies, n=1. PI3Ki, 
PI3K inhibitor PD98059; 
MAPKi, MAPK inhibitor 
LY294002.
       No virus            GFP              ERas
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Next, we performed a preliminary experiment to test the requirement of both the 
AKT and MAPK pathway for iPSC formation. Interestingly, we find that combined inhibition 
of PI3K and MAPK, but not that of individual pathways, blocks reprogramming, suggesting 
that MEFs require either one of the pathways to transform, regardless of ERas expression. 
The interaction of PI3K and MAPK signaling has been extensively studied in human cancers. 
In these cancers, MAPK signaling is often erroneously activated by mutations in the 
upstream molecule BRAF.  Mutated BRAF has been successfully used as a therapeutic target 
in solid tumors such as melanoma. Colorectal cancers frequently acquire mutant BRAF and 
aberrant MAPK signaling. However, it was shown that BRAF mutant colorectal cancers, in 
contrary to other tumors, are not responsive to BRAF inhibition by Vemurafenib. Instead, 
colonic RAS expression allows an alternative route to promote cell growth and survival 
via PI3K signaling31. Somatic RAS family members such as KRas require activation of the 
upstream EGF receptor (EGFR), and colon cancer without KRas mutations can be treated 
with EGFR antagonist Cetuximab. Prahallad and colleagues thus were able to demonstrate 
that the combination of BRAF and EGFR inhibition in BRAF mutant colon carcinoma is highly 
synergistic in attenuating tumor growth. This example supports the idea that proliferative 
cells, like cancer cells or nascent iPSCs, require either active MAPK- or PI3K-signalling at any 
time.
It has to be noted that the same MAPK inhibitor was previously shown to enhance 
reprogramming efficiency in human cells when combined with an ALK5 (TGF-β) inhibitor32. 
Our results suggest that MAPKi alone blocks reprogramming in murine cells or has no effect 
when ERas is overexpressed. Our experiment will have to be repeated before we can begin 
to understand this contradiction.
Finally, other candidate approaches to identify modulators of reprogramming have 
shed light on the reprogramming process. Since the start of this project, other candidates that 
we originally picked but have not yet tested were linked to reprogramming by other groups, 
suggesting that our candidate screen was a valid approach. For example, the transcription 
factors TbBX3, SALL4, UTF1 and NANOG were shown to enhance reprogramming when 
added to the 4 ‘Yamanaka factors’ in mouse fibroblasts14,33-35. Chromatin modifiers JHDM1B, 
JMJD1A, BRG136-38 were also shown to enhance reprogramming. Other candidate screens 
proved successful too, like Yamanaka’s original screen for reprogramming factors and a 
candidate screen for chromatin modifiers using just 20 candidates by RNAi, that found a 
chromatin modifier, DOT1L, to inhibit reprogrammingv.
In conclusion, we used a candidate screen to find that ERas and Tcl1 are facilitators 
of murine somatic cell reprogramming, most likely through activation of AKT signaling. Our 
approach was independently validated by other groups. More work is required to identify 
potential targets of ERas and Tcl1 during reprogramming.
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Abstract
The generation of induced pluripotent stem cells (iPSCs) from differentiated cells following 
forced expression of Oct4, Klf4, Sox2 and C-Myc (OKSM) is slow and inefficient, suggesting 
that transcription factors have to overcome somatic barriers that resist cell fate change. 
Here, we performed an unbiased serial shRNA enrichment screen to identify potent 
repressors of somatic cell reprogramming into iPSCs. This effort uncovered the protein 
modifier SUMO2 as one of the strongest roadblocks to iPSC formation. Depletion of SUMO2 
both enhances and accelerates reprogramming, yielding transgene-independent, chimera-
competent iPSCs after as little as 38 hours of OKSM expression. We further show that the 
SUMO2 pathway acts independently of exogenous c-Myc expression and in parallel with 
small molecule enhancers of reprogramming. Importantly, suppression of SUMO2 also 
promotes the generation of human iPSCs. Together, our results reveal sumoylation as a 
crucial post-transcriptional mechanism that resists the acquisition of pluripotency from 
fibroblasts using defined factors. 
Introduction
The reprogramming of somatic cells into pluripotent cells using the classical set of transcription 
factors, Oct4, Klf4, Sox2 and C-Myc (OKSM) and conventional culture conditions (LIF, serum) 
usually takes several weeks and yields induced pluripotent stem cells (iPSCs) at extremely 
low frequencies (0.1-3%)1. This observation suggests that reprogramming factors need to 
overcome undefined barriers that have been established by somatic cells to preserve cell 
identity and resist cell fate change. Identifying roadblocks to iPSC generation thus provides 
a valuable platform to dissect general principles of cell identity and cell fate change2. 
Previously identified barriers to reprogramming include regulators of cell cycle 
progression and senescence (e.g., P53, INK4A/ARF)3, histone and DNA modifications (e.g., 
DNMT1, KDM2B, MBD3)4-6 as well as signaling pathways and epigenetic processes that can 
be targeted by small compounds (e.g., ascorbic acid, GSK3 inhibitor, DOT1L inhibitor)7-9. 
However, suppression of some of these barriers enhances iPSC formation only under specific 
culture conditions (e.g., MBD3)5,10, potentially limiting its usefulness in different cellular 
contexts. Moreover, manipulation of certain barriers causes permanent aberrations of the 
epigenome (e.g. DNMT1)11, complicating its applications in a therapeutic setting.
More recently, unbiased shRNA screens have been performed during iPSC formation, 
leading to the identification of novel roadblocks to reprogramming12-14. Surprisingly, 
individual suppression of hits that emerged from these screens showed rather modest 
effects (2-4-fold enhancement) compared to the simultaneous suppression of multiple 
hits (5-10-fold enhancement). Furthermore, there was little overlap among independent 
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screening efforts, suggesting that reprogramming may be restrained by additional, yet to be 
identified barriers.
The goal of this study was to identify potent roadblocks to reprogramming by 
performing a serial genome-wide shRNA enrichment screen in combination with a well-
defined transgenic reprogramming system. Our screening strategy uncovered SUMO2 as a 
top-scoring hit, thus implicating protein sumoylation as a mechanism that effectively resists 
transcription factor-induced pluripotency. 
Results
Serial shRNA screen for roadblocks to reprogramming
To identify roadblocks to iPSC formation in an unbiased manner, we combined a well-defined 
transgenic reprogramming system with a genome-wide shRNA library targeting 18,464 
genes with 60,642 hairpins. We utilized murine embryonic fibroblasts (MEFs) carrying a 
doxycycline (dox)-inducible polycistronic cassette encompassing the open reading frames 
for Oct4, Klf4, Sox2 and c-Myc (OKSM) in the Col1a1 locus, the M2-rtTA transactivator in the 
Rosa26 locus and an EGFP reporter in the endogenous Pou5f1 (Oct4) locus (chaper 2)15. We 
will refer to these transgenic MEFs as “reprogrammable cells” and the genotype as “Col1a1-
tetOP-OKSM; R26-M2rtTA; Oct4-GFP”. 
The shRNA library was generated by cloning shRNAs into the pHAGE-Mir lentiviral 
vector carrying a puromycin resistance gene and a tRFP reporter16,17(see experimental 
procedures for details). Transduction of reprogrammable MEFs with an identical empty 
vector gave rise to Oct4-GFP+, tRFP+ iPSC colonies upon exposure to dox, albeit at slightly 
lower frequencies than uninfected cells (Figure 1A,B and data not shown), demonstrating 
the feasibility of an shRNA screen using these cells and vector system. 
To identify shRNAs that potently enhance reprogramming with low background signal 
from passenger shRNAs, we devised a pooled screening strategy using serial enrichment of 
hairpin libraries. Briefly, we infected reprogrammable MEFs with the pooled shRNA library 
2 days before dox induction to ensure effective suppression of targets prior to initiation 
of reprogramming. After 10 days of OKSM expression, dox was withdrawn for 4 days to 
select for stably reprogrammed, transgene-independent colonies, followed by purification 
of emerging Oct4-GFP+ cells by flow cytometry (Figure 1C). 
Enriched hairpins were amplified by PCR from genomic DNA and subsequently re-
cloned into the original viral backbone before initiating another round of viral transduction 
and reprogramming. We performed 5 rounds of reprogramming and shRNA enrichment 
before focusing on candidates (Figure 1D,E). Parallel cultures of reprogrammable MEFs 
were exposed to dox alone or transduced with the viral library in the absence of dox before 
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Figure 1. A genome-wide serial shRNA enrichment screen during iPSC generation. (A) 
Fluorescence microscopy image of a primary iPSC colony showing lentiviral tRFP expression 
and endogenous Oct4-GFP expression. (B) Gating strategy to purify Oct4-GFP+ cells from 
lentivirally transduced cultures undergoing reprogramming. (C) Schematic representation of 
one reprogramming/shRNA enrichment cycle. (D) Overview of serial enrichment screen and 
validation experiments. (E) Timeline of reprogramming experiments and strategy to collect 
control and experimental samples for subsequent analysis of shRNA library representation. 
(F) Change in shRNA library complexity during enrichment screen, i.e. number of unique 
shRNAs at the start of rounds 1-5. (G) Heatmap depicting fold-change enrichment of shRNAs 
during 5 rounds of reprogramming.  (Continued on right)
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extracting genomic DNA (Figure 1E and Figure S1); these samples served as controls for 
possible passenger hairpins that became passively enriched in expanding iPSC colonies 
or hairpins that merely affected the growth of uninduced reprogrammable MEFs. Library 
representation was then determined in all samples by deep (Illumina) sequencing of genomic 
DNA. Notably, we detected a gradual reduction of library complexity and a progressive 
accumulation of specific shRNA vectors during the 5 rounds of screening, suggesting 
enrichment of biologically meaningful hairpins (Figure 1F,G).
SUMO2 emerges as a top-scoring candidate barrier to reprogramming
We next applied stringent criteria to call hits based on the number of normalized reads 
and the cumulative fold-change of shRNAs across all rounds of reprogramming relative to 
controls (Figure S1). Analysis of shRNAs that were consistently enriched revealed several 
candidate barriers to reprogramming including FGF5, SMPDL3a and SUMO2 (Figure 1F-H). 
Of note, some of the top-scoring shRNAs affected pathways that were previously shown to 
block reprogramming including members of the FGF/FGFR and OLFR families12,18. A complete 
list of candidates with associated cumulative enrichment scores is shown in Supplemental 
Table 1. Of the 27 validated shRNAs, 7 showed a more than 2-fold increase in iPSC formation 
(Gstt4, Gm719, Sqrdl, Dnmt3a, BTBD10, Smpdl3a, Sumo2)(Figure 1H) with Sumo2 shRNA 
exhibiting the strongest phenotype. 
Given the prominent effects on reprogramming of shRNAs targeting Sumo2, we will 
focus on this gene for the remainder of the manuscript. SUMO2 (small ubiquitin-like modifier 
2) is an ubiquitin-related protein that can be covalently attached to proteins as a monomer 
or lysine-linked polymer. This post-translational modification, lysine sumoylation, controls 
the stability, activity and localization of hundreds of proteins and has been implicated in a 
number of biological processes including DNA replication and repair, heterochromatic gene 
silencing and signal transduction19. 
Suppression of SUMO2 promotes reprogramming without compromising 
proliferation or pluripotency
Using more quantitative reprogramming assays, we found that suppression of SUMO2 
increases the number of transgene-independent alkaline phosphatase-positive (AP+) iPSC-
(Continued from left) Blue bars represent lost shRNAs whereas red bars represent enriched 
shRNA relative to controls (see experimental procedures for details). (H) Validation of 
candidates identified in serial shRNA screen (mean value from 3 biological replicates +/- s.d.). 
Red bars depict shRNAs yielding a 2-fold or higher increase in reprogramming efficiency. 
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like colonies and the fraction of Oct4-GFP+ cells by 7-8 fold (16% Oct4-GFP+ cells with 
Sumo2 shRNA; 2% with control shRNA at day 8)(Figure 2A-D). We were able to recapitulate 
enhanced reprogramming with 6 independent shRNAs as well as siRNA pools targeting 
Sumo2, documenting the consistency of the observed phenotype using either permanent or 
transient knockdown approaches (Figure 2C,D and Figure S2A). Expression of Sumo2 shRNAs 
led to reduced Sumo2 transcript levels as well as a decrease of free and conjugated SUMO2 
protein levels, demonstrating specificity of the knockdown vector and diminution of global 
sumoylation levels (Figure 2E and Figure S2B). 
Considering that sumoylated Klf4 reportedly inhibits cellular reprogramming20, 
we next determined whether SUMO2 suppression leads to reduced KLF4 sumoylation. 
However, we failed to detect differences in KLF4’s sumoylation status in cells expressing 
OKSM and Sumo2 shRNAs, suggesting that SUMO2’s effect on iPSC formation may involve 
other targets (Figure S2C). Moreover, forced expression of SUMO2 during iPSC generation 
(Figure S2D) was insufficient to block reprogramming (data not shown), indicating that the 
high physiological SUMO2 levels are already saturated; enough to facilitate any sumoylation 
reaction. 
iPSCs generated with Sumo2 shRNAs could be stably propagated over many passages 
and gave rise to well-differentiated teratomas, demonstrating that transient suppression of 
SUMO2 does not compromise the self-renewal or pluripotency of iPSCs (Figure S3A). It is 
also noteworthy that endogenous Sumo2 mRNA levels were comparable between MEFs and 
iPSCs and barely changed during the reprogramming process, suggesting that SUMO2 may 
play independent roles in somatic and pluripotent cell types (Figure 2F).
To complement the aforementioned marker-based assays of reprogramming with 
a functional readout, we determined whether suppression of SUMO2 could promote the 
formation of transgene-independent iPSC colonies after reduced pulses of OKSM expression 
(Figure 2G). Indeed, we found that knockdown of SUMO2 yielded transgene-independent 
iPSC colonies after only 4-5 days of OKSM expression, whereas stable iPSC colonies only 
emerged between days 6 and 8 in controls, consistent with previous findings21 (Figure 2H). 
In agreement with this observation, we detected a significant upregulation of key ESC-
associated transcripts (e.g., Nanog, Nr5a2, Sall4) and epigenetic regulators  (e.g., Dnmt3b 
and Tet1) as well as a downregulation of MEF-associated transcripts (e.g., Twist2, Fgf18, 
Meox2) in cells expressing OKSM and Sumo2 shRNAs at day 6 of reprogramming relative to 
a non-targeting shRNA control (Figure 2I,J). 
Critically, knockdown of SUMO2 had no discernible effect on cell proliferation or 
apoptosis of bulk cultures, thus excluding the possibility that the observed phenotype is 
due to accelerated growth or reduced cell death (Figure S3B,C). Together, these results 
demonstrate that both transient and constitutive suppression of SUMO2 markedly enhances 
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and accelerates the formation of iPSCs from somatic cells.
SUMO2 suppression acts during early to mid stages of reprogramming
In order to understand how SUMO2 suppression influences the dynamics of iPSC formation, 
we utilized surface markers and a reporter allele to distinguish between early, mid and 
late stages of reprogramming. We previously showed that cells undergoing successful 
reprogramming initially upregulate SSEA1 (early stage), followed by sequential activation 
of EPCAM (mid stage) and Oct4-GFP (late stage)(Polo et al., 2012; Stadtfeld et al., 2008)
(Figure 3A). SUMO2 depletion had no pronounced effect on the earliest intermediates of 
reprogramming, as shown by comparable fractions of SSEA1+ and EPCAM+ cells at day 3 
relative to controls (5% vs. 6% for SSEA1; 4% vs. 1% for EPCAM)(Figure 3B,C and Figure S4). 
However, we noticed a 3-fold increase in the fraction of SSEA1+ cells and a 5-fold increase 
in the fraction of EPCAM+ cells by day 5 as well as an 8-fold increase in the fraction of 
Oct4-GFP+ cells by day 8 of reprogramming. These data indicate that SUMO2 suppression 
facilitates early to mid stages of iPSC formation based on surface marker expression in bulk 
cultures.
To corroborate the notion that SUMO2 suppression promotes early to mid stages 
of reprogramming, we determined iPSC colony formation efficiencies after transfecting 
reprogrammable MEFs with siRNAs against Sumo2 either once (on day 0) or twice (on days 
0 and 3)(Figure 3D,E). iPSC colony formation was essentially the same when SUMO2 was 
suppressed initially or continuously during a 6-day reprogramming period, suggesting that 
early SUMO2 suppression is sufficient to elicit enhanced reprogramming. Consistent with the 
acceleration of reprogramming upon suppression of SUMO2, we find that MEFs expressing 
OKSM and Sumo2 shRNAs for only 6 days are molecularly most similar to advanced stages 
of reprogramming (day 9 and day 12 intermediates) using a previous expression time course 
(Polo et al., 2012), whereas MEFs expressing OKSM and a control shRNA are most similar to 
day 6 intermediates, as expected (Figure 3F).
Collectively, these phenotypic, functional and molecular data suggest that SUMO2 
suppression accelerates early to mid stages of reprogramming, ultimately leading to a 
strong increase in the number of Oct4+ transgene-independent iPSCs. 
SUMO2 suppression acts independently of C-MYc and in parallel with small 
molecules 
We next investigated whether exogenous C-Myc expression is required for the enhancement 
of iPSC formation by Sumo2 shRNAs. To this end, we derived reprogrammable MEFs from mice 
carrying the Col1a1-tetOP-OKS-mCherry allele (lacking the c-Myc transgene) in combination 
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with the R26-M2rtTA allele (Figure 4A). Exposure of these MEFs to dox alone gave rise to 
extremely few if any AP+ colonies after 9-21 days of OKS expression, and no Oct4-GFP positive 
cells could be detected by day 9 of reprogramming (Figure 4B-D). By contrast, depletion of 
SUMO2 in these cells using transient transfection of siRNA pools yielded iPSC colonies and 
stable Oct4-GFP+ cells by flow cytometry as early as 9 days after OKS induction. We conclude 
that suppression of SUMO2 enhances reprogramming independently of exogenous C-Myc 
expression, thus enabling iPSC formation under suboptimal reprogramming conditions and 
in the absence of this potent oncogene.
To determine whether SUMO2 suppression acts in parallel with small molecules 
that were previously shown to enhance reprogramming, we treated reprogrammable cells 
harboring shRNAs against Sumo2 or Firefly luciferase with doxycycline in the presence or 
absence of ascorbic acid (AA)7, a DOT1L inhibitor (DOT1Li)8 and a GSK3β inhibitor (GSK3i)9 
(Figure 4E). Consistent with previous reports, we found that exposure of reprogrammable 
cells to each of these compounds significantly enhanced the generation of AP+ iPSC colonies, 
with combined AA/GSK3i treatment (AGi) exhibiting the strongest effect (Bar-Nur et al., 
2014). Strikingly, SUMO2 depletion alone even surpassed the effect of AGi exposure based 
on AP+ colony numbers (Figure 4E). Moreover, suppression of SUMO2 further enhanced 
iPSC formation in the presence of either ascorbate, GSK3i or DOT1Li (Figure 4F). These 
results underscore the strong effects SUMO2 suppression alone has on the reprogramming 
process and suggest that the sumoylation pathway may act in parallel to previously described 
facilitators of iPSC formation including AA and inhibitors of H3K79 methylation and GSK3/
WNT signaling.
Generation of iPSCs after as little as 38 hours of OKSM expression
Given the additive effect between SUMO2 suppression and small molecule enhancers 
of reprogramming, we asked whether this combination treatment would allow us to 
further reduce the minimal time period of OKSM expression required to produce stable 
transgene-independent iPSCs. We used early-passage reprogrammable MEFs (passage 2) 
carrying two copies of each the Col1a1-tetOP-OKSM and R26-M2rtTA alleles to achieve 
(Continued from right) (H) Data obtained from experiments depicted in (G) using indicated 
shRNAs and 3 biological replicates (mean +/- s.d.). (I) Scatter plot comparing microarray 
data (log2 values) of day 6 reprogramming intermediates expressing indicated shRNAs. 
Representative upregulated pluripotency genes are shown in red whereas downregulated 
somatic genes are shown in green. (J) Normalized expression levels of representative 
pluripotency-associated and MEF-associated genes in indicated samples at day 6 of OKSM 
expression. Data obtained from one experiment. Rep-MEFs, reprogrammable MEFs, ESCs, 
embryonic stem cells.
137
A screen for inhibitors of reprogramming identifies SUMO2
4
E
B
G
+ Dox    - Dox
Day 
3 654 7 8 10 14
AP stain 
0
0 
10 
20 
sh
Fir
efl
y #
1
sh
Su
mo
2 #
1
H
0 
10 
20 
30 
40 
50 
60 
Day of Dox withdrawal 
shFirefly #1 
shSumo2 #1 
3 4 10
#A
P+
  c
ol
on
ie
s/
w
el
l
865
F
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
4000 
4500 
5000 Sumo2 Nanog 
Thy1 
SSEA1+ cells
 M
EF
D
ay
 3
D
ay
 6
D
ay
 9
D
ay
 1
2
O
ct
4-
G
FP
+ 
iP
SC
s
D
ay
 1
2 
O
ct
4-
G
FP
+
Re
la
tiv
e 
tr
an
sc
rip
t l
ev
el
s
D
siR
en
illa
 
siS
um
o2
 0 
40 
80 
120 
160 
#A
P+
 c
ol
on
ie
s/
w
el
l
A
shFirefly #1 shSumo2 #1
Oct4-GFP
tR
FP
Figure 2
siRenilla
siSumo2
C
sh
Fi
re
fly
 #
1
sh
Su
m
o2
 #
1
Free 
SUMO2
Conju-
gated 
SUMO2
RAN
180 
130 
100 
70 
55 
40 
35 
25 
15 
10 
kD:
Nanog  
Nr0b1  
Nr5a2  Tet1  
Sall4  
Dnmt3b  
Sox2  
Esrrb  
Klf5  
Meox2  
Col1a1  
Vcam1  
Fgf18  
Twist2  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
sh
Su
m
o2
 #
1 
[d
ay
 6
] e
xp
re
ss
io
n 
(lo
g2
) 
shFirefly #1 [day 6] expression (log2) 
I
921
J
%
O
ct
4-
G
FP
+   
(d
ay
 8
)
3500 
5900 
0 
400 
800 
1200 
1600 
2000 
2400 
RepMEFs 
shFirefly #1 Day6 
shSumo2 #1 Day 6 
ESCs 
Sa
ll4
  
Na
no
g  
Nr
5a
2  
Tw
ist
2  
Tg
fb3
  
Sn
ai2
  
Co
l1a
1  
Re
la
tiv
e 
tr
an
sc
rip
t l
ev
el
s
Figure 2. Suppression of SUMO2 robustly enhances and accelerates reprogramming.  (A) 
Flow cytometric analysis of Oct4-GFP expression in reprogrammable MEFs after 8 days or 
OKSM expression in the presence of indicated shRNAs. (B) Quantification of data shown 
in (A); shown is percentage of Oct4-GFP+ cells per total number of cells using 3 biological 
replicates (mean +/- s.d.). (C) Alkaline Phosphatase (AP) staining of iPSC colonies derived 
from reprogrammable MEFs transfected with indicated siRNAs. (D) Quantification of data 
shown in (C); data represent mean from 3 biological replicates +/- s.d.  (E) Western blot 
analysis for SUMO2 expression in reprogrammable MEFs infected with indicated shRNA 
vectors and treated with doxycycline (dox) for 3 days. (F) Expression dynamics of Sumo2 
mRNA in MEFs, iPSCs and intermediate stages of reprogramming using a previously published 
expression time course22. Thy1, fibroblast marker; Nanog, pluripotency marker. (G) Scheme 
to determine minimal duration of OKSM expression (in days) required to achieve transgene-
independent iPSC colonies. (Continued on left)
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optimal reprogramming efficiencies15. MEFs exposed to DOT1Li, GSK3i and AA required 
only 72 hours of OKSM expression to produce the first dox-independent AP+ iPSCs, which 
is faster than any previously reported protocol (Figure 5A,B). Remarkably, suppression of 
SUMO2 further reduced this time window to 38 hours. Emerging iPSC colonies activated 
the endogenous Oct4-GFP reporter, expressed endogenous Nanog, Oct4 and Sox2, gave 
rise to well-differentiated teratomas and supported the formation of coat-color chimeras, 
indicating acquisition of an authentic iPSC state (Figure 5C-F). 
Analysis of global transcriptional patterns of these iPSCs further revealed a 
remarkable similarity with either iPSCs generated after 10 days of OKSM expression or 
with an established ESC line, suggesting that abbreviated OKSM expression in the presence 
of chemicals and Sumo2 siRNAs does not compromise the pluripotency program (Figure 
5G-I and Figure S5). These results show that 1-2 days of OKSM expression are sufficient to 
produce stable, pluripotent iPSCs when SUMO2 expression is transiently suppressed under 
optimal culture conditions. 
Finally, we tested whether suppression of SUMO2 also enhances human 
reprogramming. Towards this end, we infected human dermal fibroblasts with vectors 
expressing OKSM and either Sumo2 or Firefly (FF) shRNAs and measured the formation of 
AP+ colonies at day 21 (Figure 5J, K). Consistent with our observations in the mouse system, 
we find that suppression of SUMO2 increases the formation of human iPSC-like colonies 
by 4-6 fold (Figure 5L). We also noticed that human iPSC-like colonies expressing Sumo2 
shRNAs formed earlier than controls, suggesting acceleration of reprogramming (data not 
shown). Thus, sumoylation is a conserved reprogramming barrier across murine and human 
cells.
Discussion
Here, we identified SUMO2 as a potent roadblock to iPSC generation by combining a well-
defined transgenic reprogramming system with a genome-wide shRNA screening approach. 
In contrast to previous shRNA or siRNA screens conducted during iPSC formation, we 
employed a serial shRNA enrichment strategy, which may reduce the number of false positive 
hits and allow for selection of shRNAs with stronger phenotypes. Indeed, suppression of 
a top candidate, SUMO2, markedly enhanced and accelerated iPSC formation compared 
to individual hits that emerged from previous large-scale screens or candidates that were 
selected based on gene expression differences between somatic and pluripotent cells. 
In agreement with the notion that the expression of barrier genes does not 
necessarily have to be different between MEFs and iPSCs, we found that Sumo2 mRNA levels 
do not dramatically change during reprogramming. To our knowledge, iPSC formation after 
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Figure 3. Effect of SUMO2 suppression on defined reprogramming intermediates. (A) 
Overview of surface markers and reporter alleles to distinguish between early, mid 
and late stages of reprogramming. (B) Flow cytometry analysis of these markers at 
intermediate stages of reprogramming in the presence of indicated shRNAs (tRFP+ cells). 
(C) Quantification of data shown in (B) and Figure S4 using 3 biological replicates +/- s.d. (D) 
AP+ transgene-independent iPSC colonies obtained after transfection of reprogrammable 
MEFs with indicated siRNAs either once (day 0) or twice (day 0 and day 3) in the presence 
of dox for 6 days; iPSC colonies were scored after 4 days of dox withdrawal to capture stable 
iPSCs. (E) Quantification of data shown in (D) using 3 biological replicates (mean +/- s.d.). (F) 
Correlation analysis between microarray data obtained in this study (day 6 reprogramming 
cultures expressing either Firefly or Sumo2 shRNAs, single data points) and a previously 
reported reprogramming time course22.
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38 hours of OKSM expression represents the shortest time period that has been reported 
to obtain stably reprogrammed cells from fibroblasts. In addition to SUMO2, our screen 
uncovered a number of other candidate barriers to iPSC formation, which provide a useful 
resource for future mechanistic studies of the reprogramming process.  
While SUMO2 has not previously been recognized as a roadblock to reprogramming, 
a recent report suggested that knockdown of the upstream SUMO-conjugating enzyme 
UBC9 blocks iPSC formation23. Several reasons may account for the apparent discrepancy 
between our studies. For example, UBC9 knockdown is expected to inhibit SUMO1, SUMO2 
and SUMO3, which may be toxic to cells, whereas SUMO2 depletion may be tolerated by cells 
owing to compensation by SUMO1 and/or SUMO3. In support of this idea, Ubc9 deletion 
in vivo causes a more severe phenotype compared to individual deletion of Sumo1, Sumo2 
or Sumo324. Furthermore, knockdown of UBC9 in ESCs reportedly triggers differentiation23. 
Considering that the same constitutive knockdown vectors were used to assess UBC9’s 
role in ESC self-renewal and reprogramming, it is possible that a potential increase in 
the number of iPSCs was overlooked due to their immediate loss through differentiation. 
Indeed, a recent shRNA screen conducted during iPSC formation with retroviral vectors, 
which become silenced in iPSCs, identified UBC9 as a potent reprogramming barrier25.
Mechanistically, SUMO2 depletion may enhance iPSC formation by derepressing 
epigenetically silenced pluripotency loci26,27 as well as histone and protein biosynthesis genes 
important for cellular growth and proliferation28. Consistently, we find that key pluripotency 
genes and epigenetic regulators are expressed more robustly in SUMO2-depeted 
reprogramming intermediates compared to controls. In addition, SUMO2 suppression may 
contribute to iPSC formation by directly modulating certain pluripotency factors during iPSC 
generation. In agreement with this view, sumoylation of SOX2 and KLF4 reportedly impairs 
transcriptional activity and compromises pluripotency20,29. 
Moreover, overexpression of sumoylation-deficient variants of these transcription 
factors slightly enhances reprogramming into iPSCs, although the reported effects were 
subtle compared to the phenotype reported here. Considering these observations and our 
preliminary finding that KLF4 is not differentially sumoylated upon suppression of SUMO2, 
we surmise that SUMO2 acts at multiple levels to resist the acquisition of pluripotency rather 
than to control the activity or stability of a single protein target. It should be informative to 
identify relevant SUMO2 targets in MEFs and iPSCs using recently developed proteomics 
and ChIP-Seq28,30 approaches.
Our findings may have practical implications for basic science and cell therapy. The 
ease with which SUMO2 can be inhibited using transient siRNA delivery should facilitate the 
mechanistic dissection of the reprogramming process in more homogeneous cell cultures. 
The observation that SUMO2 depletion increases human iPSC generation, cooperates with 
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small molecule enhancers of reprogramming and obviates the need for exogenous C-Myc 
expression may further facilitate the efficient and safe generation of patient-specific iPSCs 
from rare donor cells.
Methods
Tissue culture and virus production
Reprogrammable Mouse Embryonic Fibroblasts (RepMEFs) were derived from E13.5-15.5 
embryos carrying either the Col1a1-tetOP-OKSM or Col1a1-tetOP-OKS-mCherry  alleles in 
combination with the Rosa26-M2rtTA alleles31. Reprogramming was initiated by adding 
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Figure 4. SUMO2 
suppression acts 
independently of C-MYC 
and in parallel with small 
molecules. (A) Scheme 
depicting reprogrammable 
MEFs carrrying Col1a1-
tetOP-OKS-mCherry and 
Rosa26-M2rtTA alleles. 
(B) Generation of AP+ 
transgene-independent  
iPSC colonies obtained from 
these reprogrammable 
MEFs transfected with 
indicated shRNAs after 
exposure to dox and small 
molecules for 9 days. (C) 
Quantification of data shown 
in (B), “dox only” samples 
and additional time points; 
data show mean from 3 
biological replicates +/- s.d. 
(D) Oct4-GFP expression 
of OKS reprogrammable 
MEFs treated with indicated 
siRNAs and dox for 9 days, 
followed by 5 days of dox-
independent growth. 
(E) Comparison of iPSC formation efficiencies from OKSM reprogrammable MEFs in the 
presence of either small molecules or siRNAs targeting Sumo2. Values show mean from 
3 biological replicates +/- s.d. (F) Combination treatment of reprogrammable MEFs with 
siRNA targeting Sumo2 and indicated small molecule. Values show mean from 3 biological 
replicates +/- s.d.
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20ng/ml doxycyline (dox)(Sigma, cat.# D9891-25G) to RepMEFs and, where indicated, 25μg/
ml L-Ascorbic acid (Sigma, cat.# A4544-25G), 3uM GSK3 inhibitor (CHIR99021, Stemgent, 
cat.# 04-0004), ALK5 inhibitor (Calbiochem, cat.# 616452), 1uM MEK inhibitor (PD0325901, 
Stemgent, cat.# 04-0006) or DOT1L inhibitor (generous gift from Dr. Peter Brown). Viral 
transductions, using pHage or pGIPZ vectors in combination with packaging plasmids 
psPax2 and pDM2.G, were performed by spin infection for 30 minutes at 2,150rpm at room 
temperature. The following shRNA seed sequences were used for mouse experiments: 
for pHage shRNA (shSumo2 #1): ATAAGAGCTGAATGAGCATGCC. For pGIPZ (shSumo2 #2-7; 
Dharmacon): 
#2 (V2LMM_2701): TTCTGGAGTAAAGTAGCAG; 
#3 (V2LMM_5114): TAAGAGCTGAATGAGCATG; 
#4 (V3LMM_496391): TAGTAGACACCTCCAGTCT; 
#5 (V3LMM_496392): AAACTGCACCACAGAACCA; 
#6 (V3LMM_496393): TGTTCTCAGTCTTGACTCC; 
#7 (V3LMM_496396): AATCTTAAACTGCACCACA. 
Transfections of RepMEFs with 1.5ul siRNAs (esiRNA technology, Sigma; Sumo2: 
EMU095391, Renilla: EHURLUC) were performed in 12-well plates using Lipofectamine 2000 
and Opti-MEM (Life Technologies) according to the manufacturer’s instructions. For human 
reprogramming experiments,  BJ fibroblasts were first infected with control or Sumo2 pGIPZ 
shRNA (V3LHS_388696 and V3LHS412780, GE Dharmacon) viruses. Two days later, cells were 
infected with the human pHAGE-STEMCCA virus32 to initiate reprogramming. Cells were re-
plated in fibroblast medium (DMEM and 10% FBS) and cultured for four days. Medium was 
then switched to a 1:1 mixture of fibroblast medium and human ESC medium (E8, StemCell 
Techonolgies) for another two days, and finally to 100% human ESC medium. Cells were 
stained for alkaline phosphatase activity (Stemgent) and AP+ iPSCs were counted ~ 3 weeks 
after STEMCCA infection. 
Flow cytometry 
For isolation of Oct4-GFP+ iPSCs, SSEA1+ cells were first enriched by MACS sorting using 
SSEA1 antibody coated magnetic beads (Miltenyi). Oct4-GFP+ cells were then purified 
(continued from right) and Sumo2 siRNA transfection (38hr iPSCs) (G), 38hr iPSCs and ESCs 
(H) and iPSCs derived after 10 days of OKSM and Sumo2 shRNA expression (10 day iPSCs) 
and ESCs (I). (J) Suppression of SUMO2 mRNA levels in foreskin fibroblasts using Sumo2 
or Firefly shRNA vectors as determined by qPCR. Values represent means from 3 technical 
replicates (+/- s.d.) (K) Reprogramming efficiency of cells characterized in (J) as measured 
by the number of AP+ colonies per 60,000 plated fibroblasts. Values represent means from 
3 biological replicates (+/- s.d.) (L) Representative images of brightfield and AP+ colonies 
obtained with SUMO2 and FIREFLY shRNA vectors after 14 and 21 days of OKSM expression.
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Figure 5. Generation of iPSCs after as little as 38 hours of OKSM expression. (A) Treatment 
with ascorbic acid (AA), DOT1L inhibitor (DOT1Li) and GSK3 inhibitor (GSK3i) facilitates 
the recovery of transgene-independent AP+ iPSC colonies from control and Sumo2 siRNA 
transfected MEFs after 72 hours of OKSM expression. (B) Quantification of data shown in (A) 
using 3 biological replicates (mean +/- s.d.). (C) Suppression of SUMO2 enables generation of 
Oct4-GFP+ transgene-independent iPSCs after 38 hours of OKSM expression in the presence 
of the indicated small molecules. (D) Representative immunofluorescence images showing 
expression of endogenous OCT4, NANOG and SOX2 in iPSCs generated after 38 hours of 
OKSM expression and Sumo2 siRNA transfection. (E) iPSCs shown in (C) are pluripotent 
as determined by their potential to differentiate into the 3 germ layers in teratomas. (F) 
iPSCs produced after 38 hours of OKSM expression give rise to coat color chimeras. (G-I) 
Correlation analysis of microarray data (single data points) between MEFs and iPSCs derived 
after 38 hours of OKSM expression (Continued on left)
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within the enriched SSEA1+ fraction by FACS. Gates were set based on uninfected MEFs, 
virally transduced MEFs (tRFP+) and Oct4-GFP+ iPSCs. Intermediates of reprogramming 
were analyzed by flow cytometry using the following antibodies: THY1-Viogreen (BD, cat.# 
561616) or THY1-Pacific Blue (eBioscience, cat.# 48-0902-82), SSEA1-APC (Biolegend, 
cat.# 125608) or SSEA1-PE-Cy7 (Miltenyi Biotec, cat.# 130-100-426), and EPCAM-PE-Cy7 
(eBioscience, cat.# 25-5791-80) (1:200 for 30min. at 4C). BD’s Annexin V kit was used to 
measure apoptotic cells. All cytometry data were analyzed and plotted using FlowJo 
software. 
Quantification of reprogramming efficiencies
For macroscopic detection of iPSC colonies, Alkaline Phosphatase (AP) staining was carried 
out according to manufacturer’s instructions using the Vector Labs AP staining kit (cat.# 
5100). AP staining was always performed 2 to 4 days after dox withdrawal to eliminate 
partially reprogrammed colonies and to score for transgene-independent iPSCs. Colonies 
were counted manually or by custom-made Nikon software (CL-Quant). 
Teratoma and chimera formation
For teratoma generation, iPSC lines (passage 6 or higher) were harvested and resuspended 
in 600μl media per confluent 6-well. Mice were anesthetized with Avertin and injected with 
150μl cell suspension subcutaneously. Tumours were harvested 3 to 4 weeks after injection 
and analyzed histologically. For chimera production, iPSC lines were injected as single 
cell suspension into day 3.5 blastocysts isolated from intercrosses of C57Bl/6xBDF1 mice. 
Blastocysts were transferred into pseudopregnant Swiss Webster recipient animals.
Immunofluorescence analysis 
iPSC lines (passage 6 or higher) were seeded in a 24-well plate at a low density. Once small 
colonies emerged, wells were washed with 1xPBS and fixed by a 5-10 minute incubation 
in 10% formalin at room temperature. After washes in 1xPBS, cells were blocked in 1xPBS 
containing 2% BSA and 0.1% Triton-X 100. Primary and secondary antibodies were diluted in 
blocking solution at a concentration of 1:200 and added for 1 hour at RT or overnight at 4C. 
Primary antibodies were anti-Nanog (Abcam, cat.# AB80892), anti-Sox2 (Santa Cruz, cat.# 
Sc-17320), anti-Oct4 (Santa Cruz, cat.# Sc-8628); secondary antibodies were donkey anti-
goat IgG or donkey anti-rabbit IgG Alexa Fluor 546-conjugated antibodies (Life Technologies). 
After 2 washes in 1xPBS, cells were immobilized on slides in mounting media containing 
DAPI (Vectashield, Vector Labs) and analyzed. 
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RNA expression analysis
For global gene expression analysis, total RNA was isolated from indicated samples using 
RNeasy Mini Kit (Qiagen) and analyzed by Affymetrix microarray chips. The raw microarray 
expression signals in the CEL files were normalized using the Affymetrix Expression Console 
software and RMA normalization. For quantitative PCR analysis, Brilliant III SYBR-green 
based master mix was used according to the manual (Agilent), following RNA isolation 
(RNeasy kit, Qiagen) and reverse transcription (Transcriptor First Strand cDNA Synthesis Kit, 
Roche) of Sumo2 or control knockdown samples two days after initiation of reprogramming. 
Samples were run in triplicate on the Lightcycler 480 (Roche). Primer sequences for qPCR 
were as follows: Sumo2 (forward): AAGGAAGGAGTCAAGACTGAGAA, Sumo2 (reverse): 
CGGAATCTGATCTGCCTCATTG, GAPDH (forward): AGGTCGGTGTGAACGGATTTG and GAPDH 
(reverse): TGTAGACCATGTAGTTGAGGTCA.
Scatter Plot
Microarray gene expression measurements for samples containing Sumo2 or Firefly shRNA 
for 6 days were obtained. For genes with more than one probe, the average of all probes was 
used. These expression measurements were plotted (on a log2 scale), with Firefly expression 
on the x-axis, Sumo2 knockdown expression on the y-axis, and each point representing 
a gene. Genes falling outside of the dashed lines have a fold change of greater than 1.5 
between Sumo2 knockdown and Firefly. Some key genes were highlighted, with those being 
upregulated in Sumo2 knockdown colored red, and those downregulated colored green.
Correlation Matrix
Previously published microarray gene expression measurements representing stages of 
reprogramming were obtained from GEO (GSE42379). The following samples were used: 
KH2-MEF_m2, KH2-MEF_m3, Day3_SSEA1+ M2, Day3_SSEA1+ M3, Day6_SSEA1+ M2 and 
Day6_SSEA1+ M3, Day9_SSEA1+ M2, Day12_SSEA1+ M2, iPS_KH2-SC_MEF_1-5, iPS_KH2-
SC_MEF_1-6, and iPS_KH2-SC_MEF_1-3 (GSM1038591, GSM1038592, GSM1038595, 
GSM1038598, GSM1038601, GSM1038604, GSM1038607, GSM1038611, GSM1038612, 
GSM1038613, GSM1038614), to represent day 0 of reprogramming (MEF), day 3, day 6, day 
9, day 12, and fully reprogrammed (iPS). For timepoints with multiple samples, the average 
expression measurement for each probe was used. For genes with more than one probe, 
the average of all probes was used.
The gene expression measurements of the Sumo2 knockdown and Firefly knockdown 
samples were compared to those of the samples representing stages of reprogramming. 
Only the genes that were present in both datasets were considered. To remove batch effect, 
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the “Remove Batch Effect” tool in the Partek Genomics Suite was used, which fits a linear 
model to the data which includes batch as a component, then subtracts out that component 
from the data.
A matrix was constructed with pairwise comparisons between the Sumo2 knockdown and 
Firefly knockdown samples (as the rows in the matrix) to each of the samples representing 
stages of reprogramming (as the columns in the matrix). A scatterplot was generated and a 
Pearson’s R correlation coefficient was calculated for each pairwise comparison. Scatterplots 
that are shaped closer to a straight line and have a higher correlation coefficient indicate 
that the global expression patterns of the two samples more closely match.
Western Blot analysis
Protein lysates were run on 4-20% Mini Protean TGX gels (Biorad), blotted onto Immobilon-P 
membrane (EMD Millipore) and incubated with anti-SUMO2 antibody ab3742 (Abcam) 
and anti-RAN antibody 610341 (BD) for Western blot analysis. We used anti-KLF4 antibody 
AF3158 (R&D Systems), anti-OCT4 antibody 11263-1-AP (ProteinTech) and anti-SUMO2 
antibody ab81371 (Abcam) for immunoprecipitation experiments.
Generation of pHAGE-Mir vector
The pHAGE lentiviral backbone was released from pHAGE-EF1a-eGFP-W vector (kindly 
provided by Dr. Richard Mulligan’s lab) using NotI + BamHI. Turbo RFP was PCR amplified from 
pTurboRFP-N (Evrogen) and blunt-end cloned into the above pHAGE backbone to generate 
the intermediate pHAGE-EF1a-turboRFP vector. The Mir30-shRNA cassette and PGK-Puro 
selection marker was digested from MSCV-PM using BgIII + ClaI, and blunt-end cloned into 
the BamHI digested pHAGE-EF1a-turboRFP intermediate to generate the pHAGE-Mir vector.
shRNA screen and identification of hits
RepMEFs were expanded until passage 4 in 4% oxygen, switched to atmospheric oxygen 
and infected with the pooled shRNA library as described above. For each shRNA (621,000 
shRNAs in total), 1-2 x103 cells were infected to achieve good coverage. Infected cells were 
passaged onto gelatinized 15cm cell culture dishes (Falcon) in reprogramming media (ESC 
media supplemented with ascorbic acid and doxycycline) for 10 days, and in doxycycline/
ascorbic acid-free ESC media for an additional 4 days. Cells were harvested, pooled, and 
purified with SSEA1-linked magnetic beads using an AutoMACS sorter (Miltenyi).  SSEA1-
enriched cells were then FACS-sorted for endogenous Oct4-GFP expression. 
Genomic DNA was extracted from collected Oct4-GFP+ cells by lysing the cells in 10 mM 
Tris pH 8.0, 10 mM EDTA, 10 mM NaCl, 0.5% Sarkosyl. Lysates were treated with 0.1 mg/
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ml Rnase A at 37  ̊C for 30 min, 0.5 mg/ml Proteinase K at 55  ̊C for 1-2 hr, and then phenol-
chloroform extracted, ethanol precipitated, and resuspended in 10 mM Tris-HCl pH 8.0. For 
each sample, all the genomic DNA was used as template for shRNA PCR, usually in multiple 
PCR reactions. Each 50 μl PCR reaction contained: 2.5 μg genomic DNA template, 200 μM 
dNTPs, 400 nM of each PCR primer (pHAGE-Mir-PCR: 5’- GCAAACTGGGGCACAGATGATGCGG; 
BC1R-L: 5’- CGCCTCCCCTACCCGGTAGA), 1x Q5 reaction buffer, 1x Q5 high GC buffer, and 0.5 
μl Q5 polymerase (NEB). PCR was performed with the following program: 94  ̊C 4 min, 35 
cycles of (94 ̊C 30 sec, 60  ̊C 30 sec, 72  ̊C 45 sec), 72  ̊C 10 min. PCR products (~700 bp) for 
each sample were pooled, ethanol precipitated, resuspended, and gel-purified using the 
QIAquick Gel Extraction Kit (Qiagen). The purified shRNA PCR products were used to: 1) 
generate sub-libraries for the next round of shRNA library screens; 2) generate sequencing 
libraries for Illumina sequencing.
For sub-library generation, the purified PCR product was digested with NotI and MluI, and 
the ~400 bp fragment that contains the shRNAs was gel-purified. Separetely, the pHAGE-Mir 
plasmid was also digested with NotI and MluI to recover the ~ 9kb vector backbone. 25-50 
ng of the purified shRNA fragment and 125-250 ng of the vector backbone were ligated in 
5 μl ligation reaction using NEB T4 ligase. 1 μl ligation reaction was used to transform 20 
μl Electromax competent cells DH10b (Life Technology) with electroporation. 1 μl of the 
transformation reaction was plated on one 10-cm LB-Amp (100 μg/ml) plate to estimate 
the total number of colonies, and the rest of the transformation reaction was plated on two 
15-cm LB-Carbenicillin (100 μg/ml) plates and grown overnight at 37  ̊C. To maintain the 
representation of the library, at least 100 x coverage was needed (i.e., colony number = 100 
x number of shRNAs in the library). When necessary, the entire ligation reaction may be used 
for transformation in multiple electroporation reactions to increase the number of colonies. 
The next day, lawn formed on the two 15-cm plates were scraped off and cultured in 300 ml 
LB-Carbenicillin (100 μg/ml) medium and grown at 30  ̊C for 2-3 hrs. The cloned sub-library 
DNA was extracted from collected bacteria by the Genelute Maxiprep kit (Sigma).
For Illumina sequencing, the purified shRNA PCR product was used as template for another 
round of PCR: 500 ng purified shRNA PCR product, 200 μM dNTPs, 2 μM of each PCR primer 
(p5 and p7), 1x Q5 reaction buffer, 1x Q5 high GC buffer, and 1 μl Q5 polymerase (NEB) in 
100 μl PCR reaction. PCR was performed with the following program: 94  ̊C 4 min, 2 cycles 
of (94 ̊C 30 sec, 50  ̊C 20 sec, 72  ̊C 30 sec), 20 cycles of (94 ̊C 30 sec, 60  ̊C 20 sec, 72  ̊C 
30 sec), 72  ̊C 10 min. PCR products (~120 bp) were and gel-purified using the QIAquick 
Gel Extraction Kit (Qiagen). Gel-purified products were submitted for Illumina sequencing 
on the Illumina MiSeq instrument, using a custom sequencing primer: mir30-EcoRI : 
5’-TAGCCCCTTGAATTCCGAGGCAGTAGGCA. PCR primers: 
p5-miSeq: 5’-ATGATACGGCGACCACCGAGATCTACACCTAAAGTAGCCCCTTGAATTC; 
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p7-miSeq-1: 5’-CAAGCAGAAGACGGCATACGAGACGATAGTGAAGCCACAGATGTA 
p7-miSeq-2: 5’-CAAGCAGAAGACGGCATACGAGACACTAGTGAAGCCACAGATGTA
p7-miSeq-3: 5’-CAAGCAGAAGACGGCATACGAGACTATAGTGAAGCCACAGATGTA
p7-miSeq-4: 5’-CAAGCAGAAGACGGCATACGAGACCTTAGTGAAGCCACAGATGTA
Different p7 primers were used for multiplexing purpose. 
Single-end 51 bp reads were obtained using the Illumina HiSeq or MiSeq instrument. The 
reads are expected to have an initial 22 nucleotides that identify the shRNA, followed by 
a constant region that is the same for all shRNAs and a 2 nucleotide barcode to identify 
the sample. Reads that contain perfect matches at the following 6 nucleotides were first 
extracted from the sequencing data: the 2 nucleotides adjacent to the initial 22 base 
sequence and the 2 nucleotides adjacent to the barcode on both sides. The shRNAs were 
then identified by requiring an exact match of the 22 nucleotides to the sequences in the 
shRNA library annotation file. The samples were identified by the 2 nucleotide barcodes. 
The total number of reads that were identified for each shRNA, sample, and round were 
counted. The counts were normalized to be directly comparable between samples and 
rounds by first dividing by the total number of counts for that sample and round and then 
multiplying by the total number of shRNAs in the initial library. A pseudocount of 1 was 
added to each normalized count to downweight enrichment derived from low read counts 
and to avoid division by zero in calculating fold-changes.
The enrichment for each shRNA in each round was calculated as the log2 fold change of the 
Oct4-GFP+ normalized counts over the maximum of the normalized counts of the controls 
(T0, No-Dox and Oct4-GFP- cells). The cumulative enrichment for each shRNA in each round 
was calculated as the sum of the log2 fold changes for that round and all previous rounds. 
The overall enrichment of each shRNA was defined as the maximum of the cumulative 
enrichment scores among all rounds. 
The heat map for Figure 1G was plotted using the cumulative enrichment scores. Only 
shRNAs that have at least one read in the Oct4-GFP+ sample in at least two rounds were 
used in the plot, resulting in a total of 23,853 shRNAs.
Accession numbers
Microarray expression data are available at the Gene Expression Omnibus database under 
accession number GSE76699.
Supplemental table 1 legend 
(Excell file available at URL: 
 http://www.cell.com/cms/attachment/2055690886/2061109055/mmc2.xlsx)
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List of identified shRNAs, ordered by overall (maximum) enrichment score with information 
on shRNA identifier, 22-mer target sequence, gene accession number, gene symbol/
description and enrichment scores for individual rounds.
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Illumina Sequencing
Figure S1. Workflow to obtain experimental and control samples for deep sequencing during 
serial shRNA screen. See text and methods section for details.
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Figure S2. Confirmation of reprogramming phenotype with independent Sumo2 shRNAs, 
and effect of SUMO2 suppression or overexpression on global sumoylation levels. (A) 
iPSC formation efficiencies after infecting reprogrammable MEFs with additional shRNAs 
targeting different seed sequences within Sumo2 mRNAs. iPSC colonies were quantified after 
10 days of dox treatment and 4 days of dox withdrawal. Data represent single experiments. 
(B) shRNAs against Sumo2 lead to reduction of target mRNA levels. qPCR analysis for Sumo2 
transcripts normalized to Gapdh levels. Values are means from 3 technical replicates (+/- 
s.d.). (C) Analysis of KLF4 sumoylation by immunoprecipitation-Western blot analysis. Protein 
extracts from reprogrammable cells expressing OKSM and either Firefly (FF) or Sumo2 
shRNAs for 3 days were immunoprecipitated with either KLF4 or OCT4 specific antibodies, 
followed by Western blot analysis with a SUMO2 specific antibody. Amount of recovered 
Oct4 immunoprecipitates was likely below the detection limit, explaining the lack of signal. 
Size of expected sumoylated KLF4 band is indicated with an asterisk. (D) Overexpression 
of SUMO2 in dox treated reprogrammable MEFs compared to a GFP-expressing control. 
Western blot analysis for SUMO2 in cells expressing OKSM and SUMO2 for 3 days. 
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Figure S3. Effect of SUMO2 suppression during reprogramming on cellular proliferation, 
apoptosis and pluripotency. (A) iPSC clones obtained after Sumo2 knockdown give rise to 
well-differentiated teratomas showing differentiation into ectodermal, endodermal and 
mesodermal derivatives. Shown are different regions of the same teratoma. (B) Sumo2 
knockdown does not affect cell proliferation or viability. Growth curves of reprogrammable 
MEFs expressing shRNAs targeting Firefly or Sumo2 in the presence or absence of dox (i.e., 
OKSM expression). Cell counts were normalized to the cell number at day 1 (data are mean 
+/- s.d. from 3 biological replicates).  (C) Parallel cultures as shown in (A) were stained for 
Annexin V (apoptotic cells) and DAPI (dead cells)(data are mean +/- s.d. from 3 biological 
replicates). 
156
Chapter 4 
Day 6
Day 8
shFirefly #1 shSumo2 #1
Day 3
Day 5
Day 3
Day 5
Vi
ra
l t
R
FP
SSEA1
EPCAM
Oct4-GFP
Vi
ra
l t
R
FP
Vi
ra
l t
R
FP
Supplemental Figure 4
Figure S4. Flow cytometric analysis of SSEA1, EPCAM and Oct4-GFP expression in 
reprogramming intermediates carrying Firefly or Sumo2 shRNAs. Additional biological 
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Figure S5. Unsupervised clustering of microarray expression data
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Abstract
Differentiated, somatic cells can be reprogrammed back to a pluripotent state by the 
upregulation of a few transcription factors (OCT4, SOX2, KLF4 and c-MYC; OKSM). Resulting 
induced pluripotent stem cells (iPSCs) form at a low rate, indicating many intrinsic factors 
must prohibit this transformation. In a large scale RNA-inhibition screen, we identified 
suppression of Nudt21 to stimulate iPSC formation. Nudt21 suppression increases 
expression of pluripotency associated genes, facilitates formation of iPSCs upon just 2 days 
of exogenous OKSM expression and allows for omission of c-Myc from the reprogramming 
cocktail. Nudt21 encodes for CPSF5; a factor involved in alternative polyadenylation (APA); 
the process that determines the length of the 3’UTR of many mRNAs. Preliminary analysis 
of RNA sequencing directed at the 3’UTR of all mRNAs reveals shifts in 3’UTR length upon 
Nudt21 suppression during reprogramming, affecting genes including stem cell associated 
factor Wdr5. This study identifies an APA modifying factor as a roadblock to gaining 
pluripotency; further analysis of choice of polyadenylation site and resulting proteome 
upon Nudt21 suppression during reprogramming can help clarify the role of APA during cell 
fate changes.
Introduction
Somatic cells can be reprogrammed into pluripotent stem cells (induced Pluripotent Stem 
Cells, iPSCs) using a set of transcription factors: Oct4, Klf4, Sox2 and c-Myc (OKSM). iPSCs 
have been generated in various model systems including human cells, and reproduced by 
many research groups in and outside the stem cell field. However, the efficiency of the 
classical protocol is limited to 0,01-3%, suggesting intrinsic factors prevent most cells from 
reprogramming to iPSCs1,2. We previously described a screening approach to identify genes 
that inhibit reprogramming. This screen originally identified the gene Sumo2 (chapter 4), 
and in re-analysis of an earlier 3-round screen, we identified additional hits. The top hit 
from this group was Nudt21, which encodes for the alternative polyadenylation factor 
CPSF5. Here we validated the positive effect of Nudt21 downregulation on reprogramming 
in different contexts; including with 3-factor (c-Myc-free) reprogramming. Reprogramming 
speed was optimized by combining Nudt21 knockdown with small molecule enhancers. 
We characterized Nudt21-knockdown iPSC. Finally, we explore potential mechanisms 
by determining alternative polyadenylation profiles during reprogramming, using 
polyadenylation site-specific sequencing. 
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Results
Knockdown of Nudt21 increases reprogramming efficiency and speed
We used our model of a ‘reprogrammable mouse’; a transgenic mouse with doxycycline-
inducible expression of the four reprogramming factors OKSM3. We performed a genome-
wide, serial RNAi screen for inhibitors of reprogramming to pluripotency (Figure 1A). We 
identified an shRNA targeting Nudt21 to score as a strong hit. When we analyzed the 
composition of the shRNA pool before and after a reprogramming experiment. We noticed 
that during three screening rounds, the shRNA targeting Nudt21 was relatively enriched, 
suggesting it has a beneficiary effect on forming iPSCs (Figure 1B). We were able to validate 
this result in several ways. The number of dox-independent (stable upon withdrawal of 
exogenous OKSM expression) upon Nudt21 knockdown by several different shRNAs was 
increased 6-fold (Figure 1C). Also, the percentage of cells expressing the pluripotency 
reporter Oct4-GFP after a week of reprogramming was increased by around 16-fold 
(Figure D-E). Third, more dox-independent iPSC colonies seem to be formed from Nudt21 
knockdown reprogramming cells when decreasing the duration of OKSM expression (Figure 
1F-G).  Expression of the shRNA resulted in a strong decrease of Nudt21-encoded protein 
as shown by western blot (Figure 1H). When we used alternative knockdown strategies, by 
employing small inhibitory RNAs (siRNAs) targeting Nudt21, the increase in reprogramming 
efficiency was even bigger; up to 10 fold more iPSC colonies were formed when anti-Nudt21 
siRNAs were transfected once or twice during reprogramming (Figure 1I-J). Reprogramming 
with expression of the Nudt21 shRNA resulted in iPSC that could be passaged and grown 
well under ESC conditions (not shown) and formed, upon subcutaneous injection, well-
differentiated teratomas displaying lineages from all three germ layers (Figure 1K).
Effect of Nudt21 knockdown on cell proliferation and survival, as well as 
expression of stem cell genes 
Proliferation and cell death can dictate reprogramming efficiency by determining the 
total number of cells undergoing reprogramming.  Additionally, reprogramming has been 
shown to directly depend on the number of divisions undergone by an original cell4. The 
proliferation and cell death rate was determined for Nudt21 knockdown cells undergoing 
reprogramming to dissect their contribution to the phenotype. Reprogrammable cells were 
counted daily during 4 days while cultured in media with or without doxycycline to induce 
reprogramming. Although dox-induced cells increased more in number than non-induced 
cells, no difference was noted between Nudt21 knockdown cells or control (Figure 2A). 
Later time-points were not assessed to avoid bias of having more reprogrammed cells in 
164
Chapter 5 
one culture which proliferate faster than non-reprogrammed cells. Rate of cell death was 
estimated by determining the number of Annexin V positive, DAPI negative cells; this is the 
fraction of cells that are in the early phase of cell death. At day 3 of the experiment, no 
significant difference could be noted in the percentage of Annexin V positive cells, between 
Nudt21 knockdown- or control cells (Figure 2B).
Next, the effect of Nudt21 knockdown on expression of reprogramming- or 
pluripotent stem cell related genes was assessed by RNA sequencing of messenger RNAs 
(mRNAs). At day 6 of reprogramming, transcript levels of epithelial markers Epcam and 
Cdh1 were increased in Nudt21 knockdown cells, as were of stem cell transcription factors 
Nanog and Sall4, and reprogramming associated epigenetic regulators Dnmt3b and Tet1 
(Figure 2C). A scatter plot depicts all genes that were differentially expressed between 
Nudt21 knockdown and control cells (Figure 2D). Outliers include OCT4 encoding Pou5f1, 
and many factors that were not previously linked to reprogramming or pluripotency such as 
Ly6g6c, Txnip (involved in reduction of oxidative stress), Fam25c and Morf4l1 (promotes cell 
proliferation of neural stem cells).
Some genes can be used to mark stages of reprogramming by presence of cell-
surface proteins encoded by these genes, or by fluorescent reporter expression from the 
endogenous locus6. Intermediates of reprogramming can be defined by presence of protein 
markers SSEA1, EPCAM and of the reporter Oct4-GFP5. Reprogramming cells expressing 
the Nudt21 shRNA or control were analyzed for expression of these markers at several 
timepoints (Figure 2E-F). At day 3 and 5, clear increases in cells expressing SSEA1 or EPCAM 
(continued from right) X-axis: noting when, at the start or finish of screening round 1-3, 
representation was calculated from shRNA library sequencing results. Y-axis: abundance of 
shRNAs compared to total number of shRNAs identified from sequencing data.
(C) Reprogramming efficiency using alternative shRNAs targeting Nudt21; number of AP 
positive colonies counted after 10 days of OKSM expression. 
(D) Efficiency of generating Oct4-GFP positive reprogramming intermediates at day 8 of 
OKSM expression (n=3, error bar=standard deviation) upon Nudt21 knockdown or control. 
(E) FACS plot showing one replicate of data in (D). tRFP: reporter of shRNA vector expression.
(F) Overview of experiment in (G): timed withdrawal of OKSM expression through removal 
of doxycycline from the culture media. 
(G) Reprogramming efficiency upon 3 to 10 days of OKSM expression, during Nudt21 shRNA 
expression or control; n=3, error bar= standard deviation. Student’s t-test: * p-value <0.10, 
** p-value <0.05.
(H) Western blot stained for Nudt21 encoded protein CPSF5 and loading control ACTIN. 
(I) Reprogramming efficiency of cells transfected once or twice with siRNA targeting Nudt21 
or control; AP staining of iPSC colonies (red dots).
(J) Average of three replicates of experiment shown in (I); error bar= standard deviation. 
(K) Teratoma derived from Nudt21 knockdown iPSCs; all pictures from same tumor; showing 
examples of differentiated structures from all three germ layers. 
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Figure 1. Nudt21 knockdown facilitates somatic cell to iPSC reprogramming.(A) Overview of 
shRNA screen pilot identifying Nudt21 shRNA as a hit. (B) Representation of Nudt21 shRNA 
in libraries before and after 3 rounds of reprogramming experiments. Red line: Nudt21 
shRNA. Grey lines: other top scoring shRNAs. (continued on left) 
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were detected in Nudt21 knockdown cells. Also, at day 6 a substantial group of Oct4-GFP 
positive cells arose that was absent in the control. Thus, reprogramming is enhanced within 
days of Nudt21 knockdown and OKSM expression, giving Nudt21 knockdown cells an almost 
immediate advantage in forming iPSCs. 
Fast and efficient and c-Myc-free reprogramming with Nudt21 knockdown
Above experiments suggested that Nudt21 knockdown affects reprogramming nearly 
immediately, pushing cells to express stem cell markers within days of OKSM expression. To 
optimize the reprogramming process to require minimal duration of OKSM expression and 
little handling, we tested other culture conditions recently found to enhance reprogramming 
efficiency6-9. GSK3 inhibitor (GSK3i), ascorbic acid (AA), DOT1l inhibitor (D1li), and the 
GSK3i/AA combination were tested in comparison and addition to Nudt21 knockdown. 
Reprogramming duration (OKSM expression) was reduced to 8 days because these 
conditions yield enough iPSC to overgrow the culture plate when exposed to OKSM longer. 
Nudt21 knockdown resulted in nearly as many iPSC colonies as the best culture condition 
(GSK3i/AA; ‘AGi’) (Figure 3A). When combined, Nudt21 knockdown had a strong additional 
effect on reprogramming efficiency, on top of the effect of the various culture conditions 
(Figure 3B). Next, the best culture conditions were combined with Nudt21 knockdown via 
siRNA transfection. Also, reprogrammable MEFs were used at earliest possible passage post-
derivation to further raise efficiency. In this experiment, withdrawal of OKSM expression 
after 3 days resulted in iPSC colonies in both control siRNA and even more in Nudt21 siRNA 
conditions (Figure 3C). Even after just 2 days of OKSM (48hr Dox), rare iPSC colonies emerged 
in Nudt21 siRNA transfected cells, but not in the control (not shown; all colonies were picked 
for further analysis). These iPSCs were pluripotent as assessed by Oct4-GFP expression and 
teratoma formation (Figure 3D-E). 
(continued from right) (C) Expression of epithelial- and stem cell markers (Epcam, Cdh1, 
Sall4) and epigenetic regulators (Dnmt3b, Tet1) in MEF, iPSC, and reprogramming cells 
with or without Nudt21 knockdown, as determined by RNA sequencing. Error bars indicate 
standard deviation; n=3. 
(D) Scatterplot of same dataset as in (C). Triangle shaped dots represent genes that were 
expressed at twofold lower (blue) or twofold higher (grey) levels in Nudt21 knockdown 
reprogramming cells (day 6), when compared to Firefly knockdown control; average of three 
replicates. (E) Key results from flow cytometry analyses of reprogramming intermediates 
with Nudt21 shRNA (purple) or control. X-axis designates what surface marker was analyzed 
at which day of OKSM expression (day 5 or day 8). Error bars indicate standard deviation; n=3. 
(F) Flow cytometry plots showing one replicate of experiment in (E). tRFP marks expression 
of the shRNA-carrying vector. Logarithmic scales; numbers in plots mark % of DAPI negative 
(live) single cells). 
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Figure 2. Nudt21 knockdown does not affect cell proliferation or apoptosis, does affect stem 
cell/ reprogramming related genes. (A) Number of cells counted during 4 days, with Nudt21 
shRNA expression or control, and with (top lines) or without (bottom lines) dox induction 
of OKSM expression. Error bars indicate standard deviation; n=3. (B) Same cells as in (A), 
assessed for Annexin V expression; n=3, error bars: standard deviation. Y-axis: percentage of 
DAPI negative cells that were Annexin V positive. (continued on left)
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Considering that in the future, iPSC may be derived with the goal of forming 
transplantable tissues for patients, avoiding the oncogene c-Myc in the reprogramming 
strategy has a preference.  We tested whether Nudt21 suppression could facilitate 
reprogramming without c-Myc. We used a mouse model identical to the OKSM 
reprogrammable mouse, but with a mCHERRY fluorescent reporter instead of the c-Myc 
cDNA. These OKS-mCherry reprogrammable cells require AA or AGi conditions to form iPSC 
efficiently in control conditions. However, Nudt21 siRNA transfection resulted in some iPSC in 
dox only culture conditions, and increased reprogramming efficiency in AA or AGi conditions 
(Figure 3F). Dox-only reprogramming with Nudt21 siRNA resulted in robust reprogramming 
efficiencies after 15 or 21 days of OKS expression (Figure 3G).  
Nudt21¬knockdown affects the alternative polyadenylation (APA) profile of 
reprogramming-associated mRNAs
Upon choice of a polyadenylation site (PAS) and assembly of the required factors, the 3’UTR 
of an mRNA is cleaved and subsequently polyadenylated. In mRNAs with multiple PAS, 
choice of a more distal or proximal to the stop codon can strongly affect 3’UTR length and 
preservation or removal of binding sites for regulators such as RNA binding proteins (RBPs) 
and microRNAs (miRNAs) (Figure 4A). Sequencing of mRNA directed at PAS (PAS-Seq) reveals 
what PAS are used at what ratio10. Different biological conditions are associated with a shift 
to more distal or more proximal PAS usage, however it is important to note that a shift is 
not an on/off switch between PAS but rather a changing ratio. Comparing many mRNAs in 
different biological contexts to detect global shift to more proximal or more distal PAS is 
possible and has been done in the context of cancer versus healthy tissue and stem cells 
versus differentiated cells11,12, showing that stem cells and cancer cells tend to have more 
proximal PAS usage.  
PAS localization is unique to each mRNA, thus ‘proximal’ or ‘distal’ cannot be linked 
to an absolute distance from the stop codon. Nor can each PAS usage be compared; to 
compare two samples, only PAS sites used to some degree in both samples can be compared 
by their proximal/distal ratios. This prevents systematic comparison of more than two 
samples at once. One PAS site can thus represent proximal PAS usage in one comparison, 
or distal PAS usage in the next (Figure 4A). When comparing two samples, PAS sites used in 
both samples are identified and marked as distal or proximal sites in that particular context. 
A ratio of proximally polyadenylated reads divided by distally polyadenylated reads can be 
calculated to put a number to the use of proximal or distal PAS. This proximal/distal ratio can 
then be compared between the two samples.  
When we compared PAS usage ratios between reprogramming cells (day 3 of 
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induction with OKSM) upon Nudt21 knockdown or -control, many mRNAs had significantly 
altered their proximal/distal ratio, and most of those had shifted to more proximal PAS 
usage (Figure 4B). This effect was dependent on the presence of the reprogramming factors 
or ongoing reprogramming; non-induced Nudt21 knockdown or control cells showed much 
less difference in APA profile.  When we compared these early reprogramming cells to ESCs, 
we noted that Nudt21 knockdown cells have less significantly different proximal/distal ratios 
than control cells (Figure 4C). 
The consequences of these APA events are challenging to define purely based on 
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Figure 3. Nudt21 knockdown phenotype is independent from known reprogramming 
pathways and c-Myc expression; enables ultra-fast reprogramming. (A) Reprogramming 
efficiency determined by number of AP positive colonies after 8 days of OKSM; under 
culture conditions with known reprogramming enhancing small molecules, or with Nudt21 
knockdown. Error bars indicate standard deviation; n=3. (B) Same experiment as in (A), this 
time combining Nudt21 knockdown or control with culture conditions. (C) Reprogramming 
efficiency when combining all small molecules in (A, B) and Nudt21 knockdown by an siRNA; 
after 72 hours of OKSM expression. (D) iPSC derived in same condition as in (C) but just 
48hrs of OKSM expression. (E) Teratoma derived from iPSC in (D), containing differentiated 
structures from all three germ layers. (F) AP staining of iPSC colonies to determine 
reprogramming efficiency of OKS-mCherry MEFs (lacking c-Myc), in combination with AA, 
AGi conditions and/or Nudt21 siRNA. (G) Quantification of 3 replicates of experiment shown 
in (F) after 9, 15 or 21 days of OKS expression; error bars indicate standard deviation. 
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transcriptional data. Thus, no generalizing statement of how Nudt21 knockdown affects 
reprogramming through these APA events can be made. However, by looking at individual 
mRNAs, candidates for further study can be identified.
One possible effect of a proximal shift is higher stability of the transcript due to loss 
of miRNA binding sites or binding of RBPs that facilitate mRNA degradation. The PAS-Seq 
data also allowed for quantification of overall abundance of mRNAs. To find mRNAs that 
could be responsible for the phenotype of Nudt21 knockdown, we selected mRNAs with a 
proximal shift in PAS usage and a higher abundance. Of those genes, nearly all are normally 
upregulated during reprogramming as determined by Polo et al. A few examples are shown 
in Figure 4D. Amongst them, Wdr5 is a known regulator of pluripotency and thus a candidate 
effector of the Nudt21 phenotype. Preliminary studies on the effect of Wdr5 upregulation 
on reprogramming showed a modest increase in protein levels of WDR5 and also modest 
positive effects on reprogramming efficiency. Conclusively, APA of many transcripts together 
is likely required to recapitulate the Nudt21 knockdown phenotype during reprogramming. 
 
Discussion
Here we describe how we identified Nudt21 as a roadblock to reprogramming. An shRNA 
targeting Nudt21 was consistently enriched in a pool of shRNA that was transduced into 
reprogrammable fibroblasts, retrieved and re-transduced for consecutive reprogramming 
experiments. We first confirmed that reducing Nudt21 expression was responsible for the 
reprogramming phenotype by using different methods of knockdown (alternative shRNAs 
and siRNAs) and confirming loss of Nudt21 protein upon knockdown. Nudt21 knockdown 
was found to decrease the duration of reprogramming factor expression (of Oct4, Klf4, Sox2 
and c-Myc; ‘OKSM’) needed to form pluripotency factor Oct4-expressing cells and later, 
OKSM- independent, stable iPSC colonies. Nudt21-knockdown iPSCs were confirmed to be 
pluripotent by deriving teratomas. Nudt21 knockdown reprogramming cells start expressing 
stem cell- and pluripotency factors earlier as determined by looking at cell surface markers 
and RNA expression. The Nudt21 knockdown phenotype could not be explained by alteration 
of the rate of proliferation or apoptosis. To determine synergy with inhibitors of specific 
cellular signaling pathways that are known to boost reprogramming, Nudt21 knockdown 
was combined with these inhibitor containing culture conditions. Nudt21 knockdown 
boosted reprogramming further in each of the conditions, suggesting the mechanism is 
independent of these pathways. 
Reprogramming efficiency, speed, and dependence on oncogene c-Myc are limiting 
factors in the search to derive iPSC in experimental and therapeutic settings. Thus we took 
advantage of our finding by combining it with known reprogramming boosting culture 
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conditions with small molecules6,13,14. Combination of ascorbic acid and GSK3 inhibitor (‘AGi’) 
with Nudt21 knockdown enabled efficient reprogramming of reprogrammable MEFs lacking 
overexpression of c-Myc. Combination of AGi, a DOT1l inhibitor and Nudt21 knockdown 
resulted in iPSC after just 48hrs of OKSM expression. 
Combined, our results characterize the role of Nudt21 in preventing reprogramming 
to pluripotency of murine somatic cells. It expands our toolbox of measures to optimize 
reprogramming efficiency and speed. It supports further research into posttranscriptional 
regulation and its role in cellular reprogramming. We are currently further exploring the 
mechanism behind the Nudt21 knockdown phenotype. Our leading hypothesis is that 
alternative polyadenylation occurs and helps cells to become iPSCs, due to the known role 
of the Nudt21 encoded protein CPSF5.
Alternative polyadenylation affects the processing of 3`UTRs of messenger RNAs 
(mRNAs)15.  The choice between polyadenylation sites (PASs) are made by specific factors 
in the cleavage and polyadenylation complex, among which CPSF5, encoded by Nudt21. 
This affects availability of miRNA and RBP binding sites, influencing the rate of translation 
into protein. Global APA patterns have been found to be altered in cancer cells and 
pluripotent stem cells, compared to healthy, somatic cells11,12. Since PAS location, number 
and presence of regulatory sequences in relation to PAS is specific to each mRNA, it is 
challenging to translate global patterns to gene-by-gene level mechanisms. Also, since we 
show that Nudt21 knockdown likely affects many transcripts during reprogramming (some 
effects may be secondary to the reprogramming phenotype), single target genes may not 
recapitulate the phenotype by themselves, complicating validation of possible mechanisms. 
To identify possible effectors, we compared APA affected genes to genes whose mRNA level 
was modified upon Nudt21 suppression. We found that most mRNAs that acquire shorter 
3’UTRs and gain in abundance, also are upregulated during reprogramming according to 
existing expression data. Further analysis of these individual genes, including known stem 
cell regulator Wdr5, is warranted. Expansion of the PAS-Seq dataset, using the Nudt21 
siRNAs for a stronger phenotype and analyzing more timepoints is ongoing. This effort 
should allow better understanding of how global APA is affected by Nudt21 suppression and 
in turn affects the acquisition of a pluripotent state. 
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Materials and Methods
Tissue culture, virus production, siRNA transfections, flow cytometry, quantification of 
reprogramming efficiencies, teratomas formation and Western blot analysis were performed 
simultaneously with experiments described in chapter 416.
shRNA screen and identification of hits
The shRNA screen was performed as described in chapter 416, for a total of three screening 
rounds. Solexa sequencing data were retrieved as described. Identification of hits was 
performed using algorithms in Excel. Different algorithms were used based on enrichment 
of shRNAs in samples from GFP+ iPSCs each round, lack of enrichment of negative controls 
(GFP- samples and non-induced samples), consistency of enrichment during each round 
and total enrichment. Top scoring hits from different algorithms were pooled to create a 
list of candidates for further individual validation. Nudt21 was identified as a hit based on 
enhanced reprogramming efficiency of Nudt21 shRNA expressing reprogrammable MEFs.
PAS-Seq analysis
For PAS-Seq analysis, total RNA was extracted using the Qiagen RNeasy Mini Kit and 
sequencing libraries were prepared, processed and analyzed as described10. In short, 
extracted RNA was fragmentated, reverse transcribed to cDNA using a poly-A tail selective 
oligo-dT primer. A custom oligo-dT sequencing primer was used for single end sequencing. 
Reads were mapped to the genome after removal of T’s. Reads in near vicinity of each other 
were clustered to assign a poly(A) site (PAS). Samples were compared in pairs for relative 
abundance of proximal versus distal PAS usage. mRNA abundance was determined from all 
reads. 
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Introduction
The main project in this thesis is a genome-wide screen for inhibitors of somatic cell 
reprogramming. With no previous experience with screening at this scale in the lab, we 
were grateful to collaborate with the screening library’s creator Stephen Elledge, and mostly 
with his former postdoc Guang Hu. Together we optimized the screen for our platform of 
iPSC reprogramming. Since the resulting papers do not discuss more than our eventual 
experimental design and limited materials and methods, we will use this thesis chapter to 
highlight important lessons learned along the way. 
One part will discuss important concepts considered in experimental design, such as 
the required coverage of shRNAs and how to achieve this at each step and why we looked at 
shRNAs that help reprogramming, not those that inhibit reprogramming. 
The second part focuses on technicalities that did not make the materials and 
methods section of the published paper, but are helpful regardless for anyone considering a 
screen or other experiment with reprogramming cells at this scale. 
But first, we will discuss the rationale behind using RNAi technology, on a genome-
wide level, specifically with a pooled library.
Specific gene targeting with shRNAs
Long before the rise of DNA sequencing, or even our knowledge of DNA structure, genes 
were characterized by their loss through mating, recombination or mutation. Hence the 
naming of genes after properties opposite to their function (the ‘White’ gene in fruit fly is 
required for a dark eye color). RNA interference is a sequence-specific, conserved and highly 
customizable gene silencing tool that has modernized and hugely expanded loss-of-function 
genetic experiments. 
RNA interference was first discovered in plants and worms. It requires a double 
strand RNA (dsRNA) that is broken down to ‘small interfering RNAs’ (siRNAs) that perfectly 
complement their target mRNA. Concurrent with the discovery of siRNA, several groups 
found endogenous and highly conserved microRNA (miRNA) which are processed by largely 
the same machinery as siRNAs, but target multiple genes with near perfect complementary 
sequencies. Most notably, miRNAs are derived from stem-loop structure forming RNA called 
‘short hairpin RNA (shRNA)’ and are important endogenous regulators in mammalian cells. 
shRNAs were soon developed into a stably expressed, inducible gene silencing tool for 
mammalian cells (Figure 1). 
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Genome-wide versus 
gene-of-interest screening
Many genes involved in cell fate, 
stem cell- and cancer biology have 
been suspected and indeed shown to 
affect iPSC reprogramming. Therefore 
we preferred an unbiased approach 
to candidate genes. Where a small 
shRNA screen might include 100 
candidates that need to be selected 
based on previous work, a genome-
wide screen covers all transcripts 
annotated at that time including 
genes only known in a different 
context or not functionally described 
at all. Though probably no genome-
wide screening library can truly test 
100% of its candidates, and new 
annotations constantly alter what we consider ‘all genes’, a genome-wide approach gives a 
much broader reach and leads into unknown territories. 
Pooled screening
A pooled library has all shRNAs for all genes mixed together for application to the target 
cells, as opposed to applying each shRNA to a different sample (e.g., well). Pooled libraries 
significantly ease access to genome-wide screening. Well-by-well testing requires cell culture 
automation; robots that can securely change media of 100,000+ wells. Moreover, the small 
wells complicate a quantitative assessment, such as of reprogramming efficiency, and are 
more amenable to qualitative questions such as whether or not cells remain viable in a 
given well. Lastly, there is possible well-to-well technical variation since wells are handled 
individually and have different locations on the plate. Pooled screening bypasses these 
requirements. And because the shRNAs are embedded in the DNA of their host, they can 
retrospectively be identified through a unique barcode or by sequencing of the short (19-
21bp) unique miRNA sequence. The expression vector includes a turbo-RFP cDNA allowing 
detection of successfully infected cells. 
target mRNA
passenger - loop - guide
Dicer
RISC
shRNA
RISC
Figure 1
Figure 1. Schematic depiction of shRNA mediated 
RNAi. Top strand: transduced DNA encoding shRNA. 
Dicer digests shRNA to double strand RNA (dsRNA). 
RISC: RNA-induced Silencing complex, which finds the 
target mRNA and induces cleavage at the recognition 
sequence.
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The Hannon-Elledge libraries
In a combined effort by the Greg Hannon and Stephen Elledge labs, genome-covering 
libraries of mRNA targeting shRNAs were developed, optimizing gene knockdown efficiency, 
viral delivery and shRNA expression1. Their libraries have enabled studies answering a range 
of different questions in human or murine cells. Examples are the identification of genes 
essential to the survival of mutant Ras cancer cells, cell migration and self-renewal2-4.
Concepts
Coverage of the shRNA library. 
A key requirement of a pooled screen is to allow each shRNA to exert its biological effect. In 
our case, this means that each shRNA should enter a cell that just needs knockdown of that 
particular gene to reprogram into a stable iPSC. To make sure this chance is high enough, 
each shRNA in a pooled screen is generally given cells to infect by a factor that is referred to 
No Dox +DoxStarting cells
(immediate
harvest)
FACS
Negative controls Oct4-GFP+ cells
+ Dox 10days
 - Dox 4 days
14 days
Infection with pooled shRNA library
Figure 2
Figure 2. Experimental 
design of screening 
experiment. After infection 
of cells with the shRNA 
library, 4 samples are 
generated including 3 
negative controls. One 
negative control is taken 
immediately to represent 
shRNA delivery to the cells. 
One negative control sample 
is cultured for the length of 
the experiment, but not 
exposed to doxycycline 
to reprogram. The largest 
sample is induced to 
reprogram with doxycycline 
for 10 days and withdrawn 
from doxycycline for 4 
days, before separation 
into Oct4-GFP positive 
iPSCs, and Oct4-GFP 
negative unreprogrammed 
cells. FACS: Fluorescence 
activated cell sorting. 
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as ‘coverage’. A coverage of 10 would mean that 10 cells are infected by the pooled library, 
per shRNA; so a 63,000 shRNA library would require 630,000 cells. If the coverage is too 
high, the experiment is simply bigger and using more resources then needed. However, 
a low coverage reduces the sensitivity of the entire screen; or the likelihood of an shRNA 
with the desired phenotype to be found. In that case not all shRNA can exert their biological 
effect on enough cells to be identified as hits. In reality, a large scale screen will never have 
100% sensitivity and be completely reproducible. Ensuring sufficient coverage at each 
experimental step, not just the step of cell culture, will increase the chances of finding hits. 
These are considerations per step:
shRNA library production. 
This library was created by printing oligo’s on microarrays, cleaving them off, and mass-
cloning them into viral vectors. Each of these steps may favor some shRNA sequencies 
over others (e.g. by different GC content affecting amplification). To account for this bias, 
the Elledge lab recommended a 10-fold coverage of each of the 63K shRNAs. Secondary 
library production starts with PCR amplification of shRNA sequencies from gDNA, which 
warrants the same coverage. During cloning of itself, an even higher coverage of 100-
1000x per plasmid is recommended to account for possible bias during construct ligation, 
transformation of bacterial cells, and plasmid harvest. 
Viral delivery. 
Even after optimizing infection efficiency of the reprogrammable cells (see below), 
sometimes 50 million cells at a time, we would get infection efficiencies as low as 50% up 
to 90%. Thus we had to assume half the cells did not contribute to the screen and double 
coverage. 
Reprogramming efficiency. 
This is an issue very specific to reprogramming experiments. A screen for shRNAs that 
influence cell death of cancer cells, or differentiation of ES cells, can assume that each cell 
is capable of undergoing the process of interest such as apoptosis. However, the baseline 
reprogramming efficiency is very low in the conditions of this screen. We decided to assume 
that at most 5% of cells would be amenable to be pushed over the threshold towards 
pluripotency by an shRNA, and thus increased the coverage 20-fold. 
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Large scale reprogramming
Reprogramming experiments typically require a couple of cell culture plates with small wells 
to reprogram around 20 thousand cells per replicate and condition. In this case we were 
looking to reprogram one batch of shRNA library expressing cells, up to 70 million at a time. 
In chapter 2 we describe the reprogrammable mouse model which enabled us to generate 
large quantities of reprogrammable mouse embryonic fibroblasts (repMEFs) at once and 
reprogram these cells into iPSCs at a robust baseline efficiency. 
At any step in the experiment, thorough calculation of scale is essential as usage 
of reagents, culture plates, incubators can easily get beyond feasible and requires more 
planning than usual. Another important consideration is representative sampling: the scale 
required for good coverage doesn’t mean that all material harvested is used up for the 
following steps. Representative sampling is inevitable. Think about the soonest step you 
can fairly do sampling without compromising coverage, to save on handling of material you 
will not use down the line. In our case, we realized that the input for library sequencing is 
smaller than the absolute amount of DNA retrieved from the cells. Instead of sampling after 
cell purification, gDNA preparation from cells and generation of the sequencing library, we 
already sampled after cell harvest and thorough mixing of all cells. 
Negative controls
As mentioned before, the readout of the screen is a quantification of each shRNA by deep 
sequencing, prior and after the experiment. A shift in abundance of an shRNA during the 
experiment points to a possible biological effect. Since we were interested in barriers to 
reprogramming, we looked for shRNAs that become more abundant; that enrich themselves 
in the library during reprogramming. These shRNAs must aide the repMEFs into forming 
iPSC; a more proliferative population that we then purified from the reprogramming culture. 
Some important controls for enrichment biases are (Figure 2):
- Non-reprogramming sample; a parallel, no-dox culture of repMEFs to control for  
 enrichment independent from reprogramming, such as through stimulation of   
 proliferation or inhibition of the normal cell death rate. 
- Leftover cells from iPSC purification; cells that were exposed to doxycycline,   
 possibly formed reprogramming intermediates or even iPSC, but no stable,
 reporter-expressing iPSC after dox withdrawal. This controls for impact on cell
 growth in the context of reprogramming, and negatively selects for aiding
 reprogramming without allowing establishment of pluripotency.
- Sample at the start of the experiment; to see at what relative abundance each   
 shRNA reached the target cells for a fair comparison with the end library.
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Serial enrichment strategy 
In our model of heterogeneously reprogramming cells, we still needed be more stringent 
in our selection of candidates. Individual repMEFs have individual speeds and efficiencies 
of reprogramming, for reasons not completely understood. So in our case, we risked losing 
or selecting shRNAs depending on which cell they happened to reach. In particular, we 
needed to weed out ‘passenger shRNAs’ that happened to reach a cell that was efficiently 
reprogramming regardless. To this end we added consecutive screens to our design, every 
time starting with a shRNA library derived from the prior experiment (Figure 3). This way, an 
ever-smaller screening library was created, increasingly containing true pro-reprogramming 
shRNAs. Moreover, we could select for shRNAs that consistently increase their abundance 
each round. Luckily, each round required less cells for adequate coverage, because of the 
lower number of shRNAs present in the library.
Analysis: alternative uses of the data
An interesting question often asked, was whether this setup could be used not only for 
shRNAs that get enriched in reprogramming cells, but also to find biologically relevant 
dropouts; shRNAs that target genes that are beneficial to reprogramming. Initially we were 
very skeptic of this possibility because of the likelihood of shRNAs dropping out for merely 
technical reasons. Once an shRNA drops out, you don’t know if your coverage was lacking, 
the shRNA was toxic or anti-proliferative, or primarily inhibitory to reprogramming. Plus, the 
serial screening approach does not apply.
However, we believe it is not entirely impossible to do. The negative controls are 
crucial for such a question as they can show how well the shRNA was represented in the 
fibroblasts. A dropout specific to only the iPSC fraction is interesting. When we selected 
for shRNAs that are well covered in the library and enrich in non-reprogramming cells but 
drop out of the reprogrammed cells, we did find an shRNA for Brca1, which was previously 
shown to be important for reprogramming, suggesting that this approach could be fruitful 
(Figure 4). 
Another additional way the data can be mined, is to look at shRNAs that do influence 
cellular proliferation. These were filtered out of our analysis because rate of proliferation 
is a major and well-known bias to reprogramming efficiency, which we were not interested 
in. But our data should enable a look at shRNAs that enrich specifically in the non-
reprogramming cells. 
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Validation (-rate)
After retrieving shRNA sequencing data, the identification of hits has only just started. 
An average screen of this kind will produce hits that validate upon individual scrutiny, at 
a rate of around 50%. We however were happy to see 10-20% of hits show any effect on 
reprogramming, let alone a very strong one. This influences a final important consideration: 
amount of hits to be further tested. 
A low validation rate can suggest that testing many hits will lead to more real hits. 
However, depending on your assay, cloning and testing hits individually, with the required 
replicates, is cumbersome. We strived to test 20 to 30 hits only. 
Knowing which genes to include in this list is impossible if the screen was not 
performed before, in the same model system. We tried different algorithms along the way, 
playing with the weight of different factors such as enrichment compared to one or all 
controls, fold of enrichment, multiple shRNAs targeting the same gene. It is key to set cut-
off limits, or criteria for a hit such, that a workable number of shRNAs (whether it be 10 or 
50) is selected for validation.
Technicalities
shRNA lentiviral vector
The vector in our library has a lentiviral backbone with a miRNA30 cassette with the shRNA 
coding sequence, as well as a tRFP reporter under individual, ubiquitous promotors. The 
Hannon and Elledge labs determined that not the half-processed pre-miRNA strand, but 
rather the unprocessed primary miRNA strand was most effective at producing miRNAs. 
They modeled their strands after the well-characterized mir30 miRNA.  The cassette is 
flanked with several PCR primer targets and restriction sites for easy sequencing and cloning. 
Infection with library virus
Transduction of the virus into MEF introduces some toxicity and can be of varying efficiency. 
Therefor we infected cells right before passaging the MEF onto plates for reprogramming. 
During passaging, the number of surviving cells could be counted and plated at desired 
density, infection efficiency could be measured by viral reporter expression, and the infection 
could be done in just a couple of safe, enclosed cell culture flasks as opposed to the many 
reprogramming plates. We infected at a density of around 50% to allow cell proliferation 
during infection. The virus was produced as fresh, filtered supernatant from 293T HEK cells, 
to which we added fresh MEF media 1:1 along with 1:2000 Polybrene. Since the Polybrene 
is another potentially toxic compound to the cells, we strived to wash off the virus between 
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Cell culture and harvest
In short, we experienced that likely due to handling larger quantities of cells, overall 
reprogramming efficiency was usually lower then the pilot experiments predicted. That 
said, large Petri dish-like, 15 cm culture plates served well to for a starting population of 
300 thousand cells each. We seeded MEF directly into the reprogramming media containing 
doxycycline. When looking to reduce the use of reagents and time, we noted no reduction 
in efficiency upon culturing in a reduced volume of media of 25 ml versus 30 ml per plate, 
nor when delaying the first media change to day 3 of reprogramming. 
The most practically challenging step was the harvest of many plates at a time. After 
reprogramming, non-reprogrammed MEF tend to create what seems to be a strong network 
of extracellular matrix proteins, causing the trypsinized culture to clump partially. We used 
a large pore (100 μm) to small pore (40 μm) filtering protocol to create a cell suspension for 
subsequent separation by flow cytometry. The expensive and time consuming FACS sort is a 
major bottleneck to the amount of gDNA that can be generated. Only a fraction of genomic 
DNA that can be harvested from all cells can be used to amplify the shRNAs by PCR. Thus 
Pooled 
genome-wide 
shRNA library
gDNA isolation 
PCR amplification shRNAs 
gDNA shRNA LT LTRgDNA LTR
Reprogrammable MEFs
iPSCs+Dox
FACS for Oct4-GFP
Reclone into
viral backbone
Serial enrichment of libraries
Round #1 #4#3#2 #5
Figure 3
Figure 3. Experimental design 
of serial enrichment screening. 
Top panel: the experiment 
depicted in figure 2 formed 
one round of multiple rounds 
of serial enrichment screening. 
The Oct4-GFP positive iPSCs 
were used to generate a 
secondary shRNA library. This 
library was then screened 
during reprogramming again 
like in figure 2. Bottom panel: 
we continued this cycle until 
we had performed 5 rounds. All 
intermediate libraries including 
negative controls were 
analyzed. The library became 
less complex (containing less 
shRNAs) each step, while losing 
shRNAs that do not benefit 
reprogramming (depicted as 
green or pink shRNAs).
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we took a representative fraction before the cell sort, after a very thorough mixing of all 
harvested and filtered cells. 
Prior to FACS, we increased the yield of iPSC by enriching our sample for SSEA1 
expressing stem cells by magnetic (MACS) sorting. We reached around 90% purity of Oct4-
GFP positive cells depending on the stringency setting on the AutoMACS sorter (Figure 5). 
This SSEA1+ sorted cells were purified for Oct4-GFP expression by FACS which should give 
very near to 100% purity, although the limitation on sorting time prevented us from re-
sorting to guarantee such total purity. The steps before FACS took around 12 hours for the 
largest screening rounds, during which cells were kept at 4 degrees Celsius. It was important 
to FACS right after to not lose cells to extensive cell death because of this long day. 
Genomic DNA preparation from cell samples
During each round, four samples were generated from shRNA infected cells: the ‘T0’ sample 
of immediately harvested MEFs; the ‘T1’ sample of reprogrammed, sorted, Oct4-GFP+ cells; 
the non-reprogrammed, Oct4-GFP-negative cells and the MEF that were cultured in parallel 
but without doxycycline induction (Figure 2). All cells were pelleted and immediately frozen 
at -80C. Each of these samples is subject to a PCR to retrieve the shRNAs for sequencing 
(all) or re-cloning (only Oct4-GFP positive cells). This PCR is complicated by three factors: 
concentration of the shRNA template in total genomic DNA, secondary structure formation 
of the shRNA amplicon, and possible contaminants in the large gDNA preparation. To 
address the latter, we used a phenol-chloroform extraction with phase-lock tubes. Generally 
PCR steps needed more optimization and practicing than most PCR protocols, and resulted 
in a relatively low yield.
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Figure 4. Relative 
abundance of ‘dropout’ 
shRNAs during the first 
round of screening. We 
selected for shRNAs 
well represented in the 
negative controls but 
diminished or lowered in 
the iPSC fraction (T1 Dox, 
GFPpos). Here, abundance 
of shRNAs targeting Brca1 
and Brca2 are shown in 
reprogrammed cells (Oct4-
GFP+ iPSCs) compared to 
starting population and 
controls (no dox, no GFP). 
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Recloning sequential libraries
The key of the experimental design of this screen is the serial re-screening of the shRNA 
library to select for reproducibly enriching shRNAs. We re-cloned the pooled shRNA library 
from genomic DNA of iPSC from the previous screening round to generate the screening 
library for the next round. For this purpose, all shRNAs were en masse amplified, purified, 
digested to create sticky ends and ligated into the original viral vector. These steps proofed 
difficult to do at the efficiency required for good coverage (100-1000x) of the library; count 
on optimizing this in your lab as well. 
Sequencing
We used Solexa sequencing to assess the relative abundance of each shRNA. We added 
generic adaptors with a two-nucleotide library barcode to the amplified pool of shRNA 
encoding strands from each sample. This sequencing library was mixed with up to three 
other barcoded libraries to reduce the number of Solexa flow cells required. Each flow cell 
generated 100-200 million 50 base pair reads, resulting in 25-50 million reads per sample. 
Subsequent analysis allowed separation of reads from different samples prior to counting 
individual shRNA reads. Figure 6A gives an idea of our usual outcomes from the Solexa 
sequencing in terms of total reads, mixing of the barcoded samples, and reads per sample. 
Our library required a 50 base pair readout to capture the unique 19 nucleotide 
shRNA sequence, along with the sample barcode and common shRNA loop sequence used 
to align the sequences during analysis of the raw data. A benefit of sequencing an shRNA 
library over, for example, genomic or mRNA derived libraries is the quality of data retrieved 
because the strands are homogenous, don’t require high quality of the entire strand. Also, 
the sequencing primer is designed to amplify the most variable parts of the read first so the 
software can easily distinguish neighboring spots in the flow cell. In Figure 6B the average 
read is plotted against the data quality, showing how unique sequencies of the barcodes and 
shRNA sequence are sequenced well whereas the default sequencies are not because they 
are the same in all reads. 
Analysis
We were able to rank shRNAs on many different criteria, such fold enrichment, consistency 
in enrichment, enrichment in negative controls, and many combinations. Initially we used 
an excel sheet with the data and tested different algorithms manually. Our manual algorithm 
delivered a list of 20 top hits from which we identified one of the strongest hits from the 
screen, an shRNA for polyadenylation modulator Nudt21. 
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When we repeated the screen, we obtained better coverage of the shRNA library 
and a more reliable, gradual loss of shRNAs after each round. The collaborating bio-
informaticians were able to take these higher quality data, calculate a mean value from 
the negative controls to compare to the iPSC libraries, and rank all shRNAs based on how 
much they enrich in all rounds compared to the negative controls. (Figure 7) This list was 
topped by our strongest hit from the entire project, an shRNA targeting the sumoylation tag 
SUMO2. 
Conclusion
A genome-wide screen is a powerful and relatively unbiased tool to find genes involved 
in various cellular processes. The pooled approach reduces the amount of specialized 
equipment needed and avoids using small wells for culture. In our case, this enabled a 
readout based on reprogramming efficiency of shRNA expressing cells. Furthermore, we 
piloted a serial screening approach to get reliable results in a process prone to create 
false-positives. Our approach allowed us to screen all protein-coding genes for a role 
during reprogramming. However, despite optimizations in design and execution, this is a 
demanding project, time-wise and material-wise. Smaller scale screening based on genes of 
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Figure 5. Flow cytometry analysis of samples before and after magnetic-activated cell 
sorting (MACS) for SSEA1 expression. Prior to the more stringent but less efficient FACS for 
Oct4-GFP+ iPSCs, MACS was performed for stem cell marker SSEA1 to increase the iPSC 
concentration. These flow cytometry plots show the increase of the Oct4-GFP (x-axis) 
fraction (green population) after MACS. Some iPSC still retain viral tRFP (y-axis) expression, 
but most silence the viral vector. An iPSC control sample with some contaminating feeder 
cells is shown for comparison.
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interest or gene groups such as kinases or transcription factors might be more appropriate 
when screening is a subtopic of your studies. It would be interesting to apply our lessons, 
e.g. on serial screening, to smaller scale shRNA screens. 
Take home points:
- Do not underestimate the scale of an experiment needed to properly cover a large 
 screening library. Assume everything loses efficiency when working on a large   
 scale;
- Ensure good library coverage at each step, not just in cell culture;
- Decide on a smart sampling and readout method to save work and materials;
- Consider biases and false-positive or -negative results due to technical reasons or a 
 heterogeneous cell population or process of interest, and think of appropriate   
 controls;
- Consider serial enrichment screening for heterogeneous cells or processes;
- Be prepared to use trial-and-error in your hit selection process, but keep number  
 of hits to be validated realistic;
- Ideally collaborate with someone with experience cloning the library and analyzing
  the sequencing results.
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Figure 6. Solexa sequencing output of barcoded libraries. (A) Exemplary yield from Solexa 
sequencing. Here we used two Solexa flow cells (lane 1 and 2). In each we ran four samples 
with different barcodes: ‘AT’, ‘CT’, ‘TC’ or ‘CA’. Total reads per lane were more than 200 
million; of which 43 to 64 million were assigned to each sample. A fraction of reads was 
unidentifiable (around 1 million per lane). (B) Average quality of the read (y-axis) plotted 
against the length of the read (50 base pairs, x-axis). This plot shows how well the sequence 
could be read at each position of the reads, across all reads. The top green zone means 
good quality; usable for downstream analysis. Highly variable parts such as the individual 
shRNA sequence (first 20 base pairs) and the barcode (BC) were sequenced at a high quality, 
whereas the rest of the read, containing sequences common to all the reads, was sequenced 
with a poor quality. 
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Figure 7. Ranking algorithm shRNAs based on enrichment during reprogramming rounds. 
Schematic depiction of algorithm used for picking candidates from enrichment data. Overall 
fold enrichment score was calculated by comparing all three negative controls to the iPSC 
sample. For this, number of reads were normalized per sample, before calculating fold 
enrichment per round. Then, overall (cumulative) fold enrichment was calculated for each 
shRNA, giving it a score to rank them on. 
Negative controls Oct4-GFP+ cells
# normalized reads 
from negative controls 
Maximum cumulative fold change
per shRNA and round
# normalized reads
from Oct4-GFP+ cells
Cumulative fold change of 
Oct4-GFP+ vs. max of negative controls
per shRNA
Figure 7
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Abstract
IDH mutations are important drivers in a range of malignancies including leukemia, 
glioblastoma and cholangiocarcinoma. The IDH enzymes, their substrates and their 
metabolites are highly conserved and present in all cells. Point mutations generate 
neomorphic IDH enzymes that produce the ‘oncometabolite’ 2-hydroxy-glutarate (2-HG). 
Although thought to be early mutations in tumorigenesis, they act in the context of other 
tumorigenic mutations in genetically unstable cells. To study the effect of mutant IDH (mIDH) 
expression during transformation, but in an otherwise healthy cell, we used fibroblast to 
induced pluripotent stem cell (iPSC) reprogramming as a transformation model. We were 
able to express the most common human mutant enzymes and measure high levels of 
2-HG in mouse embryonic fibroblasts (MEFs). Although the efficiency of iPSC formation was 
unaffected, or even reduced at high 2-HG levels, mIDH did facilitate early reprogramming 
as characterized by a loss of fibroblast and mesenchymal gene expression. This effect was 
dependent on reprogramming factor expression. Moreover, mIDH created a population of 
cells that did not form iPSC but also failed to revert back to THY1 expressing MEF cells. 
Macroscopically, mIDH leads to the formation of small cells that stain positive for alkaline 
phosphatase; interestingly, this phenotype was reverted by ascorbic acid. To characterize 
IDHm expression on a molecular level, we profiled early reprogramming cells both by RNAseq 
and several metabolic analyses, together revealing the most affected metabolic pathways. 
These experiments shed light on the effect of IDHm independently of a cancerous genetic 
background and illustrates the effect of a metabolic perturbance on early reprogramming 
events. 
Introduction
Our understanding of the molecular underpinnings of cancer started with the study of DNA 
mutations that amplified oncogenes or mutated tumor-suppressor genes. Some cancer 
associated mutations were found in molecules deemed too essential for cellular survival 
such as enzymes from the Krebs or TCA cycle, which drives oxidative phosphorylation, the 
most efficient route of glucose breakdown in terms of ATP (Adenosine Tri-Phoshate, the 
‘energy currency’ of the cell) production. However, mutations of the enzyme isocitrate 
dehydrogenase are found in glioblastoma multiforme, leukemia, cholangiocarcinoma and 
others1-4. Wildtype IDH1 converts isocitrate to α-ketoglutarate (α-KG) in the cytoplasm, 
IDH2 has the same function but as part of the Krebs cycle inside the mitochondria. These 
oncogenic mutations do not require homozygosity; it is not the loss or gain of function of 
these enzymes that stimulate oncogenesis. Rather, neomorphic mutations in IDH1 or IDH2 
lead to a mutant enzyme that catalyzes the ‘oncometabolite’ 2-hydroxyglutarate (2-HG). 
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Oncometabolite 2-HG is structurally highly similar to α-KG. It can bind α-KG 
dependent enzymes including epigenetic regulators such as Jumonji-domain containing 
histone demethylases and the 5mC hydroxylating Tet enzymes5. 
Mutations in IDH1 and IDH2 have been found to be potent drivers of tumorigenesis6,1,7. 
So far many studies have been conducted in the context of tumor models or patient 
derived cancer cell lines. These models harbor various other aberrations that arise during 
tumorigenesis unique to each tumor and patient or mouse. Moreover, there are no marker-
defined stages of transformation towards malignancy that can be used to dissect individual 
oncogenic events.  
Our lab specializes in studying the molecular events leading towards pluripotency 
using controlled, transcription factor induced reprogramming systems. We have defined 
intermediate stages during the reprogramming of mouse embryonic fibroblasts (MEF) to 
induced pluripotent stem cells (iPSCs), marked with cell-surface markers and an endogenous 
pluripotency reporter that can easily be tracked by fluorescence microscopy and flow 
cytometry. Moreover, we combined an expression cassette carrying all four required 
transcription factors, Oct4, Sox2, Klf4 and c-Myc, under a doxycycline-inducible promoter, 
along with the endogenous pluripotency reporter Oct4-GFP8,9.  
Reprogramming to pluripotency is a process of transformation that shares similarities 
with tumorigenesis. Importantly, like transforming cancer cells, otherwise healthy 
reprogramming cells also switch to glycolytic glucose metabolism, downregulate apoptosis 
pathways, increase cell proliferation while altering DNA methylation patterns and chromatin 
structure on a large scale. However, the resulting stem cells are capable of generating entire 
cloned animals. We used the relatively physiological background of reprogramming to 
dissect the effect of IDH mutations on all of these important molecular processes.  
Results
Human mutant IDH expression in MEF leads to high levels of 2-HG which can 
be reversed by small molecule inhibitors. 
In this study we included three different prevalent IDH mutants which are active in the 
cytosol (IDH1 R132H) or in the mitochondria (IDH2 R140Q and IDH2 R172K) (Figure 1a). 
The two IDH2 mutants differ effectively in their rate of 2-HG production; IDH2 R172K 
overexpression leads to higher intracellular 2-HG levels. The IDH enzymes are highly 
conserved between mouse and human, thus we were able to examine the effect of human 
mutant IDH expression in our murine model of iPSC formation. To confirm adequate 
expression of the enzymes in our cells of choice, mouse embryonic fibroblasts (MEFs), we 
transduced the cDNA in a constitutive lentiviral vector and assessed 2-HG production after 
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48 hours (Figure 1b).  Indeed, 2-HG was produced at high levels in all mutant IDH samples, 
but not in wildtype IDH samples. The level of 2-HG production was mutant-dependent, 
IDH2 R172K producing most of the oncometabolite. We reproduced the overexpression of 
wildtype and mutant IDH in our experimental setup for large scale profiling experiments. 
There we included mutant-specific small molecule inhibitors or solvent (DMSO) to confirm 
efficacy of inhibitors in reducing 2-HG production by the mutants and serve as an additional 
control (Figure 1c). We reached almost normal 2-HG levels by using the inhibitors, except 
for the IDH2 R172K samples which turned out to be under dosed to fully inhibit the potent 
mutant. We included these samples in the following experiments as an interesting midway 
point to very high or normal 2-HG levels. 
IDHm expressing MEF form iPSC at the same or lower efficiency
Stable iPSC colonies form after different lengths of time of reprogramming factor exposure, 
and when looking at marker-based intermediate stages, each step towards pluripotency is 
increasingly rare to occur. As a consequence, the reprogramming culture contains cells at 
different stages of reprogramming pretty soon after the induction of OKSM expression. For 
this reason, bulk-harvested reprogramming cultures are a mixture of reprogramming and 
refractory cells, unless harvested at an early time point such as day three, when a majority 
of cells has undergone the first step of losing expression of the MEF marker THY1. Our lab 
avoids additional heterogeneity due to reprogramming factor delivery by using MEFs from a 
‘reprogrammable mouse’ (repMEFs), a mouse strain that carries all alleles for doxycycline-
inducible expression of the OKSM cDNAs (Figure 2a). 
Next, we tested the effect of mIDH on cell death and -growth at days 1-3. It is known 
that cell proliferation and survival positively correlates with reprogramming efficiency, 
which could create a bias in reprogramming experiments10. To this end, we induced 
reprogramming in repMEFs expressing the different vectors and measured the rate of 
apoptosis at day 3 (AnnexinV staining, Figure 2b) and the total number of cells at day 1-3 
(Figure 2c). There was no discernable effect on the percentage of AnnexinV positive cells by 
any of the IDH overexpression vectors. However, both wildtype and mutant IDH expression 
reduced cell growth compared to the empty vector. When comparing mutant expression 
to corresponding wildtype expression, only IDH2 R172K expression resulted in a clear 
reduction of cell proliferation. 
Next we tested whether wildtype or mutant IDH overexpression would affect 
reprogramming ability and efficiency of repMEFs. We assessed stable, dox-independent iPSC 
formation by endogenous Oct4 expression (by Oct4-GFP reporter knock-in allele; Figure 2d) 
and by colony formation assays (Figure 2e). After 10 days of Dox induction and 4 days dox 
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withdrawal, flow cytometry analysis detected 
Oct4-GFP expressing cells regardless of wildtype 
or mutant IDH expression. However, IDH2 
R172K expression did reduce the abundance 
of Oct4 expressing cells. The colony formation 
assay, using alkaline phosphatase (AP) staining 
of dox-independent colonies demonstrated 
that none of the conditions prevented stable 
iPSC formation. Remarkably, the mutant 
IDH cells formed more AP staining colonies, 
although many of these colonies did not show 
the characteristic strong AP staining and sharp 
border required to count a colony as an iPSC clone.  
Mutant IDH expressing cells create iPSC-like, Oct4-GFP negative colonies that 
are eliminated by ascorbic acid exposure
Before the AP staining of iPSC colonies from IDH expressing cells, we examined them 
under light and fluorescent microscopy. We could distinguish colonies with the irregular 
shaped ESC-like dome shape of primary iPSC clones, from single layer, dense clusters of 
small cells that lacked ESC or fibroblast morphology. When we quantified the AP staining 
colony assay, counting only sharp, brightly stained colonies as true iPSC colonies, we saw no 
significant difference in the colony formation efficiency between mutant IDH or control cells 
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IDH raises 2-HG levels in mouse embryonic 
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oncometabolite 2-hydroxyglutarate (2-HG) from 
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or in the cytosol (mIDH1). (B) Overexpression of 
mIDH through viral vectors raises intracellular 
2-HG levels in mouse fibroblasts; quantification 
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of 2-HG can be effectively inhibited by small 
molecule inhibitors specific to the different 
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(Figure 3a, grey bars). When we counted solely the dimmer, fuzzy-bordered colonies, that 
appeared as dense clusters under the microscope, we noted that overexpression of each 
of the mutant IDH vectors caused an increase in the formation of these colonies (Figure 
3b, grey bars). We previously observed that ascorbic acid in the cell culture media nearly 
eradicated the presence of ‘fuzzy’ colonies in unrelated experiments. Also, our lab earlier 
described ascorbic acid to be a potent enhancer of reprogramming efficiency towards iPSC 
cells11. When we added ascorbic acid to the mutant IDH or control cells, the number of fuzzy 
colonies was reduced to nearly absent in all samples but IDH2 R172K, where they were 
significantly reduced. Also, the number of iPSC clones increased (Figure 3a-b, red bars). 
To further characterize the cell clusters that formed and were stimulated by mutant 
IDH expression, we analyzed reprogramming cultures by flow cytometry for MEF marker 
THY1 and endogenous Oct4-GFP reporter expression. After 4 days of dox withdrawal, control 
cultures contain nearly only THY1 positive or Oct4-GFP positive cells, suggesting there are 
stable iPSC or MEF (Figure 3c). Mutant IDH expressing cells, however, formed many more 
cells negative for either marker.
IDHm expressing MEF more efficiently lose their MEF identity during early 
reprogramming
To further study the ‘marker-negative population, we analyzed reprogramming cells at 
intermediate timepoints during reprogramming to see when this population is formed. We 
noticed that all mutants lose the MEF marker THY1 much more efficiently between day 3 
and 6 of reprogramming (Figure 4a; IDH1 in left panel, IDH2 in right panel). Note that THY1 
positive cells are decreased in all samples at later timepoints due to the relative expansion 
of iPSC. The next, intermediate step during reprogramming is the gain of the stem cell 
marker SSEA1. This was not affected by mIDH expression, except for a reduction in IDH2 
R172K expressing repMEFs (Figure 4b). 
Finally, when we looked at iPSC formation based on the formation of Oct4-GFP 
positive cells, we did not see any divergence between samples, except a reduced number 
of cells at all time points for IDH2 R172K expressing cells (Figure 4c). We repeated the day 
6 analyses including the mutant specific inhibitors to confirm the significant THY1 loss, and 
were able to rescue the rate of THY1 loss using the mutant IDH inhibitors (Figure 4d). 
To exclude that we were looking at an expansion of a rare THY1 negative population 
within the heterogeneous MEF prep, we also analyzed non-reprogramming fibroblasts 
expressing the mutants, but failed to see a clear THY1 loss there (Figure 4e), suggesting that 
loss of THY1 is a reprogramming factor dependent event. 
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Transcriptional profiling of reprogramming cultures with mutant IDH 
expression
Mutant IDH expression leads to tumorigenesis and aids dedifferentiation12,13. In our model 
mIDH expression does not enhance reprogramming to iPSC. However it does enhance 
formation of cells that lose MEF identity but do not gain any stem cell marker that we normally 
detect in reprogramming cells. These cells arise between day 3 and 6 of reprogramming and 
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Figure2Figure 2. Effect of mIDH on viability and reprogramming potential of reprogrammable mouse 
fibroblasts. All Figures: error bars represent standard deviation; n=3; WT= wildtype allele. 
(A) Alleles carried by reprogrammable mouse embryonic fibroblasts (repMEFs). OKSM: Tet-
driven polycistronic cassette with Oct4, Klf4, Sox2, c-Myc cDNAs. M2rtTA: reverse tetracycline 
transactivator. (B) assessment of cell viability by percentage of Annexin V presenting cells 
at day 3 of reprogramming. (C) Cell proliferation plotted as absolute cell number per well 
at days 1-3. (D) Flow cytometry analysis of cultures after 10 days reprogramming and dox 
withdrawal. Oct4-GFP: expression of pluripotency reporter allele on y-axis. Numbers in plots: 
% of viable cells. (E) Wells with reprogramming cultures after 10 days of reprogramming and 
4 days dox withdrawal, stained for stem cell marker alkaline phosphatase to detect iPSC 
colonies. 
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persist to a larger degree than in controls, even after withdrawal of OKSM and 2 weeks of 
culture. Thus we wondered what these cells are to understand what mIDH does to somatic 
cells that are transforming in a context free from other mutations involved in tumorigenesis. 
To catch the molecular events just prior to the formation of these cells, and not 
look at possible indirect effects, we decided to profile reprogramming cultures at day 3 
post induction. First we analyzed global transcription by RNA-sequencing. To validate that 
the loss of MEF identity was already taking place at the transcriptional level, we looked 
at expression of Thy1, collagens and mesenchymal-to-epithelial transition (MET) related 
molecules (Figure 5a-c). Thy1 was indeed downregulated in the mutants. Several collagens 
were downregulated and rescued by the inhibitors of mutant IDH. Tet1, which is inhibited by 
competitive binding to 2-HG instead of its cofactor α-KG, was not transcriptionally affected 
by mIDH (Figure 5d).
Next we looked at genes of interest based on earlier studies on reprogramming 
such as mesenchymal genes that are downregulated in the transition to the epithelial 
like state of pluripotent cells; and genes found to be linked to more pluripotent or more 
differentiated cells. We found no clear pattern of expression of mesenchymal genes Snai1, 
Twist or epithelial genes such as Cdh1 (Figure 5e-f). Stem cell related genes were expressed 
at very low levels in all samples this early in reprogramming (not shown). Another group 
of genes of interest were those transcriptionally altered during reprogramming in prior 
reprogramming studies. When we looked for mIDH dependent expression in this group, we 
found Prx and Ereg, genes normally downregulated during early reprogramming, and Myb 
which is upregulated during day 6-9 of reprogramming. (Figure 5g-i).
Another group of interesting genes are those described to be differentially methylated 
upon mIDH2 expression in human blood cell and leukemia cell lines 14.  We analyzed 
expression of the murine homologs in our RNAseq data. Most were not differentially 
expressed. The only exceptions were Dok1 which was slightly downregulated, and Gpc3 
which was slightly upregulated in mIDH expressing cells (Figure 5j-k). 
Finally, we looked with an unbiased view by selecting those genes that were 
consistently up- or downregulated between the mIDH DMSO or inhibitor samples. The 
vast majority of hits were downregulated by mutant expression (Table 1; selected for 2+ 
fold down- or upregulated in all three mIDH samples compared to inhibitor). This included 
genes such as Wnt pathway signaling molecules Wnt2 and Dkk2, p53-activated pro-
apoptosis signaler Palmd (ref24810057), negative stem cell proliferation regulator Gabre 
(ref18185516) and adhesion molecule Icam1 (Figure 5l-r). 
Unexpectedly, some genes were also affected by IDH2 wildtype overexpression. 
Wildtype IDH2 overexpression does produce some 2-HG as a byproduct, possibly explaining 
this. Interpretation of some of these expression patterns is complicated by overall low 
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expression levels. Genes that were upregulated in a mIDH dependent manner were Pou4f1 
(Brn-3a, neuronal transcription factor and proposed oncogene, ref 12405260) and Mob3b 
(in family of mitotic regulators; possible human tumor suppressor gene, ref 26130958). 
Overall, the RNA profiling points to some genes well known to affect oncogenesis and 
reprogramming, as well as some unexpected genes. The gene expression patterns mostly 
differ from earlier studies on gene expression upon mIDH expression, which is likely due to 
the analysis of different cell types. 
Metabolic profiling of reprogramming cultures.
We submitted the same day 3 reprogramming cultures to bulk harvest for metabolic 
profiling. We profiled by several modalities: both targeted (LCMS negative and positive 
mode) and untargeted analysis (FIA-TOF negative and positive mode).  We looked for 
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Figure 3. Formation of Oct4-GFP, THY1 negative, ‘fuzzy’ colonies is eliminated by ascorbic 
acid treatment. Error bars represent standard deviation; n=3; WT= wildtype allele. (A) 
Quantification of sharp bordered, brightly stained colonies in alkaline phosphatase assay, 
upon or without ascorbic acid (AA) treatment during reprogramming. (B) Quantification 
from same wells as in (A), counting fuzzy, dim stained colonies. (C) Flow cytometry analysis 
of reprogramming cultures after dox withdrawal. MEF marker THY1 (y-axis) plotted against 
pluripotency reporter Oct4-GFP (x-axis). Numbers in plots are % of viable cells. 
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metabolic pathways affected by either of the IDH mutants but normalized by the mutant 
inhibitors. Perhaps unsurprisingly, IDH2 mutants, which are localized to the mitochondrium, 
had a clear effect on TCA cycle metabolites and derivatives downstream of α-KG, such 
as acetyl-CoA, citric acid, fumaric acid, succinic acid and glutathione (Figure 6A-E). Our 
reprogramming phenotype was comparable for IDH1 and IDH2 mutants, so these changes 
may not be causal to that phenotype. Furthermore, phospholipid and glutathione related 
metabolites were altered such as citicolin and oxidized glutathione. 
Hif1α is degraded in α-KG dependent manner, and postulated to be affected by 
mutant IDH through 2-HG antagonism. A byproduct of the degradation reaction is the 
metabolite succinate.  The transcriptional data showed no difference in the expression of 
a range of Hif1α targets (Table 2) in mIDH expressing reprogramming cells. The metabolic 
analysis revealed no change in succinate levels either, suggesting that Hif1α regulation is 
unaffected by mIDH in our system (Figure 6D). Individual metabolites affected similarly by 
IDH1 and IDH2 mutants were glutamate and GABA (both reduced by mutants) (Figure 6H-I). 
Finally, we integrated the transcriptional data and metabolic data to detect which 
metabolic pathways were affected both at the metabolite and metabolic enzyme level. 
Three pathways were highlighted by this ‘COMBI’ analysis15; metabolism of phytanic acid 
by PHYH, aminotransferases in serine metabolism and lysine degradation by AASS  (Figure 
7-9). Of these three, AASS showed the strongest positive correlation with expression of the 
IDH mutants. AASS is involved in the conversion of lysine to glutamate, which is low in IDH 
mutant cells, suggesting this is a response to glutamate depletion. Glutamate depletion 
itself may be caused by failure to use 2-OG to form glutamate instead of 2-HG. Since this 
is such a central metabolite and affected by all IDH mutants, it could provide metabolic 
explanation of the reprogramming phenotype.
Discussion  
Mutations of IDH1 and IDH2 are potent drivers of tumorigenesis1,6,7. In this study we took 
advantage of our iPSC reprogramming model to study the oncogenic IDH mutations outside 
a cancer model. 
First we noted that mIDH expression has no discernable effect on cell proliferation, 
cell survival or overall reprogramming efficiency, except for the most potent 2-HG producing 
mutant IDH2 R172K which reduced cell growth and the efficiency of iPSC formation. 
However, a third cell population not resembling iPSC or refractory MEF, was amplified 
by expression of either mIDH. Like in normal controls, this normally rare population 
expressed no MEF or stem cell markers, only faintly stained for alkaline phosphatase, and 
nearly disappeared when ascorbic acid was added to the media. Further analysis during 
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reprogramming revealed that mIDH causes an increase in loss of MEF marker THY1 between 
day 3 and 6. This is an early event in reprogramming, normally succeeded by gain of stem cell 
markers and eventually, a stable pluripotent state or return to a MEF like THY1 positive state. 
However, mIDH caused larger populations of cells to remain marker-free throughout. We 
were able to inhibit mIDH with mutant-specific small molecules to rescue these phenotypes. 
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Figure 4Figure 4. Flow cytometry analysis of reprogramming intermediates from mIDH expressing 
repMEFs. A-C) Proportion of viable cells expressing THY1, SSEA1 or Oct4-GFP respectively, in 
mIDH1 (left panels) or mIDH2 (right panels), at different timepoints during reprogramming. 
Dox was withdrawn at day 12. (D) Quantification of the loss of MEF marker THY1 at day 6 
of reprogramming of mIDH expressing cells with or without the mIDH specific inhibitors. 
N=3; error bars represent standard deviation. (E) Quantification of THY1 loss at day 6 of 
reprogramming or dox-free culturing (grey bars) to exclude dox-independent THY1 loss or 
expansion of contaminating THY1 positive cells in the MEF culture. 
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Next we sought to characterize this loss of identity and other effects of mIDH on 
these transforming cells between day 3 and 6 of reprogramming on a transcriptional and 
metabolic level. We picked day 3 as a time just prior to the phenotype manifesting, avoiding 
secondary effects of the phenotype. Transcriptional profiling confirmed that the loss of 
expression of THY1 and other MEF related genes such as collagens, differentiation related 
genes and cell growth inhibitors. GO analysis of genes consistently affected by mIDH and 
rescued by the inhibitors revealed cell signaling (e.g. WNT pathway), morphology, and 
various metabolic processes.  
Earlier studies on the effect of mIDH on tumorigenesis in blood cells suggested that 
the high 2-HG production is oncogenic by inhibiting differentiation through antagonism of 
essential epigenetic regulators. In our system, we find that mIDH stimulates a cell population 
that seems to dedifferentiate from a MEF state but refrain from forming iPSCs unless ascorbic 
acid is added. Ascorbic acid is a cofactor to some of the same enzymes antagonized by 2-HG. 
Thus we hypothesize that in our reprogramming model, high 2-HG levels caused by the 
mIDH steers cells to a state of dedifferentiation, unable to make the epigenetic alterations 
to stabilize a pluripotent state. This could largely be due to α-KG dependent, 2-HG sensitive 
enzymes that are activated by ascorbic acid such as the TET enzymes. Ascorbic acid could 
either overcome 2-HG antagonism or compensate for inactivation of some enzymes by 
activating others.  
Since small changes in levels of metabolites or metabolic enzymes are associated 
with functional alterations of the system, we combined transcriptional data with 
extensive metabolic profiling. Looking at the metabolomics alone, most changes were 
In DMSO vs inhibitor:                                 
Upregulated Downregulated                    
Zfp869 Ccdc125 Foxs1 Samd14
Prickle1 Nynrin Ccdc8 Smpd3
6720427I07Rik Aspa Rab27a D3Bwg0562e
Lum Pde9a Icam1 Trh
Pou4f1 Gabre Nat14 Mustn1
Fbxo40 Klk8 Krtdap Palmd
Il6 Smoc2 Wnt2 Slc13a5
B230216N24Rik Serpinb9 Efcab12 Trim30d
Plb1 Slc16a3 Pgam2 Snca
Myb 9630013D21Rik Phf19 Gm17322
Mob3b Scarf2 Ccdc116 Efna1
Fndc1 Dkk2 Tubg2 Gm10443
Acbd4 Fbxo44 Trim45
Fam46b Prmt1 Gm10036
Table 1Table 1. Transcriptionally affected genes in IDHm expressing 
reprogramming cells., compared to cells treated with the 
respective IDHm small molecule inhibitor
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Figure 5Figure 5. Expression analysis of individual transcripts in day 6 reprogramming 
cultures expressing mIDH. EV= Empty vector; 1RH= IDH1 R132H; 1WT= IDH1 
wildtype; 2WT= IDH2 wildtype; 2RQ= IDH2 R140Q; 2RK= IDH2 R172K; AGX= 
mIDH specific inhibitor; DMSO=solvent only control. Relative expression 
levels from RNA-sequencing. Error bars represent standard deviation from 3 
replicates. mIDH samples without inhibitor treatment are highlighted in orange. 
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caused only by the IDH2 mutants: their expression reduced abundance of metabolites in 
the TCA cycle, glucose derivatives, pentose pathway, and acetylation pathway. However 
when we combined the metabolite levels and the transcription data of the enzymes that 
metabolize them, pathways were highlighted in all three mutants. Most notably, the lysine 
to glutamate degradation pathway involving the Aass enzyme was clearly altered by all 
mutants. Glutamate is depleted, possibly secondary to α-KG (=2-OG; 2-Oxoglutarate) 
depletion through the high rate of 2-HG production by mIDH. Most enzymes using glutamate 
are upregulated without producing higher levels of their end product suggesting that these 
cells struggle to maintain normal levels of these metabolites. 
We entertained the idea that mIDH affects HIF1α targets: 2-OG is turned into succinate 
by EglN prolyl hydroxylases. In the same reaction the enzyme hydroxylates a proline residue 
of Hif1α which marks it for degradation. However, we could find no proof suggesting that 
succinate, Hif1α or downstream factors were affected by the mIDH during reprogramming. 
Future directions 
The combination of transcriptional and metabolic data can only be performed in two-sample 
comparisons. We looked at mutants compared to empty vector, but more comparisons 
could be made. Next, based on these analysis and the ones already described here, more 
validation experiments can be done, both to confirm technical accuracy (qPCR for transcripts 
of interest, measuring individual metabolites) and further explore the dynamics of pathways 
identified as triggered by mutant IDH (metabolite tracing experiments). 
The hypothesis of mutant IDH and ascorbic acid having opposing effects, most likely 
through inhibiting or stimulating the same 2-OG dependent epigenetic enzymes, should be 
further explored. Possible experiments to this end would be to determine DNA methylation 
levels at sites known to be targeted by TET enzymes. Also, the hypothetically ‘stuck’ cells 
that remain free from MEF or stem cell marker expression after dox withdrawal could be 
isolated and further characterized for gene expression and oncogenic potential. These and 
further experiments should help crystallize the molecular consequences of mutant IDH 
Hif1a targets examined in RNAseq expression analysis
Ak3 Hk1 Krt19 Pfkl
Ccng2 Hk2 Ldha Pkm
Col5a1 Igf2 Lep Tgfa
Cp Igfbp1 Lrp1 Tgfb1
Eno1 Igfbp2 Mmp2 Tgm2
Ets1 Igfbp3 Nt5e Tpi1
Fn1 Krt14 P4ha1 Trf
Gapdh Krt18 Pfkfb3 Vim
Table 2
Table 2. Overview of Hif1α targets examined
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expression and the oncometabolite 2-HG during reprogramming.  
To conclude, our study resulted in functional, transcriptional and metabolic analysis 
of transforming cells expressing oncogenic IDH mutations. We demonstrate a loss-of-identity 
phenotype common to both IDH1 and IDH2 mutants. Future directions include metabolic 
validation of our findings and evaluation of apparent key players that our results point to as 
effectors of mutant IDH driven oncogenesis.
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Figure 6
Figure 6. Metabolic profiling of day 6 reprogramming cultures expressing mIDH. EV= Empty 
vector; 1WT= IDH1 wildtype; 1RH= IDH1 R132H; 2WT= IDH2 wildtype; 2RQ= IDH2 R140Q; 
2RK= IDH2 R172K; AGX= mIDH specific inhibitor; DMSO=solvent only control. Relative 
abundance levels from LCMS metabolomics, normalized to labeled internal control. Error 
bars represent standard deviation from 5 replicates. mIDH samples without inhibitor 
treatment are highlighted in orange.  
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Methods
Tissue culture and virus production
Reprogrammable Mouse Embryonic Fibroblasts (repMEFs) were derived from day E13.5-
15.5 mouse embryos carrying the Col1a1-tetOP-OKSM and Rosa26-M2rtTA alleles9. 
Reprogramming was induced in RepMEFs by adding 20ng/ml doxycycline (dox) and, where 
indicated, 25ug/ml L-Ascorbic acid (Sigma A4544-25G) to ESC media (Knockout DMEM, 
1,000U/ml LIF, 20% FBS). RepMEFs were expanded under hypoxic (4% oxygen) conditions 
until dox induction. MEFs were infected with overexpression vectors at passage 4, allowed 
to recover for 16 hours, selected for vector expression by drug selection, harvested, counted 
and seeded at a density of 20K cells per well of a 6-well plate. Media was changed every 
2 days. Dox was withdrawn by removing media, washing with 1xPBS, and continuing 
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Figure 7. COMBI analysis of transcriptional and metabolic profiling highlights metabolic 
pathways altered by respectively (A) IDH1 R132H, (B) IDH2 R140Q or (C) IDH2 R172K 
expression. Lines represent enzymatic conversions by enzymes in bold; dots represent 
metabolites. Green= higher expressed or more abundant in IDH1 R132H expressing 
reprogramming cells compared to empty vector control; red= less expressed or abundant. 
Note that 2-Hydroxyglutarate (2-HG; green dot on left) is overabundant; L2-HGdh converts 
2-HG to α-KG and is overexpressed.  Aass is overexpressed and its substrate glutamate is 
low in abundance. 
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culture in ESC media after 10-12 days. For virus production from overexpression vectors, 
293T cells were seeded and transfected at 50% confluency with PEI (Polyethylenimine) and 
DNA (vector + VSV-G and delta 8.9) at a ratio of 3:1 in Optimem media (Life Technologies). 
After 24 hours, supernatant was collected through a 0.4um filter and precipitated with PEG 
(Polyethylglycol) and kept at -80C for later infections. Viral transductions were performed by 
spin infection for 30 minutes at 2,150rpm at room temperature. Virus was washed away and 
fresh selection media was added ~16 hours after infections. 
Flow cytometry 
To determine viral infection efficiency and cell numbers before initiation of reprogramming, 
infected MEFs were harvested using 0.25% trypsin-EDTA (Life Technologies) and kept at 4C. 
To prepare growth curves, 3 replicates were harvested at each time point to measure cell 
counts (DAPI-negative live cells). Intermediates of reprogramming were analyzed by staining 
with THY1-Viogreen (BD), and SSEA1-APC (Biolegend) (1:200 for 30min. at 4C). To measure 
the fraction of apoptotic cells, BD’s Annexin V kit was used according to the manufacturers’ 
instructions. All cytometry data was analyzed and plotted using FlowJo software. 
Quantification of reprogramming efficiencies
For macroscopic detection of iPSC colonies, Alkaline Phosphatase (AP) staining was carried 
out according to manufacturer’s instructions using the Vector Labs AP staining kit (#5100). 
AP staining was always performed 2 to 4 days after dox withdrawal to eliminate partially 
reprogrammed colonies and to score for transgene-independent iPSCs. 
RNA expression analysis, Metabolic analysis, COMBi analysis
For global gene expression analysis, total RNA was isolated from indicated samples using 
RNeasy Mini Kit (Qiagen). RNA sequencing, metabolite harvesting and LCMS analysis, as well 
as COMBI analysis were performed as described before15. 
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Introduction to the publication ‘Failure to replicate the STAP cell 
phenomenon’
Previous chapters described studies into reprogramming mechanisms and factors involved in 
a well-established reprogramming model, using Oct4, Klf2, Sox2 and c-Myc overexpression 
to derive pluripotent stem cells. The next chapter describes a concerted effort to validate 
an alternative reprogramming method, thereby testing the role of cellular stress in 
reprogramming. 
Early 2014, Nature reported in two back-to-back publications the generation of 
pluripotent cells upon cellular stress induced by acidic conditions or mechanical disturbance. 
The authors from renowned centers of Brigham and Women’s hospital in Boston, USA and 
the Riken Institute in Kobe, Japan announced that stress induced a pluripotent cell type 
from murine somatic cells called a ‘STAP (stress acquired pluripotent-) cell’. These cells could 
be converted to STAP-stem cells by specific culture conditions. STAP-stem cells (STAP-SCs) 
behaved like embryonic stem cells (ESCs) and furthermore, could form intra and extra-
embryonic tissues, suggesting they were totipotent. Since the tools and techniques used for 
these publications were readily available to research groups in the ESC- and reprogramming 
fields, and the potential implications for reprogramming with such simple triggers were 
considerable, our groups and many others immediately tried to reproduce the results. 
In total, we made 6 attempts to generate STAP or STAP-SCs from fibroblasts or 
splenocytes.  To detect pluripotency, pluripotency reporters Oct4-GFP or Sox2-GFP- 
containing knock-in lines were used. We used the protocol from the Nature publications, 
the protocol later published by the Riken Institute as well as the protocol published by the 
Vacanti laboratory; we also performed the latter protocol in Vacanti’s lab under guidance of 
his labmembers. We analyzed resulting cells by live fluorescence microscopy, with knock-in 
reporters or cell surface markers, by immunofluorescence staining of fixed cells and by flow 
cytometry of live cells. Our experiments convinced us that the STAP publications were not 
reproducible. In July 2017, 6 months after online publication, the papers were retracted by 
Nature, following investigations of the Riken Institute pointing to several flaws in the data. 
In the months before, the online community of scientists had discredited the papers already 
by critical analysis of the data, failed reproduction attempts and even an opinion monitor 
on a popular stem cell blog (https://ipscell.com/2014/05/does-europe-know-something-
about-stap-cells-that-we-dont-latest-poll-results/). 
In this chapter, a publication in Nature is presented that resulted from collective 
data of worldwide stem cell laboratories that tried and failed to make STAP cells; including 
deeper analysis by the Daley group into alternative explanations for the data presented in 
the STAP papers. 
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Table 1. Global efforts to replicate STAP cell generation
Lab Mouse strain 
tested
Cell types tested pluripo-
tency 
reporter 
tested
STAP 
generation 
protocol 
tested
Pluripo-
tency as-
sessment 
essay
≤ of 
experi-
mental 
repli-
cates
Con-
clu-
sion
Jaenisch 
(MIT, USA)
C57BL6/129
JAX008214
MEFs, Neonatal 
Spleen, Neonatal 
adipocytes, Neona-
tal Fibroblasts
Oct4-EGFP 
Knockin 
(Jaenisch)
Obo-
kata Article; 
Obokata, 
Sasai and 
Niwa Pro-
tocol
Epiflu-
roescence 
/ FACS
17 Nega-
tive
Wernig 
(Stanford, 
USA)
C57BL6/129
JAX008214
P4 MEFs Oct4-EGFP 
Knockin 
(Jaenisch) 
Obokata 
Article
Epifluo-
rescence / 
FACS
3 Nega-
tive
Pei 
(Guang-
zhou, 
China)
C57BL6/CBA 
JAX004654
Spleen MNCs, 
CD45+ spleen cells,  
MEFs, pre-iPSCs,  
EpiSCs, mammary 
epithelial cells
GOF18-
Oct4ΔPE 
–GFP 
transgene
(Scholer/
Mann)
Obo-
kata Article; 
Obokata, 
Sasai and 
Niwa Pro-
tocol
Epifluo-
rescence / 
FACS
11 Nega-
tive
Deng 
(Peking, 
China)
C57BL6 x ICR MEFs, Neona-
tal fibroblasts, 
Neonatal bone 
marrow, Neonatal 
brain, Neonatal 
cardiac muscle cells, 
Neonatal heart, 
Neonatal lung, Neo-
natal Spleen, Adult 
Spleen 
GOF18-
Oct4-GFP 
transgene 
(Scholer 
-Identi-
cal to 
Obokata 
Article 
reporter)
Obo-
kata Article; 
Obokata, 
Sasai, 
and Niwa 
protocol
Epifluo-
rescence/ 
FACS / 
qPCR 
37 Nega-
tive
Hanna 
(Weiz-
mann, 
Israel)
C57BL6/CBA
JAX 004654
Neonatal CD45+ 
spleen cells, Neo-
natal liver, Neonatal 
brain
GOF18-
Oct4ΔPE 
–GFP 
transgene 
(Scholer/
Mann)
Obokata 
Article
Epifluo-
rescence 
/ FACS / 
STAP-SC
5 Nega-
tive
Ho-
chedlinger
(Harvard, 
USA)
C57BL6/129
JAX 008214
Neontal CD45+ 
splenocytes, E14.5 
MEFs
Oct4-EGFP 
Knockin 
Obokata Ar-
ticle; BWH 
protocol; 
Obokata, 
Sasai and 
Niwa pro-
tocol
Epifluo-
rescence/ 
IF / FACS
6 Nega-
tive
Daley 
(Harvard, 
USA)
C57BL6/CBA
JAX 004654
Neonatal CD45+ 
splenocytes, Neona-
tal lung cells, MEFs, 
Neonatal Brain, 
Neonatal Heart, 
Neonatal Liver
GOF18-
Oct4ΔPE 
–GFP 
(Scholer/
Mann)
Obokata Ar-
ticle; BWH 
protocol; 
Obokata, 
Sasai and 
Niwa pro-
tocol
Epifluo-
rescence 
/ IF / FACS 
/ qPCR / 
Teratoma 
/ Chimera
54 Nega-
tive
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Abstract
Although the reports that stress (such as exposure to acid) can coax somatic cells into a novel 
state of pluripotency1,2 have been retracted3,4, the validity of stimulus-triggered acquisition 
of pluripotency (STAP) remains unclear. Here we describe the efforts of seven laboratories 
to replicate STAP, including experiments performed within the laboratory where STAP first 
originated, as well as re-analysis of the sequencing data from the STAP reports. Neonatal 
cells treated with two STAP protocols exhibited artefactual autofluoresence rather than 
bona fide reactivation of an Oct4 (also known as Pou5f1) and green fluorescent protein 
(GFP) transgene reporter, did not reactivate pluripotency markers towards embryonic stem 
(ES)-cell-like levels, and failed to generate teratomas or chimaerize blastocysts. Re-analysis 
of the original RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing 
(ChIP-seq) data identified discrepancies in the sex and genetic composition of parental 
donor cells and converted stem cells, and revealed a STAP-derived cell line to be a mixture 
containing trophoblast stem cells, attesting to the importance of validating the properties 
and provenance of pluripotent stem cells using a wide range of criteria. 
Results
Replication efforts
To assess the reprogramming capacity of STAP protocols, we used a transgenic Oct4-GFP 
reporter, which shows GFP reactivation during Oct4/Sox2/Klf4 reprogramming, in established 
induced pluripotent stem (iPS) cells and in the gonads of mid-gestation ‘all iPS cell’ embryos 
generated by tetraploid complementation5–7 (Extended Data Figures 1 and 2a). Working 
within the Vacanti laboratory where the concept of STAP cells originated, and assisted by a 
co-author of the STAP papers, a Daley laboratory member (A.D.L.A.) attempted to replicate 
two reported STAP protocols: (1) mechanical trituration and acid treatment of mouse lung 
cells (Brigham and Women’s Hospital (BWH) protocol; see Supplementary Information), 
and (2) acid treatment of mouse splenocytes (RIKEN protocol; Methods and Extended Data 
Figure 2b). Seventy-two hours after stress treatment of lung cells, floating spheres appeared 
amidst cellular debris. Fluorescence microscopy revealed that both Oct4-GFP and wild-type 
spheres emitted lowlevel broad spectrumfluorescence detectable within both green and 
red filters, indicating autofluorescence (Figure 1a). Untreated Oct4-GFP ES cells did not 
emit the same low-level broad spectrum fluorescence as STAP-treated cells. STAP-treated 
splenocytes formed spheres with lower efficiency, but also appeared autofluorescent. Flow 
cytometry indicated STAP-treated Oct4-GFP cells did not exhibit Oct4-GFP reactivation at 
levels comparable to control Oct4-GFP mouse ES cells, and were indistinguishable from 
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stressed wildtype controls (Figure 1b). Absence of ES-cell-like levels of Oct4, Sox2 and 
Nanog transcripts and nonspecific immunofluorescence corroborated flow cytometry data 
(Extended Data Figure 2c, d). 
Rare pluripotent cells should generate teratomas in immunocompromised mice8,9, 
but STAP cells could not, unlike control ES cells (Extended Data Figure 2e, f). Replication 
of the poly-L-glycolic acid (PLGA)-based teratoma production method described in the 
original STAP reports with GFP cells to distinguish host and donor contribution produced 
distinct masses of connective tissue, muscle and scar, with minimal GFP content, indicating 
primarily host origin (Figure 1c, d and Extended Data Figure 2g). Rare GFP-positive clusters 
did not form differentiated tissues characteristic of ES-cell-derived teratomas (Figure 
1d). Autofluorescent spheres failed to enter development after morula aggregation or 
blastocyst injection (Figure 1e and Extended Data Figure 2h–j). vTherefore, pluripotency was 
undetectable in STAP experiments. 
Six other laboratories (Deng, Hanna, Hochedlinger, Jaenisch, Pei and Wernig) also 
attempted to generate STAP cells (Table 1) andmade the following observations. First, 
autofluorescent sphere-like aggregates after STAP treatment were universally seen. Second, 
transgenic reporters used by Obokata and colleagues (GOF18-Oct4-GFP, containing the 
18-kilobase genomic Oct4 fragment (GOF18)) and by the Daley, Pei and Hanna laboratories 
(GOF18-Oct4DPE-GFP, lacking the Oct4 proximal enhancer (PE) element) both exhibit activity 
in pre-implantation embryos, early post-implantation epiblast cells (embryonic day (E) 5.5), 
germ cells, and mouse ES/iPS cells; however, differential activity in late post-implantation 
epiblast (E6.5) and early passage mouse epiblast- derived stem cells has been ascribed to the 
Oct4 proximal enhancer10–12. Using the same reporter as Obokata and colleagues1,2, the Deng 
laboratory observed that the GFP signal in chemical iPS cells was easily distinguishable from 
the autofluorescence of STAP-treated cells (Extended Data Figure 2k). The Jaenisch, Wernig 
and Hochedlinger laboratories failed to observe GFP reactivation with Oct4 or Nanog knock-
in reporters, excluding a scenario of uncoupling between GFP and endogenous pluripotency 
expression10. Despite a range of tested reporters, no group documented authentic Oct4/
Nanog reporter activation that resembled bona fide ES cells.
 Third, the Deng laboratory failed to observe Oct4, Sox2 and Nanog induction 3 
and 7 days after STAP treatment, reducing the likelihood that pluripotency was transiently 
activated and silenced by day 7 (Extended Data Figure 2l). Finally, the Hanna, Wernig and 
Hochedlinger laboratories failed to generate stem-cell lines by culturing STAP-treated cells 
in leukaemia inhibitory factor (LIF) and adrenocorticotropic hormone (ACTH)-supplemented 
medium. In summary, 133 replicate attempts failed to document generation of ES-cell-like 
cells, corroborating and extending a recent report13. 
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(Continued from right) 
(A) STAP treatment produces fluorescent signal detected in both FITC (green) and TRITC 
(red) channels in STAP-treated Oct4-GFP and wild-type (WT) cells, consistent with 
autofluorescence. TRITC signal was not detected in control Oct4-GFP mouse ES cells. Note 
saturation of the green signal in Oct4-GFP ES cells at the higher exposure time required to 
detect FITC from autofluorescent spheres. (B) Absence of ES-cell-like Oct4-GFP reactivation. 
Representative flow cytometry results 7 days after STAP treatment of lung cells or 
splenocytes (BWHor RIKEN protocol, respectively) without singlet/doublet exclusion and 
live/dead-cell discrimination. GFP gates were calibrated based on control Oct4-GFP ES 
cells grown on feeders. Whereas control ES cells are bright and situated at approximately 
13105 (arbitrary units), no event resembling Oct4-GFP ES cells was detected after STAP 
treatment. One replicate per protocol is shown. iMEFs, irradiated MEFs. (C) STAP-treated 
cells do not form teratomas using PLGA-based teratoma production methods1. Photograph 
of controlmouse EScell- derived teratoma (top left) and non-teratoma STAP-PLGA mass 
(bottom left). Representative haematoxylin and eosin (H&E) stainings of a control mouse ES-
cell-derived teratoma (top right) and the non-teratomaSTAP-PLGA mass (bottom right). (D)
STAP-PLGA mixtures present no indication of ES-celllike in vivo differentiation capacity after 
injection into immunocompromised mice. Note lack of organization into representative 
tissue structures typically observed in ES-cell-derived teratomas. DAPI, 49,6-diamidino-2-
phenylindole. (E) STAP-treated lung cells fail to incorporate into preimplantation embryos 
after morula aggregation. (F) Analysis of sequencing data. Samples are classified based 
on copy number and genotype. STAP cells, STAP stem cells (STAP-SCs) and ES cells share 
similar characteristics for genotype and copy number of chromosome X. (G) Copy number 
(CN) profiles, reported as a log2 ratio (observed to expected read counts), derived using 
ChIP-seq input data. Red/ green correspond to significant amplifications and deletions 
(log2(CN)≥0.2 or ≤20.2 and P≤0.01), respectively. Grey denotes non-significant variants. 
Note the amplifications of chromosomes 8 (FI-SCs) and 6/11 (TSCs) and the single copy of 
chromosome X in STAP cells, STAP-SCs, FI-SCs and ES cells. (H) SNVs inferred from RNA-seq 
data using the mouse reference genome (derived fromC57BL6 strain). The selected SNVs are 
classified as homozygous for reference allele (0/0 genotype), homozygous for alternative 
allele (1/1 genotype) or heterozygous (0/1 genotype). Samples are clustered based on the 
sum of edit distance between each SNV. Note that each pair of replicates is always grouped 
together. A subset of samples (CD451, STAP, STAP-SCs and ES cells) shows prevalence of 
heterozygous alleles (A); FI-SC samples have prevalence of homozygous alleles for the 
reference variant (B); and, TSC and epiblast stem cell (EpiSC) samples have a larger number 
of homozygous alternative alleles (C). (I) Contamination in the FI-SC samples with TSCs. The 
expected frequency of reads covering the alternative allele for heterozygous SNVs is ,50%, 
which is observed in all samples including TSCs (left). In FISCs, it was ,12% (Extended Data 
Figure 3), suggesting false-positive calls or contamination. The alternative allele frequency 
distributions of TSC homozygous and heterozygous SNVs sets in FI-SCs (right) show peaks at
9% and 4%, respectively. These results indicate that FI-SC samples are approximately 10% 
contaminated by TSC samples. Original magnifications, 320 (a, (D) e) and 34 (c).
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Figure 1. Characterization of the STAP cell phenomenon. See Supplementary Information 
for further details. (Continued on left)
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Computational analysis of sequencing data 
We re-examined the high-throughput sequencing data from the STAP reports to investigate 
the genetic provenance of parental CD451 cells and converted STAP cells, STAP stem cells 
and FGF4-induced stem cells (FI-SCs) (Figure 1f). Comparative genomic hybridization array 
data mentioned in the original paper1 were not publicly released. Copy number variation 
(CNV) analysis conducted using ChIP-seq input samples revealed a discrepancy in sex across 
samples as well as chromosomal aberrations (Figure 1g). In the original STAP reports, the 
authors stated that they mixed CD451 cells from male and female mice owing to the small 
number of CD451 cells retrieved from individual neonatal spleens. However, our analysis 
indicates that CD451 cells were female, whereas the derived cells (STAP cells, STAP stem 
cells and FI-SCs) were all male, a clear inconsistency. We note that control ES cells were 
also male (Figure 1g). FI-SCs possessed trisomy 8, which renders mouse ES cells germline-
incompetent14 (Figure 1g). Inferred single nucleotide variants (SNVs) from RNA-seq data 
allowed classification of samples as genetically similar or dissimilar (Figure 1h). Control ES 
cells, parental donor female CD451 cells, STAP cells, and STAP stem cells all possessed similar 
SNV profiles, consistent with their derivation from a first generation hybrid of C57BL6/129 
strains, the reported genotype (Figure 1h and Extended Data Figure 3). By contrast, FI-SCs 
had an SNV profile that matched a single nucleotide polymorphism (SNP) profile of C57BL6 
strain origin, indicating distinct genetic provenance from parental CD451 and STAP samples 
(Figure 1h and Extended Data Figure 3). 
Independently sourced control epiblast stem cells and trophoblast stem cells (TSCs) 
had SNV profiles divergent from the CD451 and STAP sample cohort, as expected (Figure 
1h). An anomalous allele frequency distribution observed in FI-SCs, and reciprocal analyses 
of FI-SC heterozygous SNVs in TSCs and TSC homozygous and heterozygous SNVs in FI-SCs, 
revealed that FI-SCs were derived from a C57BL6 strain origin, with approximately 10% 
contamination from TSCs (Figure 1i and Extended Data Figure 3). These are concordant with 
the findings from a recent RIKEN report (http://www3.riken.jp/stap/e/c13document52.pdf). 
This contamination with TSCs explains the high-grade placentaforming capacity reported for 
the Fl-SCs2, an unusual feature that implied totipotency, but which seems to have been due 
to admixture of cells.
Conclusion
In summary, our replication attempts and genetic analysis indicate that existing STAP protocols 
are neither robust nor reproducible. To substantiate future claims of reprogramming and 
alternative states of potency, we urge a rigorous application of several independent means 
for validating functional pluripotency and genomic profiling to confirm cell line provenance. 
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ultimately, the essential standard of robustness and reproducibility must be met for new 
claims to exert a positive and lasting influence on the research community.
Timeline
The STAP papers1,2 were published in Nature on 29 January 2014 (both retracted3,4 in July 
2014). Below, we provide the time period in which laboratories attempted to replicate STAP 
cell generation. The Jaenisch laboratory performed STAP replication experiments from 
February to April 2014. The Hanna laboratory performed STAP replication experiments from 
February to March 2014. The Wernig laboratory performed STAP replication experiments in 
February 2014. The Deng laboratory performed STAP replication experiments from February 
to July 2014. The Pei laboratory performed STAP replication experiments from February to 
May 2014. The Hochedlinger laboratory started STAP replication experiments on the day of 
STAP paper publication (29 January 2014) and continued to April 2014. The Daley laboratory 
performed STAP replication experiments and characterization of the STAP phenomenon 
from February to November 2014.
Methods
Note on Protocols for STAP Cell Generation 
Three different protocols have been reported for generating STAP cells: 1) mechanical 
trituration and low pH treatment (BWH protocol employed in the Vacanti laboratory as 
described here); 2) low pH treatment (RIKEN protocol (found at the following URL: http://
dx.doi.org/10.1038/protex.2014.008)); and 3) mechanical trituration and ATP treatment 
(revised BWH protocol released online September 3, 2014 http://research.bwhanesthesia.
org/research-groups/cterm/stap-cell-protocol). We note that the data in our study comprises 
the first two protocols. The BWH protocol refers to an unpublished, in-house protocol 
created and used by the Vacanti laboratory to generate STAP cells. The RIKEN protocol is 
the published version described in the original STAP reports (Obokata et al, 2014; Obokata 
et al, 2014). The Daley laboratory also attempted the revised BWH protocol without success 
(data not shown). 
The three protocols contain differences and similarities. The major differences 
concern the distinct combinations of physical and chemical stressors. For example, the 
BWH protocols emphasized a combination of chemical and physical stressors, such as 
extensive mechanical trituration, whereas the RIKEN protocol primarily consisted of low pH 
treatment. However, in all three protocols, somatic cells are treated with a transient acid 
bath, although the composition of the low pH solution varied across protocols. Whereas the 
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original BWH protocol and RIKEN protocol generate low pH solutions via titration of HBSS 
with hydrochloric acid, the revised BWH protocol generates a low pH solution via titration 
with ATP. The experimental procedures followed for the BWH protocol and RIKEN protocol 
are described below. 
Mechanical Trituration and Low pH Treatment of Lung Cells (BWH Protocol) 
To trigger STAP cell generation by mechanical trituration and low pH treatment of lung cells, 
we followed a procedure involving tissue isolation, extensive mechanical trituration, and an 
acid bath (pH 5.4). The protocol described below was adapted from the website of the Vacanti 
laboratory, which can be found at the following URL: (http://research.bwhanesthesia.org/
research-groups/cterm/stap-cell-protocol) Lungs were dissected from seven- to ten-day old 
neonatal Oct4-GFP mice and wildtype mice. Dissected lungs from multiple animals were 
pooled and washed twice in 60 mm petri dishes with Hank’s Buffered Saline Solution (HBSS 
without calcium and magnesium, Life Technologies, 14170-112). To enhance enzymatic 
dissociation, the whole tissue was minced with scissors for approximately 10 minutes. The 
minced tissue was treated with collagenase P for 30 minutes and placed in an incubator/
shaker for 30 minutes at 37 degrees Celsius at 90 revolutions per minute (rpm). Following 
collagenase P treatment, HBSS was added and the total tissue suspension was centrifuged 
to create a pellet. After aspirating the supernatant, the pellet was resuspended into a small 
volume of HBSS (approximately 500 μl to 1000 μl). The resulting suspension was forcefully 
triturated for five minutes using a Pasteur pipette to further dissociate cell aggregates and 
debris. The triturated cell suspension was further triturated through a series of flame-pulled 
Pasteur pipettes. Generally, the trituration was performed for thirty minutes starting with 
the flame-pulled Pasteur pipette with the largest diameter. After sufficient dissociation was 
achieved using the large diameter pipette, trituration was performed with pipettes with 
increasingly smaller diameters. 
Following mechanical trituration, erythrocyte depletion was performed. HBSS was 
added to the triturated suspension to increase the total volume to 5 mL (approximately 3 mL 
of HBSS). An equal volume of Lympholyte (Cedarlane) (5 mL) was added to the bottom of the 
tube to create a bilayer. The tube was then centrifuged at 1500 g for 10 minutes. After ten 
minutes, the tube was rotated 180 degrees and re-centrifuged at 1500 g for an additional 10 
minutes. Following the second centrifugation, erythrocytes formed a pellet at the bottom 
of the tube. The layer between the HBSS and Lympholyte was transferred into a new 50 mL 
tube and HBSS was added to a total volume of 20 mL. The solution was then centrifuged at 
1200 rpm for 5 minutes and the supernatant was aspirated. The cells were re-suspended into 
acid solution (HBSS titrated to a pH of 5.4 by hydrochloric acid) and placed into an incubator 
at 37 degrees Celsius for 25 minutes. The pH of the experiment was periodically monitored 
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using a pH meter to confirm that the pH did not rise during the course of the experiment. 
If the pH increased significantly, the cellular suspension was centrifuged and the resulting 
pellet was resuspended into a fresh batch of acid solution. After the 25 minute acid bath, the 
cell suspension was centrifuged at 1200 rpm for 5 minutes. The supernatant was aspirated 
and the pellet was re-suspended into sphere medium at a density of approximately 100,000 
cells per mL of sphere medium. 
Sphere medium consisted of DMEM/F12 medium (Stem Cell Technologies) 
supplemented with 2% B27 supplement (Life Technologies), penicillin/streptomycin (Life 
Technologies), bFGF (20 ng/mL, Life Technologies), EGF (20 ng/mL, Peprotech), heparin 
(0.2%, Stem Cell Technologies), and LIF (1000 U, Sigma). To reduce attachment to the bottom 
of the non-adhesive plate and facilitate sphere formation, STAP-treated cultures were gently 
pipetted using a 5 mL pipette, twice per day for 2 minutes. The medium was refreshed every 
two days, unless otherwise noted. 
Low pH Treatment of Splenocytes (RIKEN protocol) 
We attempted to follow procedures as closely as possible to the original STAP paper 
published by Obokata and colleagues and the refined protocol published by Obokata, Sasai, 
and Niwa. The following protocol is adapted from and is essentially identical to the  refined 
protocol published by Obokata, Sasai and Niwa (found at the following URL: http://dx.doi.
org/10.1038/protex.2014.008 ). 
To isolate hematopoietic cells, spleens were dissected and surgically excised from 
seven- to ten-day old neonatal Oct4-GFP mice and wild-type mice. Spleens from multiple 
animals were pooled and minced with surgical scissors to facilitate tissue dissociation. We 
mechanically dissociated the spleen tissues by triturating the minced spleens with Pasteur 
pipettes. Dissociated spleen cells were re-suspended with PBS (Life Technologies) and 
strained through a cell strainer (BD Biosciences). Pelleted cells were re-suspended in DMEM 
or HBSS media (Life Technologies). 
For erythrocyte depletion, a similar protocol to the one used for processed lung 
tissues was applied to minced spleen specimens. An equal volume of Lympholyte (Cedarlane) 
was added to the bottom of the tube, causing two layers to form. The tube containing two 
layers was then centrifuged at 1000 g for 20 minutes. The lymphocyte layer was taken out 
and when indicated, stained with a CD45 antibody (PE-conjugated anti-CD45 antibody 
(Abcam) or PerCP-Cy5.5-conjugated anti-CD45 antibody (eBiosciences)) and sorted for 
CD45 on a FACSAria II (BD Biosciences). The resulting cells (unsorted splenocytes or CD45-
sorted splenocytes) were treated with 500 μl of low-pH HBSS solution (titrated to pH 5.4 by 
hydrochloric acid (HCl)) for 25 minutes at 37 degrees Celsius. Throughout the experiment, 
the pH was periodically monitored to confirm that the pH did not increase significantly 
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during the course of the experiment. If the pH rose significantly, the cellular suspension was 
centrifuged and the pellet was re-suspended into a fresh batch of acid solution. 
After the 25 minute acid bath treatment, treated cells were centrifuged at 1000 
rpm for 5 minutes at room temperature. The supernatant was removed by aspiration and 
pelleted cells were re-suspended in DMEM/F12 medium supplemented with LIF and 2% B27 
supplement at a density of approximately 100,000 cells per mL and plated onto nonadhesive 
culture plates. The medium was refreshed every 2 days until day 7, unless otherwise noted. 
The spleen data presented in Figure 1B is from unsorted splenocytes because we observed 
increased sphere-forming efficiencies when the sorting step was omitted. 
Imaging of STAP cultures 
STAP-treated lung cells were imaged every two days until seven days after initiation with 
the BWH protocol. Genetically matched, homozygous Oct4-GFP mouse ESCs were used as 
positive controls. In the Vacanti laboratory, for Figure 1A, imaging was performed with a 
Biorevo Keyence BZ9000 microscope, and BZII Analyzer software was used to acquire and 
analyze images. For capturing green and red signals, the following filters were used: Green 
signal: FITC filter; red signal: the TRITC filter. 
Flow cytometry 
STAP-treated cells were analyzed seven days after STAP treatment by flow cytometry 
to assess for reprogrammed Oct4-GFP+ cells. To distinguish authentic Oct4-GFP signal 
from autofluorescence, STAP-treated samples were compared to treated wild-type cells, 
untreated controls, and positive control mESCs. Positive control mESCs harbored an identical 
transgenic reporter, originated from the same mouse strain of STAP-treated somatic cells, 
and were used to calibrate the GFP gates for assessment of authentic reporter reactivation. 
STAP treatment was performed in the Vacanti laboratory and flow cytometry analyses were 
performed seven days after STAP treatment. Flow cytometry was performed on an LSR II at 
Children’s Hospital Boston. 
To prepare STAP-treated cells for flow cytometry analyses, cultures were trypsinized 
to generate a single cell suspension. Single cell suspensions from lungs, splenocytes, STAP-
treated cells, and mESCs were pelleted, washed, and stained with PEconjugated Annexin 
V antibody (BD Pharmingen, Cat no. 51-65875X; and Biovision, Cat No. K128-100) and 
DAPI (Life Technologies) to detect apoptotic cells and dead cells, respectively. GFP gates 
were set based on the GFP excitation/emission profile of positive control homozygous 
and heterozygous transgenic Oct4-GFP mESCs (cultured on iMEFs) containing the identical 
reporter present in STAP-treated somatic cells. The data presented in Figure 1B has no 
singlet/doublet exclusion or live/dead cell exclusion to enable comprehensive analysis for 
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any GFP signal that resembles the GFP signal of Oct4-GFP mESCs. FACS data were analyzed 
with FlowJo software (TreeStar). 
Oct4-GFP Mouse ESC Derivation and Cultivation 
To replicate the original STAP papers as closely as possible, we used a transgenic Oct4-GFP 
reporter (JAX004654). We used this reporter because the identical Oct4-GFP reporter used 
by Obokata and colleagues was not readily available. The use of homozygous transgenic Oct4-
GFP mice facilitated experimental throughput and was suggested by Niwa and colleagues 
to promote the detection of reprogramming events. Mouse ESCs were derived from E3.5 
blastocysts of mice both homozygous and heterozygous for the transgenic Oct4-GFP 
reporter to generate positive control cells for STAP replication studies. Because the somatic 
cells used for STAP replication studies were homozygous, the primary positive control cells 
used throughout this study were the homozygous Oct4-GFP ESCs. The transgenic mouse 
ESCs harboring the GOF-Oct4∆PE -GFP reporter were isolated by explanting the inner cell 
mass of an E3.5 embryo into KSR-LIF medium on iMEF feeders. Following ICM outgrowth 
formation, the outgrowth was trypsinized, plated onto irradiated CF1 mouse embryonic 
fibroblast (iMEF) feeders (GlobalStem) and continuously expanded in classical mESC 
conditions (serum/LIF medium). Homozygous and heterozygous Oct4-GFP mouse ESCs 
were cultured in standard mouse ES cell medium (serum/LIF conditions) on iMEF feeders in 
gelatinized tissue culture dishes, unless otherwise noted (such as in Figure S1) when mESCs 
were cultured in N2B27-2i/LIF to verify that the batch of B27 supplement used in the Vacanti 
laboratory can sustain the self-renewal and GFP signal of Oct4-GFP mouse ESCs). Classical 
mouse ESC medium (serum/LIF conditions) contains Knockout DMEM (Life Technologies) 
supplemented with 15% fetal bovine serum, Penicillin / Streptomycin (Life Technologies), 
nonessential amino acids (Life Technologies), nucleoside mix (Millipore), L-Glutamine (Life 
Technologies), and 1000 U of mouse leukemia inhibitory factor (LIF) (Gemini Bioproducts). 
KSR-LIF medium refers to mouse ESC medium containing Knockout DMEM, 10% Knockout 
Serum Replacer (Life Technologies), Penicillin / Streptomycin, nonessential amino acids, 
nucleoside mix, L-Glutamine, and 1000 U of mouse LIF. N2B27-2i/LIF medium refers to a 
1:1 mixture of DMEM/F12 and Neurobasal media (Life Technologies), supplemented with 
1X N2 supplement (Life Technologies), 1X B27 supplement (Life Technologies), Penicillin / 
Streptomycin, L-Glutamine, 1000 U LIF (Gemini Bioproducts), 1 uM PD0325901 (Stemgent), 3 
uM CHIR99021 (Stemgent). When indicated, LIF and B27 supplements used in our laboratory 
were substituted with Vacanti laboratory LIF and B27 supplement to validate their suitability 
for STAP replication experiments. The mouse LIF used in Vacanti laboratory was Sigma, 
Catalog No. L5158-5 ug (Lot ≤ 021M1557V). The Vacanti laboratory B27 supplement was 
Life Technologies, Catalog No. 12587-010 (Lot≤ 1582961). Notably Vacanti laboratory B27 
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supplement lacks Vitamin (A) whereas the Daley laboratory B27 supplement has Vitamin A. 
Mouse iPSC Generation and Cultivation 
Mouse iPS cells were generated to validate the Oct4-transgenic reporter for STAP replication 
studies. Mouse iPS cells were generated using standard methods16. Retroviruses (pMX-
Oct4, pMX-Sox2, pMX-Klf4, Addgene) were packaged in 293T cells using conventional 
retroviral production methods. MEFs harboring the GOF-Oct4∆PEGFP reporter were 
infected with retroviruses encoding reprogramming factors. Infected mouse embryonic 
fibroblasts were cultivated in KSR-LIF media. Two to three weeks after infection, mouse iPSC 
colonies were selected based on morphological criteria and GFP reporter activity, expanded 
and continuously cultivated in serum/LIF conditions on iMEF feeders. 
Teratoma formation analyses 
Positive control mESCs used for teratoma experiments were derived from the same mouse 
strain used for STAP replication efforts. Teratoma formation assays were performed similarly 
to previously described methods, unless otherwise noted8,9. Mouse ESCs and STAP-treated 
cells were re-suspended in Matrigel (BD Biosciences) prior to implantation for teratoma 
formation. Mouse ESCs grown on irradiated MEFs were collected by trypsin treatment, 
re-suspended as single cells and injected subcutaneously into the dorsal flanks or into 
the kidney capsule of NOD-SCID mice. STAP-treated cultures were injected for teratoma 
generation seven days after being treated with the STAP protocols. STAP-treated cells were 
not dissociated, and were instead re-suspended as clumps and injected subcutaneously into 
the dorsal flanks or into the kidney capsule of NOD-SCID mice. For production of teratomas 
from mESCs, approximately 100,000 mESCs were typically injected. For injection of STAP-
treated cultures, approximately 1 – 2 million cells were injected. After 4 – 8 weeks, teratomas 
were dissected and fixed in 10% formalin. Embedding in paraffin, sectioning of tissue, and 
hematoxylin and eosin staining were performed by the Rodent Histopathology service of 
the Dana Farber Cancer Institute. 
For subcutaneous transplantation, the following method was used. Briefly, mice 
were anesthesized with ketamine/xylazine. The dorsal flanks of the mouse were shaved 
and the skin was swabbed with Betadyne. After the mouse was shaved, mouse ESCs or 
STAP cells were injected subcutaneously with approximately 100 – 500 μl of the cellular 
suspension containing either positive control mouse ESCs or experimental STAP treated 
cells. Mouse ESC-transplanted mice typically formed teratomas within 3 – 4 weeks, whereas 
mice transplanted with STAP-treated cells were observed for at least 8 – 12 weeks. 
For kidney capsule transplantations, the left flank of the anesthesized mouse was 
shaved and the skin of the mouse swabbed with Betadyne. After the left kidney was 
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located, a small incision was made in the skin and the peritoneum to expose the kidney. 
After exposing the kidney, STAP-induced lung cells, STAP-induced splenocytes, or positive 
control mouse ESCs were injected into the kidney capsule. The peritoneum and skin were 
then closed using silk sutures. Mouse ESC-transplanted mice typically formed teratomas 
within 3 – 4 weeks, whereas mice transplanted with STAP-treated cells were observed for at 
least 8 – 12 weeks. The original Nature Article describing in vivo differentiation of STAP cells 
entailed the following: STAP cells were seeded onto a sheet composed of a non-woven mesh 
of polyglycolic acid fibers (PLGA) and cultured for 24 hours in DMEM containing 10% FBS. 
This mixture was implanted subcutaneously into the dorsal flanks of immunecompromised 
NOD-SCID mice. 
To replicate the in vivo differentiation experiments described by Obokata and 
colleagues, we obtained PLGA from a member of the Vacanti laboratory. We seeded STAP-
treated GFP+ splenocytes onto a sheet of PLGA mesh, cultured the mixtures for 24 hours 
in DMEM + 10% FBS, and subcutaneously implanted the mixture into the dorsal flanks of 
NOD-SCID mice. For subcutaneous implantations, the left flank of the anesthesized mouse 
was shaved and the skin of the mouse swabbed with Betadyne. An incision was made. The 
mixture containing the STAP-treated cells and PLGA fibers was implanted subcutaneously, 
and the incision was closed using silk sutures. The implant was typically placed near the 
incision site to facilitate implant recovery. After approximately 3 weeks or three months, the 
implant was recovered from the implantation site. Similar data was obtained between three 
week and three month STAP-PLGA implant experiments. We dissected the opposite side of 
the mouse to confirm that the same implant structure was not present. The implants were 
fixed with 10% formalin. Embedding in paraffin, sectioning, and stainings (H & E staining and 
Masson’s staining) were performed by the Rodent Histopathology service of the Dana Farber 
Cancer Institute. Additional GFP immunohistochemistry was performed in-house or by the 
Histology Core at the Harvard Stem Cell Institute. Detailed procedures for the GFP staining 
of paraffin-embedded STAP masses are described below in the immunofluorescence section 
of the methods. For validating the pluripotency of GOF18-iPSCs by teratoma formation 
capacity, similar methods to ESC-based teratoma generation were used to generate GOF18-
iPSCderived teratomas. 
Morula aggregations and blastocyst injections 
The developmental potential of STAP-treated cells was further evaluated in vivo by 
two methods: morula aggregation and blastocyst injection. Morula aggregations were 
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performed similarly to previously described methods used for mouse ES cells17. Briefly, 
STAP cells were aggregated as small clumps with E2.5 morula stage embryos in depression 
wells. The aggregates were cultured in KSOM embryo medium overnight and incorporation/
contribution was assessed 24 hours later (~E3.5) by fluorescence microscopy. Methods 
for blastocyst injection were similar to those described in the Nature STAP article with 
minor modifications. Briefly, the STAP-treated spheres were mechanically “crushed” or 
disaggregated to generate aggregates of reduced size that can fit into a blastocyst injection 
needle. Following immobilization of an E3.5 blastocyst using a holding pipette, the end of the 
injection pipette containing the STAP-treated sphere was juxtaposed against the blastocyst 
surface and swiftly introduced into the blastocyst cavity. The STAP-treated aggregates were 
released from the injection needle slowly into the blastocyst cavity. Following withdrawal 
of the needle from the blastocyst, the injected blastocyst was allowed to recover in an 
incubator. Recovered embryos were transferred into the uterus of 2.5 dpc pseudopregnant 
females. Seven to eight days later, females were sacrificed by CO2 asphyxiation and embryos 
were harvested at ~E10.5 for analysis. 
Tetraploid complementation (iPS cells) 
For validating the pluripotency of GOF18-iPS cells, tetraploid (4N) blastocysts were placed 
into KSOM embryo medium. iPS cells were injected into the blastocyst cavity using a 
microinjection pipette. After blastocyst injection, blastocysts were returned to KSOM medium 
and cultured at 37 degrees Celsius until transferred to recipient females. qPCR analysis Total 
RNA was isolated as described in the RNeasy Kit (Qiagen) and reverse transcribed using 
the Superscript III First Strand Synthesis Kit (Invitrogen). Quantitative RT-PCR analysis was 
performed in triplicate with FAST SYBR Green Mix (Applied Biosystems). Gene expression was 
normalized to GAPDH. The primer sets used to generate the data in Extended Data Figure 
2 are listed below. We note that alternative primer sets also showed lack of ESC-like Oct4, 
Sox2, and Nanog induction (data not shown). GAPDH-F: GGTTGTCTCCTGCGACTTCAACAGC 
GAPDH-R: CGAGTTGGGATAGGGCCTCTCTTGC Oct4-F: TTGGGCTAGAGAAGGATGTGGTT 
Oct4-R: GGAAAAGGGACTGAGTAGAGTGTGG Nanog-F: GGTTGAAGACTAGCAATGGTCTGA 
Nanog-R :TGCAATGGATGCTGGGATACTC Sox2-F: GCACATGAACGGCTGGAGCAACG Sox2-R: 
TGCTGCGAGTAGGACATGCTGTAGG Immunofluorescence Standard immunofluorescence 
procedures were followed. To stain mouse ES cells and STAP-treated cells, cells were fixed with 
4% paraformaldehyde, washed and permeabilized with PBS containing 0.1% Triton-X-100. 
Next, samples were blocked with PBS containing 5% FBS solution. After overnight incubation 
in primary antibody solution (PBS containing 1% FBS solution) at 4 degrees Celsius, cells 
were washed three times, and then incubated with antibody solution containing secondary 
antibodies. Cell nuclei were visualized with DAPI. The following primary antibody dilutions 
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were used: mouse monoclonal against Oct4 (1:100) from Santa Cruz Biotechnology (C:10, 
Cat No.: sc5279), rat monoclonal against Nanog (1:500) from eBiosciences (eBioMLC-51, Cat 
No.:14-5761-80). 
GFP immunostaining of paraffin-embedded STAP masses was performed using the 
following protocol. Slides with paraffin-embedded sections were de-waxed with xylene 
and rehydrated through a series of washes with decreasing percentages of ethanol. 
Antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0) by placement 
in a de-cloaking chamber at 95 degrees Celsius for 30 minutes. Immunohistochemistry 
was performed with Elite ABC kit and DAB substrate (Vector Laboratories) according to the 
manufacturer’s protocol. 
Genomic data analysis 
We used the RNA-seq and ChIP-seq data (input control) from Obokata and colleagues, 
available in the Sequence Read Archive (SRA) database (http://www.ncbi.nlm.nih.gov/
sra) with accession number SRP038104. Copy number variation analysis Input (control) 
samples from the ChIP-seq datasets were used to infer copy number profiles. Array CGH 
experiments were performed in the original publication but the data were not deposited; 
our attempt to obtain data through the editor was not successful. Reads were aligned to 
the mm9 genome using BWA18 (v.0.5.9-r16) and filtered to select uniquely aligned reads 
(“XT:A:U” flag). Copy number analysis was performed on the read counts using BIC-seq19 
after normalization by GC-content and sequence context, with parameters lambda=3 and 
bin-size=10000. We used 10kb bin size since we expect the read coverage in ChIP input to be 
uneven due variation in global chromatin status and accessibility. Single nucleotide variant 
analysis As exome or whole-genome sequencing data were not available, single nucleotide 
sequence variants (SNVs) were inferred from RNA-seq data. RNA-seq data were aligned to 
the mouse genome mm10 using Tophat 2.0.1020,21 allowing two mismatches and two indels. 
The ENSEMBL GRCm38 gene annotation was used. On average 14.6M reads were aligned 
(12.9M-16.4M), which corresponds to 84.3% of total reads. Uniquely aligned reads were 
used, and duplicates were removed. Variants were called using Genome Analysis Toolkit22 
3.0 UnifiedGenotyper, with local indel realignment and base quality score recalibration23. 
Only those variants assigned PASS by variant quality score recalibration (VQSR)23 and with 
quality score ≥100 were retained. Known mouse SNPs for various strains were obtained 
from the Wellcome Trust Sanger Institute Mouse Genomes Project24 and used during the 
recalibration steps. To remove the effect of variable read coverage (due to varying levels of 
gene expression), only the 9,739 variants with at least 30X coverage across all samples were 
considered for downstream analyses.
236
Chapter 7 
Author Contributions 
A.D.L.A. and F.F. contributed equally to this work. A.D.L.A. and
G.Q.D. conceived and designed the project. A.D.L.A. performed experiments within the 
Vacanti laboratory, where indicated. A.D.L.A., Y.F., R.M., H.-C.T., S.C. and Z.W. analysed 
STAP experiments. S.R. facilitated teratomainjections. T.W.T., B.E.P., S.I., J.C., M.B., V.K., 
E.L., M.W., J.H.H., K.H., D.P., R.J. and H.D. contributed STAP replication data. F.F. performed 
bioinformatics analyses, assisted by So.L. and Se.L., and supervised by P.J.P. A.D.L.A., F.F., 
P.J.P. and G.Q.D. wrote the manuscript.
References
1.  Obokata, H. et al. Stimulus-triggered fate conversion of somatic cells into pluripotency. 
Nature 505, 641–647 (2014).
2.  Obokata, H. et al. Bidirectional potential in reprogrammed cells with acquired 
pluripotency. Nature 505, 676–680 (2014).
3.  Obokata, H. et al. Retraction: stimulus-triggered fate conversion of somatic cells into 
pluripotency. Nature 511, 112 (2014).
4.  Obokata, H. et al. Retraction: bidirectional potential in reprogrammed cells with acquired 
pluripotency. Nature 511, 112 (2014).
5.  Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313–317 (2007).
6.  Nichols, J. et al. Formation of pluripotent stem cells in the mammalian embryo depends 
on the POU transcription factor Oct4. Cell 95, 379–391 (1998).
7.  Szabo´ , P. E., Hubner, K., Scholer, H. & Mann, J. R. Allele-specific expression of imprinted 
genes in mouse migratory primordial germ cells. Mech. Dev. 115, 157–160 (2002).
8.  Lawrenz, B. et al. Highly sensitive biosafety model for stem cell-derived grafts. 
Cytotherapy 6, 212–222 (2004).
9.  Cao, F. et al. Spatial and temporal kinetics of teratoma formation from mouse embryonic 
stem cell transplantation. Stem Cells Dev. 16, 883–892 (2007).
10. Han, D. W. et al. Epiblast stem cell subpopulations represent mouse embryos of distinct 
pregastrulation stages. Cell 143, 617–627 (2010).
11. Yeom, Y. I. et al. Germline regulatory element of Oct4 specific for the totipotent cycle of 
embryonal cells. Development 122, 881–894 (1996).
12.Ohbo, K. et al. Identification and characterization of stem cells in prepubertal 
spermatogenesis in mice. Dev. Biol. 258, 209–225 (2003).
13.Tang, M. K. et al. Transient acid treatment cannot induce neonatal somatic cells to 
become pluripotent stem cells. F1000Res. 3, 102 (2014).
237
Failure to replicate stress based reprogramming of somatic cells
7
14. Kim, Y. M., Lee, J. Y., Xia, L., Mulvihill, J. J. & Li, S. Trisomy 8: a common finding in mouse 
embryonic stem (ES) cell lines. Mol. Cytogenet. 6, 3 (2013).
15. Hou, P. et al. Pluripotent stem cells induced from mouse somatic cells by smallmolecule 
compounds. Science 341, 651–654 (2013).
238
Chapter 7 
Extended Data Figure 1. Validation of the Oct4-GFP transgenic reporter. (A) Context-
appropriate expression of the GOF18-Oct4DPE-GFP transgene reporter in the testes of 
10-day-old neonatal male mice. (B) STAP replication culture reagents sustain Oct4-GFP 
signal in Oct4-GFP mouse ES cells. Vacanti laboratory LIF and B27 supplement sustain self-
renewal and strong GFP signal of Oct4-GFPmouse ES cells in serum/LIF (left) and N2B27 
minimal media (see Methods) plus 2i/LIF (MEK inhibitor PD0325901 and GSK3-b inhibitor 
CHIR99021) (right). (C) Reactivation of the GOF18-Oct4DPE-GFP reporter during direct 
reprogramming of MEFs by Oct4, Sox2 and Klf4. Left, phasecontrast images of founder 
GOF18-mouse iPS cells. Right, GFP signal in primary GOF18-mouse iPS cells. Note the 
heterogeneous reactivation of the GOF18-Oct4DPE-GFP reporter in primary founder mouse 
iPS cell colonies (derived in knockout serum replacement/LIF). (D) GOF18-Oct4DPE-GFP 
reporter expression in established mouse iPS cell lines (passage 12). Left, phasecontrast 
images of established GOF18-mouse iPS cells. Mouse iPS cells were maintained on feeders 
in serum/LIF media. Right, note GFP signal in GOF18- mouse iPS cells. GFP is observed in 
essentially all iPS cell colonies and in most cells in each colony. GFP heterogeneity was slightly 
increased in GOF18-iPS cells compared with GOF18-ES cells. (E) Developmental potential 
of GOF18-iPS cells. Top left, phase-contrast image of a teratoma generated from GOF18-
iPS cells. Original magnification, 20x. Top right, to assess the developmental potential of 
GOF18-iPS cells, ‘all iPS cell embryos’ were generated by injection of GOF18-iPS cells into 4N 
blastocysts (‘tetraploid complementation’). A photograph of a live E13.5 embryo generated 
from GOF18-iPS cells is shown. Bottom row, gonadal contribution in all-iPS-cell embryos 
indicates GOF18-iPS cells are highly pluripotent. GFP is expressed in E13.5 days post-coitum 
(dpc) male gonads, and fluorescent cords are visible. The silencing of GFP in surrounding 
cells re-confirms the context-appropriate expression of the Oct4-GFP reporter. 
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Extended Data Figure 2. STAP replication data. (legend on next two pages)
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Legend extended data Figure 2: (A) Experimental scheme. Reactivation of the transgenic 
GOF18-Oct4DPE-GFP (Oct4-GFP) reporter to detect reprogramming after STAP treatment 
of somatic cells. (B) Two STAP protocol variants. BWH: mechanical trituration and low pH 
treatment of lung cells. RIKEN: low pH treatment of spleen cells. Stressed cells were plated 
into non-adhesive dishes and cultured in DMEM/F12 medium plus B27 and LIF. (C) qPCR 
analysis 7 days after STAP induction. Expression levels of Oct4, Sox2 and Nanog transcripts 
at ES-cell-like levels were not observed in lung cells or splenocytes after treatment with 
the BWH or RIKEN STAP protocol, respectively. Levels normalized to Gapdh. One replicate 
per protocol is shown. Although low level Sox2 and Nanog upregulation (1–2 DCt cycles; 
data not shown) was inconsistently observed, we speculate that minimal induction of 
Sox2 and Nanog messenger RNA may be due to relaxed transcriptional control in stressed 
cells. (D) Nonspecific staining observed in STAP-treated cells suggests immunofluorescence 
artefacts. ES cells and autofluorescent spheres (BWH protocol) were processed in parallel 
and stained with OCT4 and NANOG antibodies. In contrast to the specific nuclear signal 
observed in positive control ES cells, nonspecific and non-nuclear staining is observed in 
spheres generated after STAP treatment. Original magnification, 20x. (E) Assessing the 
presence of rare ES-cell-like cells in STAP-treated cultures by teratoma formation assays. 
STAP-treated cells were transplanted subcutaneously or into the kidney capsule to detect 
rare ES-cell-like pluripotent cells. If ES-cell-like cells are generated after transient low 
pH treatment with/without mechanical trituration, a teratoma containing elements 
of all three germ layers should form. STAP-treated cells did not form teratomas using 
conventional teratoma generation protocols. Left two images, immunocompromised mice 
injected subcutaneously with STAP-treated cells, which do not exhibit teratoma-like mass 
formation after approximately 4 months of observation. Right two images, kidneys after 
STAP-treated cells were transplanted into the kidney capsule indicating lack of teratoma-
like formation after 3 months of observation. Black arrows indicate kidney transplanted 
with STAP-treated cells; second kidney from same mouse not transplanted with STAP-
treated cells. (F) Immunocompromised NOD/SCID mice transplanted with STAPtreated 
cells did not formteratoma-like masses. Summary of teratoma injection experiments. Every 
assessable injection of mouse ES cells produced teratomas (7 out of 8 positive-control ES-
cell-injected mice formed teratomas within 3–4 weeks. The mouse that did not form a 
teratoma immediately died from surgical complications and therefore was discarded from 
the analysis). n=58 independent injection sessions; n=521 injection sites. Therefore, STAP-
treated cells did not form teratomas using conventional methods. (G) Extended histological 
analysis of a recovered STAP-PLGA mass (as in Figure 1c). Obokata and colleagues1,2 reported 
a distinct teratoma productionmethod that involved seeding STAP-treated cells onto a PLGA 
scaffold before implantation into immunocompromised mice. Around 10–20 million STAP-
treated cells from GFP-positive mice were seeded into PLGA. GFP-positive cells were used to 
distinguish donor- and host-derived tissues. Left, positive-control ES cells formed teratomas 
with tissue derivatives of all three germ layers. Left, original magnifications (from top to 
bottom): 340, 320, 340. Middle, recovered STAP-PLGA mass,H&E staining. Middle, original 
magnifications (from top to bottom): 320, 340, 340. Right, recovered STAP-PLGA mass, 
Masson’s staining (used to illustrate collagen deposition or presence of an inflammatory 
reaction, which commonly occur in response to foreign body implants). Right, original 
magnifications (from top to bottom): 320, 340, 360. All images were obtained from formalin-
fixed/paraffin-embedded tissue sections.
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Legend of extended data Figure 2 (continued):
(H) STAP-treated autofluorescent spheres failed to re-enter development after morula 
aggregation. Unlike ES or iPS cells, autofluorescent spheres failed to incorporate into the inner 
cell mass of the host embryos (n520), suggesting incompatibility with the pre-implantation 
embryo. (I) STAP-treated autofluorescent spheres failed to re-enter development after 
blastocyst injection. Mechanically disaggregated autofluorescent spheres were injected into 
pre-implantation blastocysts and implanted into pseudopregnant mice. From 17 implanted 
embryos, only two were recovered, which were developmentally abnormal, suggesting that 
the other 15 embryos died or were resorbed. (J) Contribution of STAP-treated lung cells 
to chimaeras was not detected after blastocyst injection. Images of two abnormal E10.5 
embryos with no obvious GFP signal that would indicate integration of donor test cells into 
the developing host embryo. Original magnification, 310. (K) Autofluorescence and Oct4-
GFP fluorescence were distinguishable by fluorescence microscopy in cells containing the 
same Oct4-GFP transgenic reporter used by Obokata and colleagues1,2 (data fromDeng 
laboratory). MEFs with the same transgenic Oct4-GFP reporter (GOF18-Oct4-GFP, intact PE) 
used in ref. 1 (passage 0) were treated with low pH solutions (pH 5.4 and 5.6, respectively). 
MEFs without low pH treatment were used as a negative control. After treatment, samples 
were cultured in suspension. Chemically induced pluripotent stem cells (CiPSC)15 containing 
the transgenic Oct4-GFP reporter were used as a positive control for green fluorescence. 
GFP fluorescence was detected using a long-pass and band-pass filter. Red fluorescence was 
also observed in low-pH-treated MEFs, but not in CiPSC, as shown in the right column. Scale 
bar, 100 mm. (L) ES-cell-like levels of Oct4, Sox2 and Nanog mRNA (analysed by qPCR) were 
not observed 3 days after STAP treatment of MEFs (data from Deng laboratory). MEFs were 
treated with low pH solutions and cultured in suspension for 3 and 7 days (following the 
RIKEN STAP protocol) and analysed. R1 ES cells were used as a positive control. MEFs that 
were not subjected to the RIKEN STAP protocol but cultured in suspension medium were 
used as the negative control (2).
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Extended Data Figure 3  Re-analysis of published STAP RNA-seq data. 
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Legend extended data Figure 3: (A) SNVs inferred from RNA-seq (from Figure 1h) were 
further filtere d to select only the known SNPs across mouse strains based on the Sanger 
database (see Methods). We compared the SNV profile inferred from STAP RNA-seq data 
to the expected profiles (simulated based on the known SNPs) in different mouse strains 
(magenta) as well as simulated first-generation hybrids of C57BL/6NJ and each of the other 
strains considered (orange). Selected SNVs are classified as homozygous for reference allele 
(0/0 genotype), homozygous for alternative allele (1/1 genotype) or heterozygous (0/1 
genotype) at each locus. Samples are clustered based on the sum of edit distance between 
each SNV using complete linkage hierarchical clustering. Note that replicates of the same 
experiment are always grouped together. A subset of samples (CD451, STAP, STAP stem 
cells and ES cells) (genotype A as in Figure 1h) are clustered with simulated first-generation 
hybrids of C57BL/6NJ and 129S1, in accordance with Obokata et al.1,2 (LPJ strains have a 
profile similar to 129S1 for the selected SNVs). Whereas FI-SCs (genotype B as in Figure 1h) 
are closer to the C57BL/6NJ strain (not the hybrid), EpiSC samples cluster with 129S1 or 
LPJ simulated SNVs profiles, both with some differences. Again the high similarity between 
129S1 and LPJ for these selected SNVs does not allow discriminating which of them is closer 
to EpiSC samples. Finally, TSC samples are clustered with other strains not mentioned by 
Obokata et al.1,2. Overall, it is clear that TSC (as well as EpiSC) samples are derived from 
independent sources compared with STAP cells. (B) Allele frequency distribution for SNVs 
shows number of reads for alternative alleles compared to the total number of reads for 
each SNV. The frequency of reads covering the alternative allele for heterozygous SNVs is 
expected to be approximately 50%, but in FI-SCs, it is nearly 12% (left, blue), suggesting 
false-positive calls or contamination (default thresholds in the variant calling algorithm 
result in incorrect classification of calls). We found that these FI-SC ‘heterozygous’ SNVs are 
predominantly homozygous for the alternative allele in TSCs (right, blue line), suggesting TSC 
samples as a contamination source in FI-SCs. The additional plots in Figure 1i confirm that 
FI-SC samples are approximately 10% contaminated by TSC samples. (C) Allele frequency 
distributions were independently calculated for all samples. As expected, the frequency of 
reads covering the alternative allele for heterozygous SNVs is approximately 50% (blue line) 
in all samples except FI-SCs (see b). In these plots, the first replicate (replicate 1) for each 
RNA-seq sample is reported; an almost identicalprofile is observed in each replicate pair.
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Overview of our findings
Within a few years since its discovery in 2006, iPSC technology graduated from a novelty 
to a trusted technology to generate pluripotent stem cells. Research groups worldwide are 
since striving to derive patient-specific cells for transplantation, drug testing, and disease 
modeling. In this thesis, we describe our efforts to understand how cells can alter their cell 
fate from somatic- to pluripotent stem cell and what mechanisms are in place to prevent 
this transformation. We also used reprogramming to pluripotency as a model to study 
oncogenic mutations. Furthermore, we examined an alternative reprogramming technique 
of deriving pluripotent stem cells, which did not uphold its promise for the field. 
The mouse model 
Our lab developed a model system suited particularly well for experiments on murine 
reprogramming to pluripotency. Our ‘reprogrammable mouse’, as described in chapter 2, 
is a transgenic mouse with inducible expression of the four reprogramming factors Oct4, 
Sox2, Klf4 and c-Myc (OKSM) in all cells. We show that upon doxycycline treatment of 
‘reprogrammable’ cells in culture, iPSCs can be derived at an efficiency of around 1%; 10-
100 times more efficient than reprogramming by individual transduction of viral vectors with 
reprogramming factors. The system helps to achieve more reproducible results as variability 
due to random viral integrations and different factor ratios in different cells are avoided.
Our mouse model allowed us to derive iPSC in a standardized and scalable way. The 
model was used to generate large samples of reprogramming intermediates to perform micro-
array based expression analysis, as described in chapter 3. Using markers of reprogramming 
intermediates and fluorescence assisted cell sorting (FACS), our group was able to separate 
these intermediates at different timepoints and characterize their expression and DNA- and 
chromatin- methylation status. A similar approach was used in parallel to characterize the 
proteome of intermediates1. Both analyses revealed which specific factors are upregulated, 
downregulated, or transiently altered during reprogramming from fibroblasts to iPSCs, 
shedding some light into the ‘black box’ of reprogramming. 
Thanks to this mouse model, large scale screening experiments were feasible. It 
removed one source of variability; the variability due to delivery of reprogramming factors. 
Also, when genes of interest were transduced in reprogrammable cells using viral vectors, 
this would not interfere with or add to toxicity caused by OKSM-vectors. 
Since the discovery of OKSM-mediated reprogramming, other combinations of 
reprogramming factors were found, as well as factors able to induce transdifferentiation 
of one somatic cell type to another. A transgenic mouse carrying an inducible polycistronic 
cassette can be generated for any reprogramming or transdifferentiation protocol, in order 
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to study the mechanism of the resulting transformation in more detail.  
In this thesis, the mouse model was used to identify factors that influence the 
reprogramming process. Two different approaches were used – a candidate screen using 
cDNAs (or ORFs), and a large-scale pooled RNAi screen. 
A cDNA screen to identify regulators of reprogramming
A screen for enhancers of reprogramming efficiency and speed was performed and described 
in addendum to chapter 3. A set of 24 cDNAs expressed by viral vectors was prepared and 
delivered into fibroblasts from our reprogrammable mouse model. The top hit from this 
screen was the gene Embryonic stem cell specific Ras (ERas). Since the expression data had 
revealed that ERas was strongly upregulated during reprogramming, in a pattern similar to 
the important pluripotency factor Nanog, these functional overexpression experiments of 
ERas validated the molecular characterizations performed in our research group (chapter 3). 
Another conclusion from this cDNA screen is that, although reprogramming can be 
enhanced by various factors, none of the candidates were able to remove all roadblocks 
to pluripotency. That is, no single factor enhanced reprogramming efficiency to 100%. 
Likely, many factors need to be manipulated in parallel to achieve this, or perhaps an 
overarching epigenetic regulator that can manipulate many factors indirectly. Manipulation 
of the chromatin binding factor MBD3 has been suggested to be capable of such dramatic 
enhancement of reprogramming but is limited by specific timing requirements2. Indeed, 
timing of depletion or overexpression of factors may be key to navigate the road to 
pluripotency: much like during development, this transition may depend on different 
conditions depending on the stage of reprogramming. 
Building on our understanding of pluripotency regulators, our candidates were selected 
as potential reprogramming factors. This ‘biased’ approach has proven successful before; 
most notably by Takahashi and Yamanaka when searching for the original reprogramming 
factors and Yu, Thomson and colleagues3 when identifying an alternative reprogramming 
factor combination. To find factors that modulate 4-factor induced reprogramming, biased 
screens have been tested primarily on chromatin modifying factors2,4,5. However, the 
4-factor reprogramming model allows to search beyond the ‘usual suspects’ for new genes 
not previously implied in pluripotency- or reprogramming regulation. These genes could 
nuance our idea of pluripotency regulation beyond known pathways and transcriptional 
programs. To this end we decided to conduct a genome-wide RNA-inhibition screen.
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RNAi screen to identify regulators of reprogramming
A search for inhibitors of reprogramming to pluripotency inspired the main project for this 
thesis. Not all cells exposed to the four reprogramming factors become iPSCs. Naturally, cells 
must be equipped with a response to exogenous signals or DNA mutations that promote 
loss of cell identity. The identification of roadblocks to iPSC formation provides insight into 
the mechanism of reprogramming to pluripotency. Possibly this information informs us 
about the maintenance of cell identity and the way cells combat signals that drive malignant 
transformation. 
For this screen we employed a pooled, genome-wide library containing 63,000 
shRNAs. This screen was unbiased, allowing us to find novel regulators that were previously 
not associated with reprogramming/pluripotency. The challenges faced when performing 
such a screen are detailed in the addendum to chapter 4 and 5. 
We identified two hits, which are described in chapters 4 and 5. The top hit, the small 
peptide SUMO2, is one of several SUMO peptide tags that affect protein function and are 
regulated in a way very similar to the better known ubiquitination system. Sumoylation of 
a target protein can inhibit its function by blocking sites of interaction with other proteins; 
it can prohibit co-localization of other proteins, it can mark the protein for degradation or 
sequestration to a particular cellular compartment6,7,8-11. Hence, it is still unclear how Sumo2 
downregulation promotes reprogramming. The effect is likely to be dose- and/or SUMO 
paralog -dependent; when all sumoylation is inhibited through knockout of the essential 
sumoylation enzyme UBC9, reprogramming is inhibited12.  Proteomic analysis of sumoylation 
patterns during reprogramming, with or without Sumo2 knockdown, should be revealing. 
Also, the sumo-removal enzymes (SENP1 through SENP7) are targets for further study; 
current knowledge suggests that not the sumoylating enzymes, but the de-sumoylating 
enzymes determine which target is sumoylated with which SUMO paralog and whether one 
or multiple SUMO peptides are attached13. Manipulation of SENP enzymes could help to 
further dissect the role of the different paralogs and mono-, di- or trisumoylation during 
reprogramming. 
The second hit was Nudt21 (chapter 5), encoding for CPSF5, a factor involved in 
alternative polyadenylation. Alternative polyadenylation (APA) occurs when a messenger 
RNA (mRNA) can be cleaved and polyadenylated at different sites in its distal untranslated 
region (3’UTR). The 3’UTR influences protein levels by being inhibited by microRNAs 
(miRNAs) or inhibited or stimulated by RNA binding proteins (RBPs). Some mRNAs even have 
a potential cleavage- and polyadenylation site (PAS) in an intron upstream of the last coding 
exon, resulting in a mRNA encoding a truncated protein. Recent papers have highlighted a 
possibly strong effect of alternative polyadenylation on regulation of cell proliferation and 
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fate, as well as oncogenesis14,15. Around 50% of all mRNAs are suspected to be regulated by 
APA, making specifying a mechanism challenging. Initial analysis of RNAsequencing aimed 
at identifying PAS site usage (PAS-Seq) was performed and pointed to genes affected by 
Nudt21 knockdown on the level of PAS choice. Further analysis of PAS-Seq and resulting 
downstream effectors of the Nudt21 knockdown phenotype is indicated. 
Many mRNAs are regulated by APA. Our preliminary PAS-Seq analysis pointed to a 
large group of targets affected by Nudt21. The effect of alternative PAS choice depends on 
how miRNA and RBP binding is affected and whether the resulting protein is truncated as a 
result. Thus there is no homogeneous effect of Nudt21 knockdown on protein abundance of 
a large group of proteins. This complicates any search for a mechanistic explanation of the 
Nudt21 knockdown phenotype. Although single genes can likely be identified that impact 
reprogramming when they undergo APA, none might recapitulate the phenotype of Nudt21 
knockdown. More detailed PAS-Seq analysis combined with proteomic analysis should 
provide a better view of which proteins are downstream effectors.   
Knockdown of Nudt21 or Sumo2 significantly increased reprogramming efficiency 
and -speed. When combining these treatments with known stimulants of reprogramming, 
such as chemical inhibition of GSK3b and DOT1l16,17, as well as ascorbic acid treatment18, 
we could reduce duration of OKSM expression to 38 hours. This may become relevant for 
reprogramming approaches that rely on transfection of reprogramming factors. Approaches 
which aim to avoid genetic manipulation by viral vectors or transgenics, have used 
transfection of modified messenger RNA or protein for the reprogramming factors. Since 
reprogramming cells divide at a high rate, transfected molecules are swiftly diluted, making 
multiple transfections necessary before reaching a factor-independent state of pluripotency. 
If the duration of dependence on exogenous reprogramming factors can be reduced to less 
than 2 days, only a single transfection could reprogram cells. Thus, protocols that currently 
require with several transfections could be made much more attractive when combined 
with Sumo2 or Nudt21 inhibiting siRNAs or small molecules.
This would benefit human reprogramming experiments most, where genomic 
alterations are a problem for downstream applications. We have shown that Sumo2 
knockdown aides enhanced human somatic cell reprogramming; a next step would be to 
perform reprogramming of human cells with Nudt21 suppression. 
It is interesting to note that both genes are normally expressed at high levels 
throughout reprogramming. Gene expression analysis during reprogramming has been 
applied widely to identify regulators of reprogramming19,20, but these results proves that 
genes that are expressed in a manner similar to ‘housekeeping genes’, can still be important 
factors. Consequently, expanding studies beyond transcriptional regulators and factors 
whose abundance are strongly regulated is justified.  
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Considerations when using a genome-wide RNAi screen 
With the popularity of RNAi screens, it is important to note the challenges in the design of 
such screens. Performing a genome-wide RNAi screen can take years to optimize; it requires 
careful design, analysis, and validation before one can start looking at the biology behind 
the results. In our case, our system required more thorough selection of true-positive hits, 
resulting in multiple extra rounds of screening. Two groups have published RNAi screens 
during reprogramming, although without clear overlap of resulting candidate genes. This 
points to the limitation of each of these screens in fully covering the genome during the 
screen. In our case, we did not find candidates all we would have expected to find. For 
example, inhibition of p53 facilitates reprogramming, but we found that coincidentally, the 
shRNAs targeting p53 had not made it into the screening library during the preparation. 
Also, differences in the screening approach can explain different outcomes. In 2010, 
Samavarchi-Tehrani et al21 performed a screen during the initiation phases of reprogramming. 
They transfected individual wells with small inhibitory RNAs (siRNAs) targeting 4000 
genes. Transfected siRNAs are expressed for several days thus mostly early modulators of 
reprogramming were found. Although comprehensive and unbiased, the library was not 
genome-wide. This is actually a strong point of the study: combining a limited library with 
state-of-the-art automated single well culture and analysis made individual siRNA testing 
possible. This ensures that each siRNA is appropriately tested. However, the resources 
required will not be available to most research groups.
A more recent shRNA screen by Qin et al22 looked at human iPSC formation, co-
transducing the four reprogramming factors with an shRNA vector. In a method similar to ours, 
shRNAs were retrieved through amplification from genomic DNA of iPSCs and sequenced 
to reveal enriched shRNAs. Unlike our approach, only a single round was performed with 
a much more complex library of 600,000 shRNAs. The multiplicity of shRNAs targeting 
the same gene allowed them to identify true hits. This could compensate for the lowered 
specificity from screening one round, where shRNAs may get enriched by hitchhiking onto 
an already reprogramming cell. However, the coverage of 50 cells per shRNA in a pooled 
screen, in an experiment with low overall reprogramming efficiency likely resulted in low 
coverage of the shRNAs. 
For future projects, achieving good coverage of the library should be a primary focus. 
Therefore, the necessity and added value of genome-wide screening versus using select 
libraries or handpicked candidates should be considered. Next, an efficient screening model 
is required. For this, one should consider what percentage of cultured cells realistically 
participates in the screen. In our case, we were interested in screening in reprogramming 
cells. Of our cultures cells, in optimal conditions, near 1% would reprogram into iPSCs. Even 
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if reprogramming efficiency would be boosted several fold by our candidate shRNAs, the vast 
majority of cells would still not contribute to the screen because they are not reprogramming 
regardless. In screens testing cell death or proliferation, this is not as problematic; every cell 
should be capable of dividing or dying. The efficiency of whichever biological process one is 
interested in, should be optimized prior to a large screen.
To conclude, a future screen should use a highly complex library covering a limited 
number of genes, with high degree of coverage (depending on the base efficiency of the 
process of interest), in one or two rounds of screening. 
Reprogramming to pluripotency as a model for oncogenesis
As discussed in the introduction, reprogramming to pluripotency has clear similarities to 
malignant transformation; by definition, pluripotent cells are tumorigenic themselves. 
However, cancer cells often harbor genetic aberrations that make each tumor unique. 
Reprogramming to iPSC does not require DNA mutations, eliminating a source of bias for 
experiments. In chapter 6, we use reprogramming as a model to study cancer by introducing 
a cancer-related mutated gene into reprogramming cells. The gene of interest is Isocitrate 
Dehydrogenase or IDH1 and IDH2, in which a neomorphic mutation provides the ability 
to produce the ‘oncometabolite’ 2-HG instead of the physiological metabolite α-KG. One 
problem we did encounter when modeling cancer with reprogrammable fibroblasts, is 
that key cancer related genes in some cases are very specific to the tissue from which the 
cancer arises. Only gene expression of genes that are not tissue-specific, but rather cellular 
process-specific, such as DNA methylation, can be compared between our reprogramming 
model and cancer cells. 
Our observations during reprogramming suggest that expression of human 
mutant IDH1 or IDH2, in reprogrammable fibroblasts during reprogramming, facilitates 
dedifferentiation but mildly inhibits iPSC formation; iPSC formation takes longer and 
only in case of the strongest mutant is reprogramming efficiency affected. This could be 
caused by inhibition of DNA demethylation through the Tet enzymes; these enzymes are 
alpha-ketoglutarate (α-KG) dependent and inhibited by competitive binding of 2-HG23. 
DNA methylation patterns of mutant IDH-derived iPSC or intermediates should reveal how 
mutant IDH affects cell fate in this setting. 
Failure to reproduce STAP phenomenon
Finally, we tried to reproduce the STAP phenomenon of inducing pluripotency or even 
omnipotency by applying chemical or mechanical stress to somatic cells. We have performed 
several protocols, with several independent colleagues in the lab, and even with on-site help 
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from the Vacanti laboratory; all without success. As we know now, alternative explanations 
to the derivation of true pluripotent stem cells were found for the key data in the STAP 
papers, and they were subsequently retracted. In the future, such impactful papers might 
require the journal to consult independent technical experts, such as flow cytometrists, 
bioinformaticians and pathology technicians who encounter highly technical data daily, 
unlike many reviewers. This should ensure an objective standard of data quality and quickly 
identify intended or unintended errors in key data.  
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Chapter 9 
English
A pluripotent stem cell represents one of the earliest stages of development of an embryo, 
when choices for intra-embryonic lineages are yet to be made. During development, cells 
become restricted to their lineage and eventually cell type. However, genetic information for 
the pluripotent state remains in place and is occasionally reactivated unintentionally, with 
factors such as c-Myc contributing to cancer formation. The pluripotent state can be induced 
by reactivating pluripotent stem cell factors experimentally. A couple of years before work 
on this thesis started, a relatively simple and highly reproducible technique was discovered 
to derive induced pluripotent stem cells (iPSCs) by overexpression of transcription factors 
Oct4, Sox2, Klf4 and c-Myc (OKSM). In this thesis, we used somatic cell reprogramming as a 
model to identify enhancers and inhibitors of reprogramming. 
The ‘reprogrammable mouse’ model aides reprogramming experiments by allowing 
exogenous factor expression without transfection of viral vectors or other methods that 
may add to interexperimental variation. Cell lines from this mouse contain a doxycycline-
inducible polycistronic cassette with the OKSM cDNAs, as well as an endogenous Oct4-
driven fluorescent (GFP) reporter. 
Reprogramming to iPSC takes 8-12 days in most protocols, during which cells pass 
through distinct molecular states. Transcriptional analysis as well as analysis of epigenetic 
marks identifies which genes and loci are activated, inactivated, or transiently regulated 
during reprogramming. Embryonic Ras (ERas) was identified as a strong enhancer in a gain-of-
function screen for enhancers of reprogramming and is upregulated during reprogramming 
based on transcriptional data. 
Although a molecular roadmap of reprogramming can be drawn, the response of 
individual cells to reprogramming cues is heterogeneous and in general low efficiencies are 
achieved. This complicates large scale screens. However, a genome-wide loss-of-function 
screen was successful by using a serial-enrichment approach. Sumo2 and Nudt21 were 
identified as inhibitors of reprogramming whose downregulation markedly increases 
reprogramming efficiency. Inhibition of Sumo2 or Nudt21 enhanced reprogramming 
speed even in high-efficiency protocols using small molecule inhibitors such as DOT1l 
inhibitor and the ascorbic acid/ GSK3b inhibitor combination, leading to iPSCs formed 
after just 38-48 hours of OKSM expression. Also, reprogramming without oncogene c-Myc 
was greatly enhanced. Derived iPSCs proved to be pluripotent in teratoma formation 
assays and chimera contribution assays. Also human reprogramming was enhanced by 
Sumo2 downregulation. Transcriptional analysis showed an upregulation of pluripotency 
associated factors in reprogramming cells with downregulated Sumo2 or Nudt21 but did 
not point to specific responsible downstream regulators. SUMO2 is a small peptide which 
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can be conjugated to target proteins in a process called ‘sumoylation’, which is molecularly 
similar to ubiquitination. Based on literature, many cellular processes are affected by 
sumoylation, including epigenetic regulators of cell fate and proliferation. Nudt21 encodes 
for CPSF5, involved in regulation of the length of the 3’UTR of messenger RNAs. Analysis 
of ‘alternative polyadenylation’ of 3’UTRs transcriptome-wide shows that multiple sites 
can be used to cleave the pre-mRNA and start the poly-A tail; modulating translational 
regulation by 3’UTR binding miRNAs and RNA binding proteins. In this thesis, we show that 
Nudt21 downregulation causes alternative polyadenylation, including stem cell factor Wdr5, 
pointing to the likely mechanism of the reprogramming phenotype.  
Questions of cell fate changes beyond the stem cell field can be found in oncology. 
Oncogenic mutations in the isocitrate dehydrogenase enzymes (mIDH), important in e.g. 
the citric acid cycle, occur in glioblastoma multiforme, leukemia and cholangiocarcinoma, 
amongst others cancer types.  Mutant IDH was previously shown to induce an 
undifferentiated state in leukemic cells. This thesis provides evidence that expression 
of mIDH in reprogramming cells causes a loss of differentiation markers but not a gain 
of pluripotency. Analysis of the metabolome of these cells suggests possible metabolic 
mechanisms. Moreover, a mechanism of inhibiting α-KG dependent epigenetic regulators 
was suggested in experiments with the enzyme co-factor ascorbic acid (vitamin C). 
Finally, a new reprogramming method was presented during work on this thesis. 
Efforts to reproduce the method were unsuccesfull, regardless of the protocol used and 
assistance from the laboratory behind the findings. In a collaboration between seven stem 
cell laboratories, the irreproducibility and faults in the supporting data were identified. 
Nederlands
Een pluripotente stamcel vertegenwoordigt een vroeg stadium in de ontwikkeling van een 
embryo, als de differentiatie naar verschillende cellijnen nog volgt. Uiteindelijk leggen cellen 
zich toe op een cellijn en celtype. Echter, de genetische informatie voor een pluripotente 
cel blijft aanwezig in elke cel en kan per abuis gereactiveerd worden. Omdat pluripotentie-
gerelateerde genen zoals c-Myc de proliferatie en overleving van een cel stimuleren, dragen 
zij bij aan oncogenese. Tegelijkertijd kan ook een gezonde pluripotente cel gevormd worden 
uit lichaamscellen. Enkele jaren voordat het hier beschreven onderzoek van start ging, 
werd ontdekt dat pluripotente stamcellen experimenteel geïnduceerd kunnen worden door 
geforceerde expressie van vier pluripotente stamcel-gerelateerde transcriptiefactoren: 
Oct4, Sox2, Klf4 en c-Myc (OKSM). De verworven cellen worden geïnduceerde pluripotente 
stamcellen genoemd (induced pluripotent stem cells, iPSCs). In dit proefschrift gebruiken 
we deze ‘herprogrammerings’ techniek als model om het herprogrammeren naar een 
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pluripotente stamcel te bestuderen en factoren te identificeren die daarin een rol spelen.
Voor de meeste experimenten gebruiken wij de ‘herprogrammeerbare muis’ als 
model. Cellen van deze transgene muis hebben geen virale vectoren met OKSM nodig om 
OKSM productie in de cel te veroorzaken en hierdoor de cel te herprogrammeren. Ze hebben 
een doxycycline-induceerbare polycistronische cassette met de cDNAs van de 4 factoren. Dit 
betekent dat cellen van deze muis de vier herprogrammeringsfactoren gaan produceren 
zodra ze in contact komen met doxycyline. Met behulp van dit model is vastgesteld dat 
embryonale fibroblasten via specifieke tussenstadia gaan gedurende herprogrammering. 
Deze tussenstadia zijn bestudeerd door transcriptie en DNA methylatie genoom-wijd te 
analyseren en vergelijken met andere tussenstadia, fibroblasten en de uiteindelijke iPSCs. 
Een groep genen is getest op hun vermogen herprogrammering te bevorderen, waarop 
onder andere embryonale Ras (ERas)  werd gevonden; ERas wordt normaliter geleidelijk 
aan meer tot expressie gebracht in herprogrammerende cellen zoals bleek uit analyse van 
de tussenstadia. 
Met behulp van RNA-inhibitie konden ook inhiberende factoren worden gezocht op 
grote schaal; genoom-wijd. Omdat herprogrammeren met OKSM een langzaam, inefficiënt 
en heterogeen verlopend proces is, is het lastig om op grote schaal een screen te doen zonder 
verlies van gevoeligheid en specificiteit van de screen. Hierop werd een zichzelf herhalende 
screen ontworpen om vals-positieve resultaten te vermijden. Twee top kandidaten bleken 
Sumo2 en Nudt21. RNAi remming van Sumo2 of Nudt21 zorgde voor sterke toename van 
snelheid en efficiëntie van herprogrammeren, ook in de afwezigheid van c-Myc. Efficiënte 
herprogrammeringsprotocollen konden hiermee worden verbeterd en de benodigde duur 
van OKSM expressie kon worden teruggebracht tot onder de 48 uur (normaal 6-8 dagen). De 
iPSCs die daarmee werden gevormd doorstonden alle kwaliteitstesten. 
SUMO2 is een kleine peptide die aan andere eiwitten geconjugeerd kan worden in 
een proces genaamd ‘sumoylatie’, wat erg lijkt op ubiquitinatie. Sumoylatie lijdt tot het 
stabiliseren of juist vernietigen, aantrekken van andere eiwitten of juist afstoten ervan, 
volledig afhankelijk van het doeleiwit. Het fenotype van Sumo2 remming in herprogrammering 
kan dan ook op veel mechanismes berusten. Echter is een rol in epigenetische regulatie, wat 
belangrijk is voor herprogrammeren, wel reeds beschreven. 
Nudt21 codeert voor CPSF5, een factor die helpt bepalen waar het distale eind, de 
onvertaalde regio (3’UTR) van een pre-mRNA wordt geknipt en verlengd met adenosines 
(polyadenylatie). Alternatieve polyadenylatie zorgt dat delen van een mRNA die gevoelig 
zijn voor regulatie door micro-RNAs of RNA bindende eiwitten, wel of niet aanwezig blijven; 
dit bepaalt dan de mate van translatie van het mRNA naar eiwit. Analyse van de 3’UTRs van 
alle mRNAs liet zien dat Nudt21 remming tijdens herprogrammering zorgt voor alternatieve 
polyadenylatie, onder andere van stamcelfactor Wdr5. 
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Tijdens het ontstaan van kanker (oncogenese) ondergaan cellen ook grote 
veranderingen van karakter, inclusief het weer meer kunnen delen en minder 
gedifferentiëerd raken. Derhalve werden herprogrammerende cellen gebruikt als model 
voor oncogene mutaties in de Isocitraat dehydrogenase (IDH) enzymen die onder andere in 
de citroenzuurcyclus een rol spelen. Van mutante IDH (mIDH) was al bekend dat het helpt 
om leukemiecellen in een ongedifferentieerde staat te houden. Tijdens herprogrammeren 
viel op dat de fibroblasten met expressie van mIDH wel sneller fibroblastmarkers verloren, 
maar niet makkelijker iPSCs werden. De staat van het metabolisme en van transcriptionele 
activiteit in deze cellen werd geanalyseerd. Ook werd de interactie van mIDH met vitamine 
C getest; hieruit bleek dat vitamine C een deel van het fenotype kon terugdraaien. Dit wijst 
erop dat enzymen die vitamine C als co-factor gebruiken en gevoelig zijn voor de metaboliet 
van mIDH mogelijk een belangrijke rol spelen. Onder deze enzymen zijn enkele belangrijke 
epigenetische factoren. 
Tot slot werd een nieuwe methode om pluripotente stamcellen te maken getest. Toen 
bleek dat deze methode niet gereproduceerd kon worden, restte de vraag hoe dat kon en 
hoe de ontdekkers hun data hadden verworven. Een groep van ervaren stamcellaboratoria 
groepeerde hun pogingen om verschillende varianten van de methode te testen, met de 
conclusie dat geen ervan werkte. 
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List of abbreviations
2-HG  β-hydroxyglutarate
3’UTR  3 prime Untranslated Region (downstream of protein coding   
  sequence)
α-KG  α-ketoglutarate
AA  Ascorbic Acid (Vitamin C)
AGi  Combination of AA and GSK3b inhibitor
Alk5i  Alk5 inhibitor (TGF-beta signalling inhibitor)
AP   Alkaline Phosphatase
APA  Alternative Polyadenylation
ATP  Adenosine Tri-Phosphate
CPSF5  Cleavage and Polyadenylation Specificity Factor 5
D1li  Dot1l inhibitor
dox  Doxycycline
dsRNA  double stranded RNA
ECC  Embryonal Carcinoma Cell
EGC  Embryonic Germ Cell
EMT  Epithelial-to-Mesenchymal Transition
ERas  Embryonic Ras
ESC  Embryonic Stem Cell
FACS  Fluorescence Activated Cell Sorting
FF  Firefly (negative control for RNAi experiments)
gDNA  genomic DNA
GFP  Green Fluorescent Protein
ICM  Inner Cell Mass; clump of cells within a blastocyst-stage embryo
IDH  Isocitrate Dehydrogenase
iPSC  induced Pluripotent Stem Cell
LCMS  Liquid chromatography–mass spectrometry
MACS  Magnetic Activated Cell Sorting
MEF  Mouse Embryonic Fibroblast
MET  Mesenchymal-to-Epithelial Transition
mIDH  mutant Isocitrate dehydrogenase
miRNA  microRNA
MSC  Mesenchymal Stem Cell
Nudt21  Nudix hydrolase 21, gene which encodes CPSF5
OKS-mCherry polycistronic cassette with Oct4, Klf4, Sox2 and mCherry reporter  
  cDNAs
OKSM  (polycistronic cassette with cDNAs of) Oct4, Klf4, Sox2 and c-Myc 
ORFs  Open Reading Frames
PAS   Polyadenylation site
PASSeq  PAS sequencing
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PCR  Polymerase Chain Reaction
PPP  Pentose Phosphate Pathway
PSC  Pluripotent Stem Cell
repMEF  Reprogrammable MEF (containing dox-inducible OKSM)
RFP  Red Fluorescent Protein
RNAi  RNA inhibition
RNAseq  RNA sequencing
SCNT  Somatic Cell Nuclear Transfer
Senp  Sentrin-specific protease; Sumo protease
shRNA  short hairpin RNA
siRNA  small interfering RNA
STAP  Stimulus Triggered Acquisition of Pluripotency
STAP-SC STAP-Stem Cell
STEMCCA Stem Cell Cassette; contains OKSM
SUMO2  Small Ubiquitin-like modifyer 2
TCA cycle Tricarboxylic Acid cycle
Tcl1  T Cell Lymphoma 1
TF  Transcription Factor
WB  Western Blot
WT  Wild Type
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